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Abstract 
CCR4 is a chemokine receptor notably expressed on T helper 2 and regulatory 
T cells. CCR4 binds the chemokines CCL17 and CCL22. These are involved in T cell 
homeostasis and inflammatory diseases including asthma and atopic dermatitis, 
making CCR4 a potential therapeutic target. Previous studies suggested that CCL22 
is dominant over CCL17 with respect to ligand-induced internalisation and 
desensitisation of CCR4. The biology of CCR4 was investigated in this project using 
point mutational studies. A C-terminal lysine within the conserved helix VIII region 
was determined to be dispensable for CCL22-induced chemotaxis but required for 
CCL17-induced chemotaxis, suggesting that the two chemokines stabilised distinct 
receptor conformations. The highly conserved GluVII:06 of helix VII was shown to 
be critical for chemokine binding and receptor function. 
Seven small molecule allosteric antagonists of CCR4, supplied by 
GlaxoSmithKline, were hypothesised to bind either a classical intrahelical site (site 1) 
within the receptor or a novel intracellular site (site 2). 22 amino acids were predicted 
to be involved in the binding of the antagonists. Antagonist binding was indirectly 
investigated by inhibiting either function or chemokine binding of the receptor 
mutants. Mutation of leucine 118 in transmembrane helix III significantly reduced 
CCR4 sensitivity to site 1 antagonism in chemotaxis and chemokine-binding assays. 
Mutants of phenylalanine 305 and leucine 307 at the end of transmembrane helix VII 
also showed a reduction in antagonist 2 sensitivity. 
Direct investigation of the effects of mutation on antagonist binding was 
performed using tritium-labelled antagonists. Mutation of GluVII:06 prevented site 1 
antagonist binding to CCR4. Further investigation of site 1 antagonist binding was 
hindered by high non-specific binding of the compounds. A low-affinity site for the 
tritium-labelled site 2 antagonist was identified on untransfected cells, possibly within 
endogenously expressed chemokine receptors. This antagonist therefore may have 
potential as a broad-spectrum chemokine receptor inhibitor. 
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1.1 – The immune system 
The immune system exists to protect organisms from invasion by 
microorganisms such as bacteria and viruses. Leukocytes, more generally known as 
white blood cells, are one of the factors responsible for carrying out the functions of 
the immune system. Leukocytes can be broadly grouped into two categories based on 
whether they function in the innate or adaptive immune response, although both 
branches of the immune system are intricately linked. The innate response is the first 
line of defence against pathogens, taking place within minutes of an infection. The 
innate response involves processes including pattern recognition of common non-self 
molecular structures, such as bacterial cell wall proteins. In contrast, the adaptive 
response takes hours or even days to initiate, due to the fact that somatic 
rearrangement of genes is required to generate molecules to bind the foreign antigen 
(Chaplin, 2003; Barton, 2008). 
The leukocytes of the innate immune system include granulocytes (named due 
to the presence of large granules in their cytoplasm) such as neutrophils, eosinophils 
and basophils. Neutrophils phagocytose microorganisms, and can release granules 
containing reactive oxygen and nitrogen species to disrupt the physical structure of 
the microorganism (Nathan, 2006). Eosinophils also release granules to counter 
infections of parasitic organisms such as helminths; the main constituents of these 
granules are major basic protein and various other toxic products that induce tissue 
damage (Rothenberg and Hogan, 2006). Basophils are a source of histamine, which 
when released causes smooth muscle contraction and vasodilation, leading to the 
characteristic swelling and redness associated with allergy (Schroeder, 2009). Mast 
cells are also a source of histamine, which they release in response binding of at least 
two molecules of the immunoglobulin IgE which have been cross-linked by antigen 
(Williams and Galli, 2000; Abraham and St John, 2010). 
Other cell types involved in the innate immune response are the monocytes, 
macrophages and dendritic cells. Like the granulocytes, they are derived from a 
myeloid lineage. Monocytes produce inflammatory cytokines and can differentiate 
into macrophages and dendritic cells. Macrophages are phagocytic cells that can clear 
apoptotic cells and microbes. Dendritic cells are professional antigen presenting cells 
that residue in tissues such as the skin, where they phagocytose infectious organisms 
and display antigen on their cell surface after processing. Dendritic cells migrate to 
17 
 
the lymphoid organs where they interact with B and T cells, thus engaging the 
adaptive immune response (Geissmann et al., 2010). 
To trigger the adaptive immune response, antigen needs to be encountered by 
B cells, T cells and antigen presenting cells (APCs). APCs such as dendritic cells take 
up antigen from the tissues, after which they migrate via the lymphatic system to the 
secondary lymphoid organs which include the spleen and lymph nodes. Here the 
dendritic cells present antigen in order to activate the adaptive immune response. The 
adaptive immune response has two major branches; humoral immunity mediated by B 
cells, and cell-mediated immunity involving the production of cytokines and killing 
cells in a process mediated by cytotoxic T cells, macrophages and natural killer cells 
(Murphy, 2011). 
In cell-mediated immunity, APCs such as dendritic cells and macrophages 
encounter antigen in the tissues, and then display it on their cell surface in complex 
with major histocompatibility (MHC) proteins. For example, an APC that has 
encountered antigen in the tissue migrates via the lymphatic vessels to the secondary 
lymphoid organs. Here, the APC encounters naïve T cells that have entered the organ 
from the bloodstream via a process called diapedesis. Intracellular antigens, such as 
those from viruses are displayed with MHC type I proteins. Extracellular antigens, 
such as those from bacteria, are displayed with MHC type II proteins. For example, a 
macrophage that has phagocytosed a virus-infected cell displays viral antigens in 
complex with MHC I; these are presented to naïve T cells which causes them to 
differentiate into CD8
+
 antiviral cytotoxic T cells. A dendritic cell that has 
phagocytosed bacterial antigen displays it in complex with MHC II to naïve T cells, 
causing them to differentiate into CD4 T helper cells. These cells then help B cells in 
mediating humoral immunity. 
In humoral immunity, antigen is encountered by B cells. Like professional 
APCs such as dendritic cells, B cells migrate to the lymph nodes. B cells interact with 
helper T cells in the germinal centers, leading to proliferation of the B cells and 
subsequent production of antibodies. Antibodies perform a variety of functions, 
including the can opsonisation of microorganisms in order to facilitate phagocytosis 
by cells such as macrophages, neutralise toxins and viruses. Opsonisation involves 
the binding of the Fab region of antibody to the microorganism, after which the Fc 
region of the antibody is bound by a receptor on the surface of the phagocyte. This 
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facilitates phagocytosis. Antibodies also activate other cell types such as mast cells 
(Murphy, 2011). 
T helper (TH) cells are important for the initiation and maintenance of 
adaptive immunity. These can be split into various subtypes, including TH1 and TH2 
cells. Upon contact with an antigen-presenting cell, secretion of interleukin-12 
stimulates the naïve T cell to differentiate into a TH1 cell, while interleukin-4 
stimulates TH2 differentiation. TH1 cells secrete cytokines such as interferon-γ (IFN-
γ), which has antiviral activity in addition to stimulating macrophages to kill 
phagocytosed bacteria. TH2 cells secrete the cytokines IL-4, IL-5 and IL-13. These 
promote antibody production by B cells, eosinophil migration and activation, further 
TH2 differentiation, and synthesis of the antibody IgE, thus furthering the humoral 
response (Murphy, 2011). Another subset of T cells known as TH17 cells also plays a 
role in inflammation. TH17 cells produce the pro-inflammatory cytokine IL-17, and 
mediate neutrophil and macrophage recruitment during infections. They also have 
shown to be involved in autoimmune diseases such as multiple sclerosis (Dong, 
2008). 
The immune system is highly complex and involves the coordination of 
multiple cell types throughout all the tissues of the body. It is through the action of 
chemokines and their receptors that many immune cells reach their target destinations 
within the tissues. For example, chemokines are required for dendritic cell immune 
surveillance throughout the tissues and for their migration to the lymphoid organs in 
order to present antigen to T cells. Chemokines are also required for the migration of 
phagocytic cells to sites of bacterial infection, in addition to a whole host of other 
processes. Chemokines are therefore an important factor in the immune system as 
they allow its component cells to carry out their effector functions. 
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1.2 – Chemokines 
Chemokines, chemotactic cytokines, are a family of low molecular weight 
proteins that range from 8 to 10 kDa in size (Harrison and Lukacs, 2007). 
Chemokines guide the migration of cells expressing chemokine receptors, in a 
process termed chemotaxis. Chemotaxis is the migration of a cell along an increasing 
concentration gradient of a chemoattractant substance. There are over 40 known 
chemokines present in humans; these are divided into four subfamilies based upon the 
number and position of conserved N-terminal cysteine residues, which provide 
stabilisation of the chemokine tertiary structure through the formation of disulphide 
bonds (Laing and Secombes, 2004). Most chemokines, despite their diversity in 
sequence, share a similar tertiary structure; an N-terminal 6-10 amino acid signalling 
domain, an N-loop binding domain, a three-stranded β-sheet, followed by a C-
terminal helix (Allen et al., 2007). Figure 1-1 shows the tertiary structure of CXCL8, 
which is representative of other chemokines (Fernandez and Lolis, 2002). 
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Figure 1-1 – Tertiary structure of CXCL8 
Ribbon structure of CXCL8, with the various domains labelled (Fernandez and 
Lolis, 2002). 
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There are four chemokine subfamilies; CC, CXC, XC and CX3C. These are 
named due to the arrangement of the first pair of cysteines. The cysteines in the CC 
subfamily are adjacent, while in the CXC subfamily they are separated by one amino 
acid. Three amino acids separate the cysteines of the CX3C subfamily, while the first 
cysteine is absent in chemokines of the XC subfamily (Murphy et al., 2000). As 
shown in figure 1-1, the cysteines create intramolecular disulphide bonds that provide 
stabilisation of the chemokine tertiary structure. 
Chemokines can also be loosely organised according to their function. 
Inflammatory chemokines are those involved in migration of cells during an 
infection, allergic reaction or other inflammatory stimulus; these chemokines are not 
constitutively expressed but rather are induced by the inflammatory processes. 
Homeostatic chemokines however are constitutively expressed; these chemokines 
direct the migration of cells involved in immune system development, immune 
surveillance, and immunological memory (Moser and Willimann, 2004). Table 1-2 
shows the chemokines classified by sub-family along with their functions, and the 
receptors they bind. 
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Systematic name Other names Function Chromosome Receptors 
CC subfamily     
CCL1 I-309 I 17q11.2 CCR8 
CCL2 MCP-1 I 17q11.2 CCR2 
CCL3 MIP-1α, LD78α I 17q11.2 CCR1, CCR5 
CCL3L1 LD78β I 17q12 CCR1, CCR3, CCR5 
CCL3L2 LD78β I 17q12  
CCL4 MIP-1β I 17q12 CCR5 
CCL4L1 AT744.2 I 17q12  
CCL4L2  I 17q12  
CCL5 RANTES I, Pt 17q12 CCR1, CCR3, CCR5 
CCL7 MCP-3 I 17q11.2 CCR1, CCR3, CCR5 
CCL8 MCP-2 I 17q11.2 CCR1, CCR3, CCR5 
CCL11 Eotaxin D 17q11.2 CCR3, CCR5 
CCL13 MCP-4 I 17q11.2 CCR2, CCR3 
CCL14 HCC-1 P 17q12 CCR1, CCR3, CCR5 
CCL15 HCC-2, Leukotactin P 17q12 CCR1, CCR3 
CCL16 HCC-4 U 17q12 CCR1, CCR2, CCR5, CCR8, H4 
CCL17 TARC D 16q13 CCR4 
CCL18 PARC H 17q12 PITPNM3 
CCL19 MIP-3β, ELC H 9p13.3 CCR7 
CCL20 MIP-3α, LARC D 2q36.3 CCR6 
CCL21 SLC, 6Ckine D 9p13.3 CCR7 
CCL22 MDC D 16q13 CCR4 
CCL23 MPIF-1 P 17q12 CCR1, FPRL-1 
CCL24 Eotaxin-2 H 17q11.23 CCR3 
CCL25 TECK H 19p13.2 CCR9 
CCL26 Eotaxin-3 I 7q11.23 CCR3, CX3CR1 
CCL27 CTACK, ILC H 9p13.3 CCR10 
CCL28 MEC H 5p12 CCR10, CCR3 
CXC subfamily     
CXCL1 Gro-α I, ELR 4q13.3 CXCR2 
CXCL2 Gro-β I, ELR 4q13.3 CXCR2 
CXCL3 Gro-γ I, ELR 4q13.3 CXCR2 
CXCL4 PF-4 Pt, non-ELR 4q13.3 CXCR3-B 
CXCL4L1 PF4V1 Pt, non-ELR 4q13.3 CXCR3-B 
CXCL5 ENA-78 I, ELR 4q13.3 CXCR2 
CXCL6 GCP-2 I, ELR 4q13.3 CXCR1, CXCR2 
CXCL7 NAP-2 Pt, I, ELR 4q13.3 CXCR1, CXCR2 
CXCL8 IL-8 I, ELR 4q13.3 CXCR1, CXCR2 
CXCL9 MIG I, non-ELR 4q21.1 CXCR3 
CXCL10 IP-10 I, non-ELR 4q21.1 CXCR3 
CXCL11 I-TAC I, non-ELR 4q21.1 CXCR3, CXCR7 
CXCL12 SDF-1α/β H, non-ELR 10q11.21 CXCR4, CXCR7 
CXCL13 BLC, BCA-1 H, non-ELR 4q21.1 CXCR5, CXCR3 
CXCL14 BRAK, bolekine H, non-ELR 5q31.1 Unknown 
CXCL16 SR-PSOX I 17p13.2 CXCR6 
CXCL17 DMC U 19q13.2 Unknown 
Other subfamilies     
XCL1 Lymphotactin, 
ATAC, SCM-1α 
D 1q24.2 XCR1 
XCL2 SCM-1β D 1q24.2 XCR1 
CX3CL1 Fractalkine I 16q13 CX3CR1 
 
  
Table 1-2 – Summary table of chemokines, their functions, and receptors 
Chemokines are classified by subfamily. Both systematic and other names are 
shown. Abbreviations; I – inflammatory, H – homeostatic, D – dual 
inflammatory/homeostatic, U – unknown, P – plasma or platelet chemokine 
activated by cleavage, Pt – platelet chemokines, ELR – contains the ELR motif, H4 – 
histamine receptor 4, PITPNM3 – phosphatidylinositol transfer protein membrane 
associated 3, FPRL-1 – formyl peptide receptor-like 1. Adapted from Zlotnik and 
Yoshie, 2012. 
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Inflammatory chemokine production is induced when inflammatory mediators 
such as TNF-α, IFN-γ or antigens are present. TNF-α production by mast cells during 
inflammation (Gordon and Galli, 1990) has been demonstrated to induce the 
production of ELR-motif neutrophil-attracting chemokines (Lakshminarayanan et al., 
1997; Smart & Casale, 1994). These chemokines, which include the inflammatory 
chemokine CXCL8, bind the receptors CXCR1 and CXCR2 expressed on 
neutrophils. Once they have migrated to the source of the initial inflammatory 
stimulus, neutrophils perform a variety of functions including phagocytosis of 
microorganisms and the release of toxic anti-bacterial proteins such as elastase, 
myeloperoxidase, cathepsins, and defensins (Lacy, 2006). IFN-γ has been shown to 
induce the production of CXCL9, CXCL10 and CXCL11, which are chemotactic for 
activated T cells expressing the receptor CXCR3 (Flier et al., 1999). Such T cells 
include the TH1 subset of T helper cells, which promote antiviral immunity by 
activating macrophages and NK cells. 
The CC group contains both inflammatory and homeostatic chemokines. 
CCL2, which is induced by the pro-inflammatory cytokine IL-1, is chemotactic for 
inflammatory monocytes expressing CCR2 (Luster and Rothenberg, 1997). Other 
examples of pro-inflammatory CC chemokines include CCL5, which at low 
concentrations attracts memory T cell expressing CCR5 (Schall et al., 1990); these 
cells can then rapidly induce an inflammatory response. CD45R0-expressing memory 
T cells are those that have previously encountered antigen, and as such are able to 
quickly respond to a second antigen exposure. 
The homeostatic chemokines CCL19 and CCL21 direct migration of CCR7-
expressing dendritic cells throughout the lymphoid tissues during immune 
surveillance, as well as guiding T cells into the lymph nodes (Förster et al., 2008). It 
is within the lymph nodes that dendritic cells present antigen to naive T cells, causing 
them to differentiate into effector T cells. 
T cells development involves the differentiation of haematopoietic progenitor 
cells into thymocytes, which occurs in the bone marrow. These thymocytes then 
migrate into the thymus, where they develop into T cells through several 
differentiation steps, including the expression of cell-surface antigens such as CD4 
and CD8, as well as the T cell receptor. Mature T cells are then able to differentiate 
into effector T cells after antigen presentation by cells such as dendritic cells (Zúñiga-
Pflücker, 2004). The migration of thymocytes into the thymus is a homeostatic 
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process that is directed by chemokines. The chemokines CCL17 and CCL22, which 
bind the receptor CCR4, have been shown to attract thymocytes during their 
development in the thymus (Chantry et al., 1999; Annunziato et al., 1999). 
CCL17 and CCL22 also function as inflammatory chemokines; CCR4 is 
expressed on TH2 cells (Bonecchi et al., 1998), regulatory T cells (Iellem et al., 2001) 
and mast cells (Juremalm et al., 2002), which suggests a role in allergic disease. TH2 
cells, as described in section 1.1, are important mediators of the adaptive immune 
response, in that they secrete cytokines such as IL-4, IL-5, and IL-13 that encourage 
antibody production and class switching by B cells and induce eosinophil activation. 
Indeed, CCR4-positive cells are recruited to the skin in atopic dermatitis and are 
associated with the pathogenesis of the disease due to their inflammatory roles 
(Kakinuma et al., 2001; Vestergaard et al., 2000). Thus, chemokines such as CCL17 
and CCL22 have dual functions, as both homeostatic and inflammatory mediators of 
migration. 
Another method of chemokine classification is by genetic similarity. Most 
chemokines cluster in particular regions on the chromosomes, and there are two 
major clusters of either CXC or CC chemokines. The CXC cluster is located on 
chromosome 4q13.3-q21.1, and is split into the GRO and IP-10 regions based upon 
the representative chemokine for each region. The CC cluster is located on 
chromosome 17q11.2 and is split into the MCP and MIP regions. This CXC/CC 
clustering also broadly matches the inflammatory/homeostatic division of the 
chemokines. There also exist CC and XC mini-clusters; the CC mini-cluster on 
chromosome 16 for example contains dual-action inflammatory/homeostatic 
chemokines CCL17 and CCL22 (Nomiyama et al., 2010). The chromosomal 
locations of the chemokines are shown in table 1-2. This clustering of CC and CXC 
chemokine alludes to their origins; gene duplication and subsequent genetic diversion 
undoubtedly occurred during the evolutionary past of chemokines, leading to the 
diverse number and types we see today. 
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1.2.1 – Chemotaxis 
Chemokines guide the migration of cells expressing their receptors along a 
gradient of increasing concentration. This process, chemotaxis, is used by many cell 
types in order to traverse the body and the tissues within. Amoebae such as 
Dictyostelium discoidium also use this process to migrate toward bacteria (Devreotes 
and Zigmond, 1988). In multicellular organisms, the immune system in particular 
utilises chemotaxis in order to selectively attract different leukocytes to areas of 
inflammation (Rot and von Andrian, 2004). 
Chemotaxis is one component of a multi-step process known as 
transendothelial migration. Cells that leave the bloodstream and enter the tissues must 
squeeze through the endotheliu; this migration depends on a variety of factors and 
mediators. A leukocyte passing through a blood vessel is initially captured by a group 
of proteins expressed on endothelium known as selectins. The L, P and E selectins 
tether the leukocyte, initiating a process known as rolling. The leukocyte slows its 
movement and begins to roll across the endothelium under shear stress from blood 
flow; interestingly this shear stress is required for rolling behaviour, as the cells 
detach if blood flow is interrupted. Chemokines and adhesion molecules expressed on 
the endothelium then initiate activation and arrest of the rolling leukocyte. 
Chemokines are presented on the endothelial surface by glycosaminoglycans 
(GAGs), and bind with high affinity to chemokine receptors, causing the leukocyte to 
stop rolling and begin crossing the endothelial barrier. Integrins such as VLA-4 and 
LFA-1 mediate leukocyte adhesion during this process. The leukocyte can cross the 
endothelium by either the paracellular or transcellular route; the former involves 
migrating between endothelial cells, whereas the latter involves the leukocyte passing 
through an endothelial cell (Ley et al., 2007). A summary of this process is shown in 
figure 1-3. 
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Figure 1-3 – The steps of leukocyte migration 
The main steps of leukocyte migration are shown; the three original steps are bolded. The 
mediators of each step are shown in the grey boxes. A leukocyte is captured by the 
endothelium by selectins, which initiates rolling under shear stress. Chemokines activate 
the leukocyte, and integrins mediate arrestin. Migration then occurs via the paracellular or 
transcellular route. ESAM - endothelial cell-selective adhesion molecule; ICAM1 - 
intercellular adhesion molecule 1; JAM - junctional adhesion molecule; LFA1 - 
lymphocyte function-associated antigen 1; MAC1 - macrophage antigen 1; MADCAM1 – 
mucosal vascular addressin cell-adhesion molecule 1; PSGL1 - P-selectin glycoprotein 
ligand 1; PECAM1 - platelet/endothelial-cell adhesion molecule 1; PI3K - 
phosphoinositide 3-kinase; VCAM1 - vascular cell-adhesion molecule 1; VLA4 -very late 
antigen 4. From Ley et al., 2007. 
27 
 
Once out of the blood vessel and through the endothelium, the leukocyte 
responds to chemokine gradients present in the tissue, and undergoes chemotaxis 
toward the source of the chemokine where it can carry out its effector function. 
During the process of migration, lymphocytes probe the surface of endothelial 
cells in order to create transcellular pores through which to migrate (Carman et al., 
2007). It has also been shown that shear forces generated by blood flow enhance the 
formation of these filopodia during lymphocyte crawling across the endothelial 
surface (Shulman et al., 2009). More recent research however has shown that 
chemokines such as CCL2 exist in vesicles just below the apical surface of the 
endothelial cells, and these are probed by lymphocyte filopodia (Shulman et al., 
2011). As the lymphocyte migrates through the endothelium the vesicles are 
consumed by these protrusions; the authors hypothesised that this allows the cell to 
remain responsive to chemokine stimulation as only specific parts of the lymphocyte 
membrane are exposed to chemokine at one time. They also showed that the arrest of 
crawling lymphocytes on the endothelium was independent of G proteins, which are 
involved in the transduction of chemokine receptor signals. This signifies that 
lymphocyte arrest is not dependent on chemokine receptors, unlike transendothelial 
migration. Instead, integrins were shown to be essential for lymphocyte arrest, since 
the blocking of integrins prevented this process (Shulman et al., 2011). 
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1.3 – G protein-coupled receptors 
GPCRs are one of the largest families of proteins; more than 1% of human 
genes code for GPCRs (Venter et al., 2001). As such, the functions of these receptors 
and the ligands they bind vary greatly. GPCRs communicate a host of signals from 
ligands such as photons, lipid hormones, neurotransmitters, and proteins (Lagerström 
and Schiöth, 2008). Previous classification systems grouped GPCRs into subfamilies 
based on physiological and structural features. Once such system is shown in figure 
1-4 (Bockaert and Pin, 1999). A more recent system grouped GPCRs into five 
families according to the GRAFS phylogenetic categorisation system; the Glutamate 
(G), Rhodopsin (R), Adhesion (A), Frizzled/Taste2 (F), and Secretin (S) families 
(Bjarnadóttir et al., 2006; Schiöth and Fredriksson, 2005). 
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Figure 1-4 – GPCR ligand types and family tree 
Three families of GPCRs are apparent based on their amino-acid sequences. Family 1 
contains most GPCRs; 1a receptors bind small ligands in the transmembrane domains; 1b 
receptors bind larger peptides using the N-terminus, extracellular loops and 
transmembrane domains; 1c receptors bind ligand with their large N-terminus. The 
unrelated family 2 receptors bind ligand in a similar manner to family 1c. The family 3 
receptors bind ligand using a lobed region on their N-terminus. From Bockaert and Pin, 
1999. 
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The Frizzled/Taste2 family contains 10 frizzled receptors and the smoothened 
receptor present in Drosophila melanogaster, as well as the 25 human Taste2 
receptors. The latter are involved in the taste of bitter compounds. The Secretin 
family of GPCRs consists of 15 hormone-binding receptors such as the calcitonin 
receptor, secretin receptor, and parathyroid receptor. Each member of this family 
binds its cognate peptide hormone via its large N-terminal domain. The Glutamate 
receptor family consists of 22 proteins, which include the sweet and umami taste 
receptors TAS1R1-3. These receptors bind ligand with their large ‘Venus fly-trap’ N-
termini. The second largest class of GPCRs, the Adhesion family, has 33 members 
that are divided into 8 subgroups. Most of these receptors are orphan receptors, in that 
their endogenous ligands are still unknown (Lagerström and Schiöth, 2008). 
The Rhodopsin family is the largest GPCR family, containing approximately 
670 receptors. This family is highly diverse and contains receptors that are involved 
in a myriad of processes that include vision, olfaction, adrenaline production, calcium 
release, water homeostasis and cell migration (Lagerström and Schiöth, 2008). The 
Rhodopsin receptors have comparatively short N-termini compared to other families 
such as the Adhesion receptors. This N-terminus binds ligand along with the 
extracellular loops and portions of the transmembrane domains. The Rhodopsin 
family is further divided into four groups – α, β, γ, and δ - that are based upon the 
specific type of ligand the receptor binds. The α-group receptors bind biogenic 
amines, and include the histamine, dopamine, serotonin and cannabinoid receptors. 
These receptors contain a ligand-binding pocket within the transmembrane bundle 
(Strader et al., 1989; Swaminath et al., 2004). The β-group receptors bind peptides, 
which are larger than the molecules that the α-group receptors bind. This group 
includes endothelin and oxytocin receptors (Lagerström and Schiöth, 2008). Due to 
the larger ligands that these receptors bind, the N-terminus and extracellular loops are 
involved in ligand binding in addition to sites within the transmembrane domains. 
The γ-group receptors contain members that bind peptides and lipid-like compounds 
(Fredriksson et al., 2003), and include the chemokine receptors, which direct cell 
migration. Lastly, the δ-group contains the olfactory and thrombin receptors 
(Fredriksson et al., 2003). 
Rhodopsin was the first GPCR to be identified and cloned (Nathans and 
Hogness, 1983), and is responsible for the detection of light in photoreceptor cells. In 
most GPCRs, ligand binds the orthosteric site within the transmembrane domain, 
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leading to conformational change and receptor signalling through heterotrimeric G 
proteins. The ligands of these GPCRs can dissociate from the receptor and return it to 
its inactive form. Rhodopsin however is different in that the receptor consists of the 
protein opsin covalently bound to the chromophore retinal. The bound retinal of 
rhodopsin is isomerised upon exposure to photons from its cis form to its trans form, 
which induces conformational change within the opsin molecule, leading to receptor 
activation and subsequent downstream signalling (Nathans & Hogness, 1983; Okada 
& Palczewski, 2001; Palczewski et al., 2000). Therefore, it is a conformational 
change in the covalently-bound ligand that leads to receptor activation rather than the 
binding of ligand itself. The trans-retinal is eventually hydrolysed, causing it to 
dissociate from opsin. This is replaced by newly-synthesised cis-retinal (Palczewski 
et al., 2000). 
 
GPCRs have seven α-helical domains that span the cell membrane, an 
extracellular amino terminus (N-terminus), an intracellular carboxy terminus (C-
terminus), and three extracellular and intracellular loops linking the transmembrane 
domains. When activated by ligand, GPCRs shift into a conformation that allows 
coupling to G proteins through their intracellular face, which then allows signal 
transduction. Residues in the intracellular loops, C-terminus and intracellular ends of 
the transmembrane domains bind these heterotrimeric G proteins. The G proteins 
consist of α, β, and γ subunits. GDP is normally bound to the Gα subunit of the G 
protein; when the GPCR shifts to an active conformation and recruits the G proteins, 
GDP dissociates and is replaced by GTP. This then causes the Gβγ complex to 
dissociate from Gα-GTP. Once dissociated from each other, the Gα subunit and Gβγ 
complex can activate or inhibit different downstream signalling partners (Johnston 
and Siderovski, 2007). 
In mammals there are four families of Gα proteins (Gαi/o, Gαq, Gα12, and Gαs), 
as well as five β and twelve γ subunits. These can activate or inhibit various 
signalling partners, which include; phospholipase C, phosphatidylinositol 3-kinase, 
adenylyl cyclase, potassium channels, calcium channels, GPCR kinases, as well as 
the MAPK and JAK/STAT kinase pathways (Offermanns, 2003). Following 
activation of these signalling partners, secondary messengers are produced. Adenylyl 
cyclase activation leads to cAMP production, which then activates protein kinase A; 
this then phosphorylates a host of other proteins leading to cellular function. Another 
32 
 
secondary messenger that is produced is inositol triphosphate, which causes the 
release of calcium from intracellular stores within the endoplasmic reticulum. 
Calcium then activates further signalling partners, including the small GTPase Ras, 
which activates pathways such as the ERK/MAPK cascade, leading to gene 
transcription (Chao et al., 1992; Cullen & Lockyer, 2002). The immune system in 
particular relies on Gαi signalling through chemokine receptors; this was determined 
through the use of Pertussis toxin, which uncouples Gαi proteins from GPCRs 
(Spangrude et al., 1985; Burns, 1988). 
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1.3.1 – GPCR structure and signalling 
Bacteriorhodopsin was identified as a seven transmembrane domain protein 
based on electron microscopy, which showed the presence of seven α-helices lying 
perpendicular to the cell membrane (Henderson and Unwin, 1975). Bovine rhodopsin 
was compared to bacteriorhodopsin and the sequence conservation between the two 
receptors, particularly the presence of hydrophobic residues, suggested that it had a 
seven transmembrane domain structure. Only once the receptor was crystallised and 
its three-dimensional structure analysed was the seven transmembrane domain 
structure confirmed (Palczewski et al., 2000). Figure 1-5 shows the crystal structure 
of rhodopsin. This structure however was of an inactive receptor, crystallised in the 
dark with retinal in its cis form. Covalently bound cis-retinal acts as an inverse 
agonist of rhodopsin, locking the GPCR structure into an inactive conformation 
(Tesmer, 2010). Structures of active receptors were needed in order to shed more 
light on how GPCRs functioned. 
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Figure 1-5 – Crystal structure of bovine rhodopsin 
Ribbon drawing of the structure of bovine rhodopsin, shown parallel to the cell 
membrane. The intracellular C-terminus is shown at the bottom and the extracellular N-
terminus at the top. The seven transmembrane domains are shown in the centre, along 
with covalently-bound retinal in yellow. © miyano@riken  
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Other GPCR structures have indeed since been solved, such as the human β2-
adrenergic receptor (β2AR). In order to crystallise the β2AR, much of the third 
intracellular loop was replaced with a more rigid structural domain; this was done in 
order to reduce basal activity levels of the receptor which hindered crystallisation 
attempts. However, as with rhodopsin, this crystal structure could not provide a full 
picture of G protein coupling. Since the intracellular loops are required for G protein 
binding, the replacement of the third loops therefore removed a key structural element 
in this binding (Rasmussen et al., 2007; Rasmussen et al., 2011; Rosenbaum et al., 
2007; Warne et al., 2008). 
In conjunction with sequence analysis of other GPCRs, the crystal structures 
of these receptors revealed several motifs that were both highly conserved and 
potentially important for receptor structure and function. One example is an eighth 
helix, located at proximal end of the C-terminus of the receptor. Helix VIII is 
amphipathic, meaning that it possesses both hydrophilic and lipophilic properties. 
This explains the observation that helix VIII lies parallel to the membrane, with 
charged residues clustering on the cytosolic side of the helix, whereas hydrophobic 
residues such as phenylalanine, methionine, and leucine are on the side of the helix 
facing the lipid membrane (Palczewski et al., 2000). 
Squid rhodopsin (Murakami and Kouyama, 2008) and the human A2A 
adenosine receptor (Jaakola et al., 2008) were also crystallised, but again these were 
done so in inactive states. The squid rhodopsin structure revealed several motifs that 
were not present in the bovine structure; transmembrane helices V and VI extended 
into the cytoplasm, which was believed to be required for G protein coupling. Overall 
9 helices were observed, 7 transmembrane and two cytoplasmic. Another feature 
unique to squid was the presence of a short 310 helix – a less common helical motif 
compared to the α-helix – linking helices VIII and IX. This short linker helix was 
thought to be involved in the folding of the seven transmembrane domains by acting 
as an anchor for these helices (Murakami and Kouyama, 2008). 
The NPXXY motif is another example of a conserved motif in GPCR 
structures, located at the cytoplasmic end of helix VII. Hydrophobic interactions were 
shown to occur between the tyrosine of this motif and a phenylalanine of the 
amphipathic C-terminal helix VIII. These interactions were hypothesised to be 
required for receptor function (Fritze et al., 2003; Palczewski et al., 2000). Before the 
publication of the rhodopsin structure, previous mutational studies had demonstrated 
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the importance of this conserved region in receptor expression, ligand binding and 
receptor activity. An M3 muscarinic receptor mutant that had the proline of the 
NPXXY motif mutated to alanine had reduced levels of receptor activation, in terms 
of phosphatidyl inositol hydrolysis (Wess et al., 1993). In the β2-adrenergic receptor, 
mutation of the asparagine of this motif to alanine resulted in uncoupling from G 
proteins, loss of agonist binding, and poor cell-surface expression. Mutation of the 
proline to alanine reduced receptor coupling and decreased the level of kinase activity 
following receptor activation (Barak et al., 1995). Subsequent studies and crystal 
structures of other GPCRs confirmed the importance of this NPXXY motif in 
receptor function. 
 
Another highly conserved motif is the E/DRY motif. This is present in many 
GPCRs, located in the second intracellular loop at the end of helix III. It consists of 
either a glutamic acid or aspartic acid followed by an arginine and a tyrosine. Like the 
NPXXY motif, its conservation in other receptors is indicative of potential function. 
In rhodopsin, a salt bridge was identified between the E/DRY motif and a glutamic 
acid located in helix VI. This was believed to form an ‘ionic lock’, fixing the receptor 
in an inactive conformation (Palczewski et al., 2000). Bovine opsin was crystallised 
without bound ligand, and the structure revealed a broken ionic lock. This structural 
rearrangement, including others such as the rotation of helix VI and stabilising 
interactions between other transmembrane domains, were believed to be part of the 
receptor activation process involving recruitment of G proteins (Park et al., 2008). 
Crystallisation of opsin in complex with a synthetic G protein showed an outwardly 
rotated helix VI, breaking the ionic lock. The R of the E/DRY motif was shown to not 
interact with the E/D of this motif and helix VI residues, but instead interacted with 
the main binding crevice of the G protein. The rotated helices and interaction of the 
arginine were also stabilised in part by the NXXPY motif (Scheerer et al., 2008). 
 
The human chemokine receptor CXCR4 has also had its crystal structure 
solved (Wu et al., 2010). Previously no other chemokine receptors had been 
crystallised and therefore all models were based upon more distantly-related receptors 
such as rhodopsin or the β2-adrenergic receptor. The CXCR4 structure provided far 
more insight into how chemokine receptors may be structurally organised and what 
similarities and differences they have when compared to other GPCRs. Compared to 
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the β2-adrenergic receptor and adenosine receptor, the extracellular portion of helix I 
of CXCR4 is shifted towards the centre of the transmembrane bundle. The residues of 
the helices that face inwards are involved in ligand binding. It was revealed in the 
CXCR4 structure that helix II makes a tighter turn than was previously believed 
based on homology models. This means that residues of helix II that face the ligand-
binding pocket were inaccurately predicted, since the models did not account for this 
rotation. This is significant since it changes what amino acids were believed to 
contact ligand upon binding. Surprisingly, despite the high level of conservation with 
other receptors, helix VII was shorter than in other structures, ending after the 
NPXXY motif. In addition, the CXCR4 structure lacked the short C-terminal helix 
VIII. However, since CXCR4 contains only a partially conserved motif in this region, 
the authors suggested that this eighth helix may only form under certain conditions 
(Wu et al., 2010). The crystal structure of CXCR4 is shown in figure 1-6. 
More recently, the crystal structures of the δ-, κ-, and μ-opioid receptors have 
been solved (Granier et al., 2012; Wu et al., 2012; Manglik et al., 2012), along with 
the structure of the nociceptin receptor (Thompson et al., 2012). These receptors are 
members of the Rhodopsin family of GPCRs. The former three share approximately 
70% sequence identity with each other, while the nociceptin receptor shares 
approximately 60% sequence identity with the other three. All four receptors are 
involved in the central nervous system, regulating process such as pain, mood, and 
homeostasis (Filidoza and Devi, 2012). 
The δ-opioid receptor, like the other opioid receptors, has two distinct 
structural regions in its ligand binding pocket; the lower portion of the pocket is 
highly conserved and recognises the core of the ligand and determines ligand 
efficacy, while the upper portion of the pocket is more divergent between receptors 
and determines ligand selectivity (Granier et al., 2012). 
The κ-opioid receptor shows strong conservation with the δ-opioid receptor 
but structurally is more similar to the dopamine receptors than to the other opioid 
receptors. It contains the previously mentioned C-terminal helix VIII, which lies 
parallel to the membrane. The κ receptor also lacks the glutamic acid/aspartic acid of 
the DRY motif; however the ‘ionic lock’ is still present in the form of an interaction 
between the arginine of this region and a threonine in helix VI. The κ receptor also 
contains the highly conserved NPXXY motif at the intracellular end of helix VII (Wu 
et al., 2012). 
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The μ-opioid receptor also lacks the salt bridge formed by the glutamic or 
aspartic acid of E/DRY motif with a residue in transmembrane helix VI. However, 
the arginine of this motif forms a salt bridge with the aspartic acid, which in turn 
forms a polar interaction with another arginine in intracellular loop 2 in a similar 
manner to that in the β2-adrenergic receptor. The arginine of the E/DRY motif also 
forms an interaction with a threonine in helix VI, as in the κ-opioid receptor. Like the 
κ receptor, the μ receptor has a deep and narrow ligand-binding pocket compared to 
other crystal structures such as CXCR4 (Manglik et al., 2012). 
The nociceptin receptor is less similar to the other opioid receptors than they 
are to each other, and has more proline residues through the transmembrane helices. 
This causes several kinks to develop, which causes the helices to be shifted compared 
to other receptors. For example, helix V is shifted compared to the κ- and μ-opioid 
receptors, giving a larger gap between helices VI and V, which in turn results in a 
larger binding pocket. Helices VI and VII are also titled further in towards the 
orthosteric binding pocket when compared to CXCR4 (Thompson et al., 2012). 
These structures therefore have provided valuable insight into the activation 
mechanisms of GPCRs, including the conserved motifs that are required for G protein 
interaction. Despite the variety of Rhodopsin class GPCRs, they share broadly similar 
activation mechanisms. In terms of GPCR activation, the conserved motifs previously 
described all act in concert in the shift from an inactive receptor state to an active one. 
 
In summary, binding of an agonist to the ligand-binding pocket of the receptor 
induces large-scale conformational changes in the receptor structure, which translates 
into intracellular signalling. In general, the movement of helix VI in particular is 
important for this process, as it rotates during receptor activation, allowing G protein 
access due to the breaking of the aforementioned ionic lock created by interactions 
between the E/DRY motif and residues within helix VI. The arginine of this motif 
acts as a micro-switch, since breakage of the ionic lock causes this amino acid to 
interact directly with G proteins. A micro-switch is a highly conserved residue of a 
GPCR that exists in distinct conformations and thus forms different interactions 
depending upon the activation state of the receptor (Nygaard et al., 2009). A diagram 
of the ligand binding pocket of GPCRs based on crystal structures and homology 
modelling is shown in figure 1-7. This shows the diversity of ligand-binding domains 
between class A GPCRs; while the receptors share the same seven transmembrane-
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domain architecture the diversity of the extracellular face allows discrimination 
between different ligand types. 
In addition to the arginine of the E/DRY motif, various other ‘micro-switches’ 
are also involved in receptor activation. TrpVI:13, a tryptophan located at the bottom 
of helix VI is believed to act as one such micro-switch; upon receptor activation the 
side chain of this amino acid rotates away from helix VII, where it is facing when the 
receptor is in an inactive conformation, to be stabilised in a new position by a 
phenylalanine in helix V. In addition, TyrVII:20 of the NPXXY motif also acts as a 
micro-switch. In rhodopsin, this tyrosine interacts with helix VIII in an inactive 
conformation, and with the rotated helix VI in the active conformation. In the inactive 
conformations of the β2-adrenergic and adenosine receptors however, this tyrosine 
forms hydrogen bonds with a water molecule located between helices I, II, VI and 
VII (Nygaard et al., 2009). Thus, the various structural domains and micro-switches 
of GPCRs work in concert to translate ligand binding into a functional response. 
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Figure 1-6 – Crystal structure of the chemokine receptor CXCR4 
Ribbon drawing of the CXCR4 crystal structure, in complex with the inhibitor IT1t. The 
N-terminus and three extracellular loops are highlighted in brown, blue, green and red. 
Disulphide bonds between extracellular domains are shown in yellow. Red circles show 
water molecules located within the structure. From Wu et al., 2010. 
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Figure 1-7 – Diversity of the ligand binding pockets of class A GPCRs 
Side and top views of the ligand binding domains of the β2-adrenergic receptor bound to 
carazolol (A), the A2A adenosine receptor bound to ZM24138 (B), the M2 muscarinic 
receptor bound to quinuclidinyl benzilate (C), the sphingosine-1-phosphate receptor 
bound to ML056 (D), and the μ-opioid receptor bound to β-funaltrexamine (E). The 
variation in ligand binding domains allows discrimination between different ligand types, 
and leads to pockets of varying depth. Note the differences in position of extracellular 
loop 2 in particular. Adapted from Granier and Kobilka, 2012. 
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1.3.2 – Chemokine receptors 
Chemokine receptors are a class of Rhodopsin GPCRs, of the γ sub-group. 
Like other GPCRs, they contain seven membrane-spanning α-helices, three 
extracellular loops, an extracellular N-terminus, three intracellular loops, and an 
intracellular C-terminus. Chemokine receptors couple to G proteins in the same 
manner as other GPCRs, and following chemokine binding to the N-terminus and 
extracellular loops, cell migration is induced. Chemotaxis, the migration of cells 
along an increasing concentration gradient of chemoattractant, is one of the main 
effector functions of chemokine binding to chemokine receptors. It is via chemotaxis 
that many cell types migrate through tissues in the body (see section 1.2.1). 
Chemokine receptors are present on multiple cell types, particularly immune 
cells such as leukocytes. CXCR1 and CXCR2 were the first chemokine receptors to 
be identified, and are predominantly expressed on neutrophils (Holmes et al., 1991; 
Murphy & Tiffany, 1991). Chemokine receptors were then identified as Rhodopsin 
class (formerly class A) GPCRs (Vassilatis et al., 2003). So far, 18 chemokine 
receptors have been identified that couple to Gαi proteins, with a further five 
exhibiting atypical behavior (Zlotnik and Yoshie, 2012). 
One such atypical receptor is D6. This chemokine receptor is known to bind 
12 CC chemokines, although it does not signal in response to their binding. D6 does 
not signal due the lack of the DRYLAIV motif in its second extracellular loop; as was 
described in section 1.3.1 this motif is critical for receptor coupling to G proteins and 
thus signalling. D6 undergoes constitutive internalisation and recycling to the 
membrane via the endosomes, which is where the receptor-bound chemokine is 
removed and targeted for degradation in the lysosomes. D6 therefore acts as a 
chemokine scavenger and regulates levels of inflammatory chemokines (Nibbs et al., 
2009). 
Another such atypical chemokine receptor is DARC (Duffy antigen receptor 
for chemokines). This receptor binds many inflammatory chemokines of both the CC 
and CXC classes. Like D6, it lacks the DRYLAIV motif and thus cannot couple G 
proteins or induce signalling. However in contrast to D6, DARC promotes migration 
by acting as a transporter of chemokines. DARC was shown to be localised 
intracellularly with chemokines, suggestive of a role in their internalisation. It was 
also shown that it underwent transcytosis, transporting chemokines from one side of 
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endothelial cells to the other. Thus, by moving tissue-derived chemokines to the 
luminal side of the endothelium, DARC supports the chemotaxis of leukocytes in the 
blood vessels (Pruenster et al., 2009). 
 
Chemokine receptor classification follows that of chemokines; there are four 
families – CC, CXC, CX3C and XC – that are based on the relative position of 
cysteine pairs within the chemokine. While chemokines are denoted 
CCL/CXCL/CX3CL/XCL, their cognate receptors are denoted CCR/CXCR/CX3-
CR/XCR. 
To date, 18 chemokine receptors have been identified that induce chemotaxis 
via G proteins. A further 5 atypical receptors have als o been identified that do 
not induce chemotaxis. As there are 48 known chemokines, some chemokines 
evidently bind to more than one receptor. For example, the receptor CCR1 binds the 
chemokines CCL3, CCL5, CCL7, CCL8, CCL13, CCL14, CCL15, CCL16, and 
CCL23. Other receptors such as CXCR4 only bind one chemokine, in this case 
CXCL12. To add a further layer of complexity to this system, some chemokines bind 
to multiple receptors; CCL5 for example binds to CCR1, CCR3 and CCR5 (Zlotnik 
and Yoshie, 2012). The chemokines and their cognate receptors are shown in table 1-
2. 
This phenomenon of multiple chemokines binding to one receptor, and 
multiple receptors binding one chemokine, has been commonly described as 
chemokine ‘promiscuity’ and suggests a redundancy within the system (Lukacs et al., 
1999; Power et al., 1995; Mantovani, 1999). Chemokines were first characterised by 
their ability to stimulate chemotaxis in vitro, before the complexity of receptor 
subtypes was realised. For example, before the different T-cell subsets such as TH1, 
TH2, Treg, and TH17 cells were discovered, CD3
+
 (cluster of differentiation notation 
for the T-cell receptor) T-cells were assayed for chemotactic ability to various 
chemokines. Some of the receptors that TH1 cells express include CXCR3 and CCR5, 
while TH2 and Treg cells express CCR4 and CCR8 (Bonecchi et al., 1998; Iellem et 
al., 2001). TH17 cells express CCR6 (Lim et al., 2008; Singh et al., 2008). Therefore, 
a mixed population of these cells migrated to a large number of chemokines due to 
the range of receptors expressed on the differing T-cell types. Without the knowledge 
that different sub-populations of cells existed, it was surmised that the different 
chemokines were performing redundant functions (Schall and Proudfoot, 2011). 
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The multiple chemokines and receptors may therefore not be redundant, but 
rather guide the migration of specific cell subsets with each performing specific 
functions. For example, the naturally occurring CCR5Δ32 mutation leads to a 
truncation of the last 32 amino acids from the C-terminus of CCR5. People with this 
mutation appear healthy, and in fact have increased resistance to HIV-1 infection 
since the virus uses CCR5 as a coreceptor for entry into T cells. This may have 
suggested that CCR5 was therefore playing a redundant role since a severe truncation 
of CCR5 that rendered it non-functional had no effect on health. However it was then 
discovered that people carrying the truncated form of CCR5 had an increased 
susceptibility to West Nile virus (Glass et al., 2006). CCR5 is expressed on TH1 cells, 
and was believed to play a role in restraining West Nile virus infection (Loetscher et 
al., 1998; Glass et al., 2006). Chemokine receptors therefore may have non-redundant 
roles that are not immediately apparent. 
 
1.3.2.1 – Posttranslational modification of chemokine receptors 
Chemokine receptors undergo posttranslational modifications in the Golgi 
apparatus or endoplasmic reticulum, and these processes have essential biological 
roles. N-glycosylation is a process in which carbohydrates are linked to the nitrogen 
atoms of asparagine (N) residues, whereas O-linked glycosylation involves linkage of 
carbohydrates to the hydroxyl-oxygen of serine (S) and threonine (T) residues (Spiro, 
2002). Tyrosine residues also can be sulphated (Moore, 2009). 
Glycosylation has been shown to be required for the intracellular trafficking 
of certain GPCRs. Mutants of the β2-adrenergic receptor in which sites of 
glycosylation were removed showed a 50% reduction in trafficking to the cell 
surface, however receptors that did reach the membrane showed no impairment in 
coupling to G proteins, indicating that the oligosaccharide additions were only 
necessary for receptor export to the cell surface and not receptor function (Rands et 
al., 1990). 
CCR5 was one of the first chemokine receptors to be shown to undergo 
glycosylation and sulphation. The chemokine receptor was shown to contain O-linked 
oligosaccharides such as sialic acid but not N-linked oligosaccharides. Inhibition of 
sulphation did not reduce cell-surface expression of CCR5 but did however reduce 
binding affinity of the chemokines CCL3, CCL4 and CCL5, as did mutation of 
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potentially sulphated tyrosines to phenylalanine (Farzan et al., 1999). Later studies 
confirmed these data, and also showed that O-linked glycosylation was also required 
for chemokine binding (Bannert et al., 2001). 
Similar results were shown in the case of murine CCR8. Mutants of this 
chemokine receptor in which potentially sulphated N-terminal tyrosines were mutated 
to phenylalanine had reduced ligand-binding capacity. Sulphation was believed to add 
extra negative charges to a region of the receptor that was already acidic, thereby 
facilitating interactions with CCL1, which like other chemokines is basic. The 
replacement of tyrosines with phenylalanines not only removed the sulphation sites, it 
introduced hydrophobic side-chains that were proposed to disrupt ionic interactions 
with the chemokine, further demonstrating the importance of tyrosine residues in the 
N-terminus of the chemokine receptor, which as described along with the 
extracellular loops binds chemokine. Like the β2-adrenergic receptor mutants, CCR8 
mutants in which glycosylation sites were removed showed reduced trafficking to the 
cell surface (Gutiérrez et al., 2004). 
The atypical chemokine receptor D6 was also shown to be glycosylated, 
however unlike CCR8 and other receptors (Farzan et al., 1999; Farzan et al., 2002; 
Fong et al., 2002; Preobrazhensky et al., 2000), this modification was not required for 
ligand binding. Glycosylated and deglycosylated D6 showed identical binding of the 
chemokine CCL3, as did D6 mutants that had glycosylation sites removed (Blackburn 
et al., 2004). With the exception of D6, chemokine receptor glycosylation and 
sulphation has shown to be important for ligand binding. 
Palmitoylation is another form of modification that can modulate the 
biological activities of receptors. Palmitoylation is the addition of a palmitate, a fatty 
acid, to cysteine residues. Bovine rhodopsin was the first GPCR demonstrated to be 
palmitoylated, on two cysteines in its C-terminus (Ovchinnikov et al., 1988). 
Subsequent research showed that CCR5 was also palmitoylated on its C-terminus, 
and that disruption of this modification led to a reduction in cell-surface expression 
and proteolytic degradation of the receptor (Percherancier et al., 2001; Blanpain et al., 
2001). Since cysteines in the C-termini are conserved in approximately 80% of 
GPCRs, palmitoylation likely has important functions in other chemokine receptors. 
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1.3.2.2 – Chemokine receptor signalling 
Chemokine binding to chemokine receptors is believed to occur in two steps. 
In the first step, the chemokine binds with high affinity to the N-terminus of the 
receptor. In the second step, the chemokine also binds to the extracellular loops of the 
receptor with low affinity. This model was postulated after the switching of 
CCR2/CCR5 N-termini and extracellular loops showed the high affinity interactions 
require the N-terminus; for example, CCR2 with its N-terminus exchanged with that 
of CCR5 only bound its ligand, CCL2, with low affinity (Monteclaro and Charo, 
1997). 
Subsequently, it was determined that different regions of the chemokine 
interact with specific residues of the extracellular loops, in addition to the 
transmembrane domains. The second extracellular loop of CCR5 was found to be 
important for ligand selectivity; the core domain of the chemokine interacted with the 
loop, and point mutants of the second extracellular loop were able to bind CCL5 but 
not CCL3 (Blanpain et al., 2003). 
Other domains within the receptor helices were also required for function. The 
TXP motif is a highly conserved motif in the transmembrane helix II of chemokine 
receptors, and the proline of this motif is required for maintenance of helical structure 
and in turn chemokine binding and activity (Govaerts et al., 2001). An aromatic 
cluster of amino acids around the TXP motif in transmembrane helices II and III were 
mutated in CCR5, which led to a reduction in chemokine activation but not binding 
(Blanpain et al., 2003). These aromatic residues were required for the interhelical 
interactions necessary to stabilise helical conformations in ligand-induced activation 
(Govaerts et al., 2003). 
Chemokine binding results in the receptor coupling to G proteins, which 
induces subsequent downstream signalling. As will be described, ligand binding to 
the N-terminus of the receptor results in a conformational shift of the transmembrane 
helices; in particular helices 3 and 6 tilt inwards which results in an opening up of the 
C-terminal face of the receptor. This allows signalling proteins such as G proteins to 
bind the receptor. 
 Chemokine receptors predominantly signal through Gαi proteins; migration 
of leukocytes in vitro and in vivo is significantly reduced after treatment with 
Pertussis toxin (PTX), a bacterial endotoxin that uncouples Gαi proteins from GPCRs 
by catalysing the ADP-ribosylation of the Gαi protein; this makes it unable to 
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exchange GDP for GTP and thus renders it inactive (Burns, 1988). After PTX 
treatment, lymphocyte and neutrophil motility was significantly reduced in 
chemotaxis assays (Spangrude et al., 1985), as was lymphocyte migration into the 
spleen (Cyster and Goodnow, 1995) and lymph nodes (Spangrude et al., 1984). PTX 
treatment was later shown to specifically inhibit chemokine receptor signalling; 
CXCL8 signalling was abolished after treatment with the toxin (Wu et al., 1993). In 
CXCR4, Gαi proteins were shown to bind to the third intracellular loop of the 
receptor (Roland et al., 2003). 
As described in section 1.3, Gαi proteins inhibit the signalling protein adenylyl 
cyclase. They also activate Rac, which is a member of the GTPase family of proteins 
that acts in the G protein signalling cascade (Belisle & Abo, 2000; Benard et al., 
1999). As a result of Rac activation, actin polymerisation occurs, which is essential 
for cell motility (Viola and Luster, 2008). It also appears that different isoforms of 
Gαi have opposing functions; in T cells, the Gαi2 isoform was required for CXCR3-
mediated chemotaxis, since deletion of this protein ablated the chemotactic response. 
In mice, deletion of the Gαi3 isoform however resulted in an increase in receptor 
signalling and the chemotactic response, indicating that it played an antagonistic role 
in CXCR3-mediated signalling (Thompson et al., 2007). 
 
Chemokine receptor signalling is a tightly regulated process. Due to the 
complexity of the chemokine system, in which different cells and tissues express 
varying levels of multiple chemokines, and the cells that respond can express a large 
combination of different receptor types, there needs to be a system in place to 
attenuate receptor signalling in order to fine-tune the chemotactic responses of 
migrating cells. 
One such mechanism for regulating this signalling activity is by receptor 
desensitisation, through the action of GPCR kinases (GRKs) and β-arrestins. β-
arrestins are proteins initially thought to only function by desensitising GPCRs by 
blocking interaction with G proteins (Lefkowitz and Whalen, 2004). Murine β-
arrestin-knockout cell lines however showed that internalisation of the β2-adrenergic 
receptor was significantly reduced, indicating that these proteins not only bound the 
C-terminus of GPCRs but mediated their endocytosis as a mechanism of receptor 
regulation (Kohout et al., 2001). 
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In order for β-arrestins to bind the GPCR and initiate endocytosis, they require 
GRKs to phosphorylate serine and threonine residues on the intracellular loops and 
C-terminus of the receptor, which leads to the binding of β-arrestins. This recruitment 
of β-arrestins thus prevents further G protein signalling due to the inability of the G 
proteins to couple with the receptor. The β-arrestins also serve as a scaffold for other 
proteins that in turn cause the receptor to internalise, leading to a reduction in 
signalling and therefore prevention of overstimulation of the cell (Borroni et al., 
2010; Vroon et al., 2006). β-arrestins recruit clathrin and its adaptor AP2, allowing 
receptor endocytosis to proceed via clathrin-coated pits, which are membrane 
invaginations that internalise the receptor (Borroni et al., 2010). β-arrestins have been 
shown to regulate signalling of the chemokine receptors CCR5 (Aramori et al., 1997), 
CXCR1 (Barlic et al., 1999), CXCR4 (Cheng et al., 2000), as well as the 
internalisation of the non-signalling receptor D6 (Galliera et al., 2004). 
β-arrestins have also been shown to signal as well as mediate receptor 
endocytosis. In addition to functioning as a scaffold for clathrin and its adaptor 
protein AP2 in order to induce endocytosis, β-arrestins also recruit signalling partners 
such as kinases in order to activate G protein-independent pathways. Such kinases 
include c-Jun amino-terminal kinase (JNK) and extracellular-signal-related-
kinases/mitogen-activated protein kinases (ERK/MAPK). These kinases then go on to 
phosphorylate and activate other signalling partners leading to processes (Reiter and 
Lefkowitz, 2006). 
Murine lymphocytes which were knockouts of β-arrestin and GRKs had 
impaired chemotactic ability; the β-arrestin2 and GRK6 knockout T and B cells 
showed significantly reduced CXCR4-induced migration to CXCL12, while GRK5 
knockouts were no different to WT cells (Fong et al., 2002). CXCR4-mediated 
chemotaxis to CXCL12 was enhanced by the transfection of cells with β-arrestin 2, 
and this effect was determined to be due to the action of p38 MAPK since a 
dominant-negative mutant of this kinase blocked the chemotactic effect of the β-
arrestin (Sun et al., 2002). A similar role was found for p38 MAPK in the signalling 
the viral chemokine receptor US28, which is constitutively phosphorylated by GRKs. 
The C-terminus of US28 including the β-arrestin-interacting domain were required to 
activate p38 MAPK (Miller et al., 2003). 
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These studies indicate that in addition to the desensitising roles described 
previously, β-arrestins and GRKs can be involved in receptor signalling through G 
protein-independent pathways. 
 
The role of GRKs and β-arrestins has been investigated in the chemokine 
receptor CCR7. CCR7, which is notably expressed on dendritic cells, binds the 
chemokines CCL19 and CCL21. CCL19 induces receptor internalisation, whereas 
CCL21 does not (Bardi et al., 2001); CCL19 was later determined to also cause 
receptor desensitisation by the recruitment of GRKs, leading to phosphorylation of 
the CCR7 C-terminus (Kohout et al., 2004). Interestingly, both chemokines induce 
chemotaxis through CCR7, meaning that the differential activity of these ligands is 
likely not through G proteins. 
This phenomenon of differential activity of ligands through a single receptor 
is known as biased agonism or functional selectivity; the premise of this being that 
different ligands stabilise unique receptor conformations leading to the recruitment of 
different signalling proteins and kinases, ultimately producing ‘biased’ signalling 
outputs (Kenakin, 2009). 
As described previously in section 1.3.1, several key domains and micro-
switches were identified as being important for the receptor activation process. Some 
of these sites were identified using GPCR crystal structures, whereas others used 
metal-ion chelators to determine key receptor domains. Histidine residues were 
introduced at sites of interest within the receptor, and zinc or copper chelated between 
them to form a bridge. This allowed helix-helix interactions to be studied, and led to 
the proposition of the global toggle switch model. This model states that the 
intracellular segments of the GPCR move outwards while the extracellular segments 
of the transmembrane helices move inwards; specifically, the extracellular portions of 
helices VI and VII tilt towards helix III (Schwartz et al., 2006; Hoffmann et al., 
2008). 
The model of receptor toggles and switches ties in with the notion of biased 
agonism, in that the full repertoire of micro-switches may not necessarily be toggled 
after ligand binding, and that different ligands activate different sets of switches 
(Nygaard et al., 2009). For example, to use the above example of CCL21 and CCL19 
inducing different effects upon GRKs and resulting receptor phosphorylation levels, it 
may be the case that CCL19 activates a slightly different set of micro-switches in the 
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receptor architecture compared to CCL21, thus affecting subtle conformational 
changes and therefore the recruitment of downstream signalling partners. 
The β2-adrenergic receptor has been shown to signal in a biased manner. 
Some ligands of this receptor activate both G protein- and β-arrestin-mediated 
signalling pathways. Three ligands however were found to show a bias towards the β-
arrestin pathway. The ligands CPB (N-cyclopentylbutanephrine), isoetharine, and 
ethylnorepinephrine showed a greater degree of β-arrestin recruitment and activation 
of β-arrestin-dependent kinases relative to G protein activation, when compared to 
other ligands (Drake et al., 2008). 
The biased pathways of β2AR signalling were characterised by fluorine-19 
nuclear magnetic resonance (
19
F-NMR). This involved labelling cysteines in helices 
V, VII and VIII with 2,2,2-trifluoroethanethiol. The movements of the receptor 
helices altered the chemical shifts of the labelled cysteines; by comparing the 
variation in shifts resulting from different agonists binding to the receptor, it could be 
determined that some agonists induced different receptor conformations to others. For 
example, the β-arrestin biased ligand isoetharine produced shifts in helix VII, whereas 
the unbiased agonist isoproterenol did not produce such a shift (Liu et al., 2012). 
Previous studies have shown that GRK phosphorylation of β2AR – which is necessary 
for β-arrestin recruitment – occurs on helix VII, and that the Gα subunit contacts 
helices V and VI of the receptor without contacting helix VII (Nobles et al., 2011; 
Søren et al., 2011; Westfield et al., 2011). 
Together, these data indicate that the different ligands of the β2AR stabilise 
distinct conformations leading to biased signalling outputs. Biased signalling through 
chemokine receptors such as CCR7 may therefore occur in a similar manner, due to 
both structural conservation between GPCRs and the shared repertoire of signalling 
proteins they recruit. 
 
1.3.2.3 – Helix VIII 
Like other GPCRs, chemokine receptors contain a highly conserved region 
downstream of helix VII. This region in other receptors such as rhodopsin is known 
as helix VIII, an amphipathic alpha helix running parallel to membrane due to a 
concentration of lipophilic residues on one side and hydrophilic residues on the other 
side. However, as described in section 1.3.1, the crystal structure of the chemokine 
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receptor CXCR4 did not reveal the presence of this helix, when compared to the 
structures of the human β2-adrenergic receptor, the human A2A adenosine receptor, 
and bovine rhodopsin. In addition, compared to other chemokine receptors this region 
is less conserved in CXCR4; in particular it lacks a phenylalanine at the end of helix 
VIII and a putative cysteine palmitoylation site further downstream which would 
anchor the helix in the membrane. This may account for the lack of the helix 
observed in the receptor structure. While some other chemokine receptors lack this 
phenylalanine they possess other hydrophobic amino acids such as leucine or 
isoleucine which are believed to play a similar role in helix VIII formation (Wu et al., 
2010). 
Helix VIII however was identified in other GPCR structures, such as bovine 
rhodopsin, the human β2-adrenergic receptor, the human adenosine A2A receptor, 
squid rhodopsin, the murine δ-, and μ-opioid receptors, and the human κ-opioid 
receptor (Cherezov et al., 2007; Granier et al., 2012; Jaakola et al., 2008; Manglik et 
al., 2012; Murakami & Kouyama, 2008; Palczewski et al., 2000; Wu et al., 2012). 
The C-terminal helix VIII has been shown to play an important role in GPCR 
function. Leukotriene B4 (LTB4) is a chemotactic lipid inflammatory mediator that 
signals through the GPCRs BLT1 and BLT2. Like other GPCRs, BLT1 has a putative 
C-terminal helix VIII downstream of helix VII. Receptor mutants of BLT1 in which 
the helix VIII region was truncated or substituted bound a greater level of LTB4 than 
WT BLT1 despite comparable surface expression. In addition, the mutant receptors 
showed prolonged calcium signalling compared to WT receptors (Okuno et al., 
2003). Molecular modelling and helical wheel analysis predicted that an interaction 
between a tyrosine in helix VII and a phenylalanine in helix VIII stabilised the 
inactive BLT1 conformation by keeping helix VIII at a right-angle to membrane. 
Therefore, mutation of this region prevented this stabilisation, thus accounting for the 
increases seen in receptor activation (Okuno et al., 2003, 2005). Point mutations of 
leucines of this region indicated that helix VIII inhibits LTB4-dependent 
internalisation of BLT1 in addition to inhibiting the inactive receptor conformation 
(Aratake et al., 2012). 
The protease-activated receptors (PARs) are an interesting subtype of 
Rhodopsin family, in that in order to be activated they have to be proteolytically 
cleaved. For example, PAR1 is cleaved by proteases such as thrombin at its N-
terminal extracellular domain, revealing a tethered ligand that activates the receptor. 
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Activated PAR1 then induces processes such as platelet aggregation (Vu et al., 1991). 
Molecular modelling of PAR1 predicted a C-terminal helix VIII, while truncations of 
this region resulted in a receptor that activated poorly in response to thrombin. More 
fine-grained analysis of this region involved point mutagenesis of potentially critical 
amino acids to determine their specific contribution to receptor function. Mutation of 
glutamic acid 377 and aspartic acid 379 in helix VIII – which were predicted to form 
an interaction with intracellular loop 1 and helix VII, respectively – resulted in 
reduced receptor activation. The authors of this study postulated a 7-8-1 mechanism, 
in which helix VII interacted with helix VIII, which in turn interacted with 
intracellular loop 1, resulting in PAR1 activating Gq proteins (Swift et al., 2006). 
Similar results were obtained with the β1-adrenergic receptor (β1AR). This 
receptor shares 48% sequence similarity with its related receptor, β2AR. Helix VIII 
was identified in β2-AR (Rosenbaum et al., 2007), and is strongly conserved between 
the two receptors, indicating that β1AR likely also possesses this C-terminal motif. 
Like β2AR and rhodopsin, it was predicted that polar side chains of helix VIII such as 
arginine, lysine and glutamine would be clustered on the side facing the cytoplasm. 
Point mutations of amino acids in this region disrupted ligand binding to the receptor; 
mutation of the polar aspartic acid 382 to a non-polar leucine reduced ligand binding 
by 200-fold. Neutralising or reversing the charge of arginine 384 by mutating it to 
glutamine or glutamic acid resulted in a constitutively active receptor that was 
resistant to desensitisation. Like aspartic acid 382, this arginine was predicted to be 
on the cytosolic face of helix VIII, and due to their roles in receptor activation 
believed to be sites of G protein coupling (Delos Santos et al., 2006). 
Similar roles have been observed for helix VIII in other GPCRs. In the 
thyrotropin-releasing hormone receptor it was shown to be phosphorylated by GRKs 
(Gehret et al., 2010); helix VIII in the bradykinin receptor was shown to be involved 
in receptor trafficking and signalling (Feierler et al., 2011); and residues within this 
region of the cannabinoid receptor 1 were required for ligand binding (Ahn et al., 
2010). 
The viral chemokine receptor ORF74 is encoded by the Kaposi sarcoma-
associated herpesvirus 8 and shares a high degree of homology with human 
chemokine receptors, and with CXCR2 in particular. ORF74 is constitutively active 
and binds multiple human chemokines including CXCL1, CXCL8, CXCL10, 
CXCL11, and CXCL12. Some of these chemokines, such as CXCL1, act as agonists 
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by increasing the activity of the receptor, while others such as CXCL12 act as inverse 
agonists and reduce the activity of the receptor. The broad range of ligands for 
ORF74 supports its role in tumourigenesis. ORF74 is also constitutively active, and 
acts as an oncogene by using chemokine signalling to drive endothelial proliferation 
and inflammatory cell recruitment (Holst et al., 2001). 
As in many other GPCRs, helix VIII of ORF74 plays an important role in 
receptor function and chemokine binding. Despite showing normal levels of cell-
surface expression, a helix VIII truncation mutant of ORF74 showed significantly 
reduced receptor activation in response to CXCL1 and CXCL10. This mutant also 
lost the ability to bind CXCL8, while retaining the ability to bind CXCL11. A point 
mutant of glutamic acid 323 produced similar results. These results indicated that 
helix VIII of ORF74 and the residue E323 in particular contact G proteins and that 
their removal rendered the receptor unable to couple to these proteins and induce 
signalling. CXCL8 binding was ablated since it has been could only bind ORF74 
when it was coupled to G proteins; CXCL10 binding was retained since it did not 
require coupling to G proteins (Verzijl et al., 2006). 
 
In summary, helix VIII plays a critical role in many GPCRs including the 
chemokine receptor ORF74. Helix VIII is involved in many aspects of receptor 
function, including ligand binding, trafficking to the cell surface, and desensitisation 
of signalling. Polar residues on the cytosolic side of helix VIII likely contact G 
proteins, as demonstrated in multiple crystal structures and mutational studies. 
The absence of helix VIII in CXCR4 structure was believe to be due to the 
lack of a cysteine residue downstream of this region (Wu et al., 2010). It was 
described in section 1.3.2.1 that chemokine receptors such as CCR5 are palmitoylated 
on C-terminal cysteines. Due to the lipophilic nature of these palmitate groups, they 
would likely serve to anchor parts of the C-terminus to the membrane. Since helix 
VIII in other GPCRs has been shown in other GPCRs to lie parallel to the membrane, 
this palmitoylation likely plays a role in this orientation. The CXCR4 C-terminus 
contains no cysteine residues, unlike other chemokine receptors. Therefore, 
considering this and the highly conserved sequences of this region, helix VIII likely 
exists in other chemokine receptors. 
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1.4 – CCR4 
The 360 amino-acid chemokine receptor CCR4 was first cloned from the 
basophil cell line KU-812 (Power et al., 1995). At the time, only five other 
chemokine receptors had been identified; CXCR1 and CXCR2 (Holmes et al., 1991; 
Murphy & Tiffany, 1991), CCR5 (Neote et al., 1993), CCR2 (Charo et al., 1994), and 
the Duffy antigen receptor for chemokines (DARC) (Neote et al., 1993). Sequence 
comparisons showed CCR4 had 49% identity to CCR5 and 47% identity to CCR2. 
CCR4 was later discovered to respond to the chemokines CCL17 (TARC; thymus 
and activation-regulated chemokine) (Imai et al., 1997) and CCL22 (MDC; 
macrophage-derived chemokine) (Imai et al., 1998). Both chemokines bound 
selectively to CCR4-transfected cells, and induced cell migration and calcium release. 
The ligands CCL17 and CCL22 have been reported to exert differential 
effects upon the receptor; CCL22 treatment induced significant receptor 
internalisation whereas CCL17 did not, when surface expression was assessed by 
flow cytometry. Confocal microscopy showed intracellular pools of CCR4 following 
CCL22 treatment but not after CCL17 treatment. This internalisation required lipid 
rafts; filipin, an inhibitor of raft-mediated endocytosis, prevented CCL22-induced 
internalisation. Pertussis toxin (PTX), which uncouples G proteins from receptors, 
did not affect internalisation. This indicated that the CCL22-induced internalisation 
did not require G protein coupling (Mariani et al., 2004). These data suggest that the 
ligands have differential activity through the receptor. 
As described in section 1.3.2.2, GPCRs can signal through both G protein- 
and β-arrestin-mediated pathways. It also has been shown that the signalling of a 
ligand through a receptor does not necessarily lead to the equal activation of both 
pathways. Some ligands induce more G protein-biased signalling outputs while others 
lead to β-arrestin-biased outputs. This biased agonism may be a product of subtly 
different receptor conformations induced by different ligands for a receptor. Figure 1-
8 shows the difference between balanced and biased agonism. 
In the case of CCR4, the described data show that CCL22 induces a greater 
level of CCR4 internalisation compared to CCL17, indicative of potential β-arrestin-
biased recruitment in response to CCL22 binding to the receptor. The selective 
activity of GRKs has been shown for CCR7 with respect to phosphorylation of its C-
terminus in response to CCL19 but not CCL21(Kohout et al., 2004), and CXCR4-
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mediated chemotaxis required β-arrestins (Fong et al., 2002b; Sun et al., 2002). Since 
these chemokine receptors show outputs that involve β-arrestins and biased ligand-
induced signalling, the CCR4 data suggest that it too signals differentially in response 
to its ligands CCL17 and CCL22. 
In addition, the highly conserved helix VIII region is likely located in the C-
terminus of CCR4. This helix VIII has been identified in the C-terminus of 
Rhodopsin-type GPCRs and as described has many important roles in receptor 
function and ligand binding. 
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Figure 1-8 – Biased agonism through a GPCR 
In balanced signalling (a), an agonist induces equal levels of G protein- and β-arrestin-
mediated signalling. In biased agonism however (b), an agonist can induce a greater level 
of β-arrestin signalling (top) or a greater level of G protein signalling (bottom). Adapted 
from Rajagopal et al., 2010. 
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1.4.1 – CCR4 and its ligands in the immune system 
Most chemokine genes are clustered into 2 groups on the chromosomes; a 
CXC cluster on 4q13.3, and a CC cluster on 17q12. These clusters contain 
chemokines that are mainly involved in inflammatory responses (Zlotnik and Yoshie, 
2012). CCL17 and CCL22 however are located on 16q13 (Nomiyama et al., 1998). 
This suggests that these chemokines, and thus CCR4, have a role in homeostasis since 
other known homeostatic chemokines are also located outside of the CC 
inflammatory cluster. For example, CCL19 and CCL21, which bind CCR7, are 
located on 9p13 (Nagira et al., 1997; Yoshida et al., 1998). These chemokines direct 
migration of CCR7-expressing dendritic cells during immune surveillance and 
passage through the lymphatic tissues (Förster et al., 2008). 
Indeed, CCR4-expressing Treg cells (Iellem et al., 2001) are involved in 
immune homeostasis. Treg cells express the transcription factor Foxp3, which is 
critical for their suppressive function; Foxp3 knockout mice show a paucity of these 
cells and develop autoimmune diseases and cancers. The immune responses to 
foreign antigens also became stronger in these mice (Sakaguchi et al., 2008). Foxp3 
enhances transcription of factors associated with immune suppression such as 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4); this protein transmits inhibitory 
signals to T cells upon Treg contact (Waterhouse et al., 1995). Therefore, the lack of 
these cells removed attenuating mechanisms resulting in the development of a strong 
immune response. 
Treg cells also require the presence of the cytokine interleukin 2 (IL-2); mice 
lacking this cytokine have similar phenotypes to Foxp3 knockouts (Sakaguchi et al., 
2008). Since IL-2 is produced by activated T cells, which are the targets of Treg cells, 
IL-2 serves as a positive feedback mechanism to control the T cell response; if the T 
cell population becomes too large the resulting levels of IL-2 lead to Treg development 
and thus suppression of the response (Laurence et al., 2007). 
In addition to their role in immune homeostasis, CCR4, CCL17, and CCL22 
are involved in inflammatory reactions, indicating that the chemokines have dual 
function. CCR4 is also expressed by TH2 cells (Bonecchi et al., 1998), which are 
involved in the immune responses to allergens and parasites; these cells release 
cytokines such as interleukin 4 (IL-4) and 5 (IL-5) (Mosmann and Sad, 1996; 
Mosmann et al., 1986). IL-4 is required for TH2 cell differentiation, while IL-5 
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mediates eosinophil activation. Eosinophils subsequently release cytotoxic granules 
in an effort to combat parasite infection (Sanderson, 1992). Both CCL17 and CCL22 
are produced by dendritic cells, which are used to attract both regulatory (Treg) and 
inflammatory (TH2) CCR4-expressing T cells (Tang and Cyster, 1999; Sallusto et al., 
1999). 
Mast cells are another cell type involved in the inflammatory response. Mast 
cells express the receptor FcεRI, which binds the Fc portion of the antibody IgE with 
high affinity. B cells produce this antibody, which after binding to mast cells and 
cross-linking by antigen induces degranulation, a process by which granules 
containing mediators such as histamine are released into the extracellular medium. 
This leads to capillary dilation and thus swelling, redness and recruitment of other 
inflammatory cells (Williams and Galli, 2000). Mast cells have since been shown to 
express CCR4, both on those derived from cord blood (Juremalm et al., 2002), and on 
those obtained from the airways of patients with allergic asthma (Kaur et al., 2005). 
CCR4 and therefore its chemokines may be involved in the actions of these 
inflammatory cells during the immune response to allergens. 
 
1.4.2 – CCR4 and its ligands in disease 
As has been described, GPCRs constitute 1% of all human genes and are 
involved in a wide variety of cellular processes. It is therefore unsurprising GPCRs 
are also involved in disease; indeed, half of all clinically-used drugs target GPCRs 
(Gurevich and Gurevich, 2008). Chemokine receptors, due to their important role in 
the immune system are thus implicated in allergy, autoimmunity, inflammatory 
conditions and other associated pathologies. CCR4 and its ligands are associated with 
several diseases such as asthma, atopic dermatitis, allergic rhinitis, and some cancers. 
Asthma is an inflammatory disease, typically characterised by eosinophilic 
inflammation, elevated IgE and TH2 cytokine production, airway hyperresponsiveness 
(AHR), and mucus secretion (Heijink and Van Oosterhout, 2005; Lloyd and Hessel, 
2010). CCR4-expressing TH2 cells are a major component of the disease. In asthma, 
allergen that passes through the epithelial barrier of the lungs is processed by 
dendritic cells and presented to T cells, leading to the generation of helper cells. TH2 
cells, while not the only subset involved in the pathogenesis of asthma, are important 
drivers of inflammation. They secrete the cytokines IL-4, IL-5 and IL-13. IL-4 
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promotes further TH2 activation, IL-5 activates eosinophils, and IL-13 stimulates B 
cells to produce the antibody IgE. IgE binds mast cells with high affinity, leading to 
histamine and cytokine release, causing swelling and further cell recruitment (Qian 
and Wahl, 2009). 
CCR4-positive cells have been identified in the skin (Campbell et al., 1999a) 
and implicated in atopic dermatitis. Patients with the disease had increased levels of 
CCL17, which correlated with increased eosinophils numbers since CCR4
+
 TH2 cells 
induce eosinophilia via the action of IL-5. In the skin lesions, CCL17 was present in 
dendritic cells, keratinocytes and endothelial cells (Vestergaard et al., 2000; 
Kakinuma et al., 2001), indicating that local cells were inducing CCR4-positive cell 
migration to the site of inflammation. 
CCR4 is also implicated in the pathogenesis of various cancers such as adult 
T-cell leukemia (ATL). ATL is caused by the human T-cell leukaemia virus type 1 
(HTLV-1), which infects CD4
+
 T-cells. The majority of HTLV-1-infected cells 
express CCR4, which then migrate to CCL17 or CCL22 in the tissues and act as Treg 
cells, contributing to tumour survival by limiting the host immune response (Yoshie, 
2005). 
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1.4.3 – CCR4 as a therapeutic target 
Due to its role in disease, CCR4 is a potential target for therapeutic 
intervention. Since in diseases such as asthma and atopic dermatitis there is a large 
influx of CCR4-expressing TH2 cells into the afflicted tissue, blocking CCR4-
dependent migration could provide a way to ameliorate disease states; by limiting the 
number of TH2 cells, production of the cytokines IL-4, IL-5 and IL-13 would be 
reduced, thus preventing further exacerbation of the immune response. Since some 
cancers rely on CCR4-directed metastasis (Olkhanud et al., 2009), inhibition of this 
receptor would aid in the therapy of these diseases. In addition, in diseases such as 
Hodgkin’s lymphoma, CCR4-expressing Treg cells are recruited in order to dampen 
local immune responses and aid the tumour in immune evasion (Ishida et al., 2006). 
Recently, the anti-CCR4 antibody mogamulizumab has gained marketing approval 
for treatment of adult T-cell leukemia (Ishida and Ueda, 2011; Beck and Reichert, 
2012). 
The effect of blocking or removing CCR4 or CCR4-positive cells has been 
investigated in several studies. TH2 cells from CCR4-deficient mice were adoptively 
transferred to WT mice, after which they showed a failure to migrate to the lung in 
response to allergen exposure, in addition to showing a reduction in the level of TH2 
cytokines IL-4, IL-5 and IL-13. Levels of CCL17 were also significantly reduced 
compared to WT mice (Mikhak et al., 2010). This shows that CCR4 was required for 
maintenance of the TH2 response. Similar results were observed after blockade of 
CCL17 and CCL22 in mice, which resulted in reduced CD4
+ 
T cell and eosinophil 
recruitment and cytokine production (Kawasaki et al., 2001; Lloyd et al., 2000). 
Conflicting studies have also been performed that do not show CCR4 
blockade ameliorating disease states. For example, treatment of allergic airways 
disease in guinea pigs by CCR4 blockade with the 10E4 antibody did not reduce the 
number of CCR4-positive cells migrating to the lung. Eosinophil numbers and 
chemokine production was also unaffected (Conroy et al., 2003). In addition, CCR4 
knockout mice showed no difference to WT mice in a model of allergic airways 
disease. Interestingly however the same mice showed resistance to endotoxic shock 
induced by the bacterial membrane component lipopolysaccharide (LPS). These mice 
showed decreased mortality and production of macrophage-associated cytokines such 
as TNF-α in response to LPS (Chvatchko et al., 2000). 
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There are several factors to consider when attempting to block CCR4 for 
therapeutic purposes. Antagonising CCR4 on TH2 cells may result in compensation 
by the receptor CCR8, since it is also expressed on this T cell subset (Roos et al., 
1997; Iellem et al., 2001; Panina-Bordignon et al., 2001). CCR8 expression has also 
been shown to increase in asthma, along with its ligand CCL1 (Mutalithas et al., 
2010; Montes-Vizuet et al., 2006). This has been proposed to explain the failure of 
CCR4-blocking studies. 
Studies of CCR8 have also shown variable results; some studies of CCR8 
knockout mice have shown no difference to WT mice whereas others showed a 
reduction in airways inflammation (Goya et al., 2003; Gonzalo et al., 2012; Chensue 
et al., 2001; Chung et al., 2012). If CCR4 and CCR8 are indeed compensating for one 
another in these studies, it may be necessary to block both chemokine receptors in 
order to reduce TH2 cell migration. The observed variability in CCR4 and CCR8 
studies may also be due to the different models used and also a result of blocking of 
all CCR4- and CCR8-expressing cells. CCR4 and CCR8 are also expressed on Treg 
cells, and blocking these in addition to TH2 cells may counteract any anti-
inflammatory effects; Treg cells act to attenuate the immune response, and their 
blockade could have the potential to exacerbate rather than ameliorate inflammatory 
conditions. Thus it would be desirable to block TH2 cells but not Treg cells. A method 
of selectively targeting cell populations would prove invaluable in developing 
therapeutic chemokine receptor antagonists. 
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1.4.4 – Small molecule antagonists of CCR4 
Agonists and antagonists are ligands that either promote or block receptor 
activation. These are typically classified as either orthosteric or allosteric. Orthosteric 
ligands bind to the same site as the endogenous ligand, and thus have to compete with 
it for receptor binding. Allosteric ligands however bind to site distinct from the 
ligand-binding site and modulate receptor function from there (Müller et al., 2012). 
Agonists and antagonists of both classes have been investigated for their therapeutic 
benefit due to their ability to alter receptor function. 
In the context of chemokine receptors, receptor antagonists are a well-
researched group of ligands since many chemokine- and chemokine receptor-related 
diseases involve the infiltration of unwanted inflammatory cells. By antagonising the 
chemokine receptors responsible for directing the migration of these cells, it may be 
possible to ameliorate disease states and symptoms. For example, as previously 
described in section 1.4.2, asthma involves the influx of large numbers of CCR4-
expressing TH2 cells into the lung. These cells then propagate an immune response to 
allergen resulting in the accumulation of eosinophils and other inflammatory cells 
that cause damage to the tissues. By blocking CCR4 with an antagonist the aim would 
be to prevent this TH2-mediated response. 
Small molecule drugs are of interest to pharmaceutical companies since their 
small size allows them to be administered orally, rather than intravenously as is done 
for larger molecules such as antibodies. Allosteric antagonists of chemokine receptors 
are of particular interest as they provide a feasible way for a small molecule to block 
the function of large proteins. In addition, unlike orthosteric antagonists, allosteric 
antagonists cannot be competed with; in a disease state, there may be a large excess 
of endogenous ligand meaning that the dose of orthosteric antagonist necessary to 
inhibit the receptor response would be quite large. By using an allosteric antagonist 
this problem could be bypassed; by modulating receptor function to prevent it from 
binding ligand, the receptor response could be blocked with a comparatively lower 
dose. Another important property of allosteric ligands is that they are probe 
dependent, meaning that their effects on different orthosteric ligands are not the same 
(Scholten et al., 2012). For example, a small molecule metal ion chelator complex has 
been shown to enhance CCL3 binding for CCR1 while also blocking CCL5 binding 
(Jensen et al., 2008). 
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As described in section 1.3.2.2, endogenous orthosteric ligands of GPCRs can 
be biased agonists of the receptors. For example, the C-terminus of CCR7 is 
phosphorylated by GRKs in response to binding by CCL19 but not CCL21 (Kohout 
et al., 2004). Other examples include the preferential activation of β-arrestin 
signalling over G protein signalling by some β2-adrenergic receptor ligands and not 
others (Drake et al., 2008). This phenomenon relates to the concept of allostery, in 
that different ligands modulate the receptor in a way that results in differential 
signalling outputs. Allosteric antagonists in the same fashion can modulate the 
different signalling pathways for the same ligand; for example, an allosteric 
modulator of a glutamate receptor enhanced the calcium mobilisation induced by its 
orthosteric agonist but decreased the level of kinase activation (Zhang et al., 2005). It 
may then also be possible for an allosteric antagonist to selectively inhibit the 
responses of one orthosteric ligand and not another. To use the example of 
chemokines and their role in disease, it may be possible to target the response of 
CCR4 to CCL17, which as shown is a ligand highly expressed in atopic skin diseases, 
but leave the CCR4 response to CCL22 unaffected. Selectively inhibiting the 
response to specific ligands may therefore provide a way to reduce the side-effects 
associated with less targeted therapies (Galandrin et al., 2007). 
Many allosteric chemokine receptor antagonists have been developed, for 
receptors including CCR1 (Vaidehi et al., 2006; de Mendonça et al., 2005), CCR2 
(Mirzadegan et al., 2000), CCR4 (Andrews et al., 2008), CCR5 (Garcia-Perez et al., 
2011; Watson et al., 2005), CXCR1/CXCR2 (Bertini et al., 2012), CXCR3 (Scholten 
et al., 2012), and many others (Scholten et al., 2012). 
Notable examples include the CCR5 inhibitor Maraviroc, which is an 
allosteric antagonist of CCR5. Maraviroc binds to a region within the transmembrane 
helices of CCR5 and prevents it from binding the chemokine CCL3. CCR5 serves as 
a co-receptor for HIV entry, and Maraviroc has been licensed for HIV therapy. The 
allosteric mechanism of inhibition of CCL3 binding also prevents CCR5 from 
binding the viral gp120 glycoprotein; Maraviroc induces conformational changes that 
prevent the second extracellular loop of CCR5 from interacting with a loop structure 
in gp120 (Garcia-Perez et al., 2011). Maraviroc is both the first chemokine receptor 
antagonist to pass clinical trials and the first anti-retroviral drug that does not target 
viral proteins. 
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AMD3100, a CXCR4 antagonist, was also developed for HIV treatment since 
some strains of the virus use CXCR4 to enter macrophages, but later withdrawn due 
to toxicity issues. In mice, CXCR4 and its ligand CXCL12 were shown to be required 
for the retention of haematopoietic stem cells in the bone marrow, most likely to 
maintain a reserve of these cells and support their survival (Sugiyama et al., 2006). 
This stem cell retention was disrupted in human patients treated with AMD3100, 
leading to the mobilisation of these cells from the bone marrow into peripheral 
tissues. As a result of this, AMD3100 was licensed as plerixaflor/Mozobil for 
autologous bone marrow transplant patients suffering from non-Hodgkin lymphoma 
and multiple myeloma (De Clercq, 2010). 
Despite these successes, many chemokine receptor antagonists have failed to 
pass clinical trials for several reasons. One such reason is toxicity or unwanted side-
effects; the CCR5 antagonist aplaviroc entered clinical trials for HIV-1 treatment but 
resulted in high liver toxicity (Allegretti et al., 2012). A CCR3 antagonist was 
discontinued due to it also inhibiting the human ether-a-go-go related gene (hERG) 
ion channel (Pease, 2011). The hERG protein is a potassium-selective ion channel 
involved in cardiac function, specifically the beating of the heart. Since several hERG 
inhibitors led to arrhythmia and death, other antagonists in development are screened 
for anti-hERG activity and discontinued if this activity is too high (Sanguinetti and 
Tristani-Firouzi, 2006). 
Poor efficacy has also been a problem in chemokine receptor antagonist 
development. The development of the CCR1 antagonist BX 471 for multiple sclerosis 
was stopped in Phase II trials after it failed to show efficacy. A similar lack of 
efficacy was shown for GW701897B, a CCR3 antagonist indicated for allergic 
rhinitis. A CXCR3 antagonist, AMG487, also proved ineffective in Phase II trials for 
psoriasis (Pease and Horuk, 2009; Allegretti et al., 2012). 
Several factors may have contributed to these antagonists not producing the 
desired therapeutic outcome. One such factor relates to the apparent redundancy in 
the chemokine system, as described in section 1.3.2. For example, CCR1 and CCR2 
both guide the migration of macrophages, and since these cells are involved in the 
pathogenesis of rheumatoid arthritis both receptors were targeted for therapy as it was 
believed they were performing redundant functions. However, CCR1 has been shown 
to be the main driver of macrophage recruitment into arthritic joints, despite the 
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presence of CCR2 on these cells. This therefore explains the negative results of 
CCR2 antagonists for rheumatoid arthritis (Schall and Proudfoot, 2011). 
The correct dosage of antagonist is another factor that must be taken into 
account when trying to inhibit chemokine receptors. It has been postulated that in 
order to effectively inhibit a response the levels of drug in the blood must be high 
enough to bind over 90% of the target receptors, since positive feedback can result 
from even a small number of unoccupied receptors. Indeed, antagonists of CCR1 
used at high doses have shown positive clinical effects (Schall and Proudfoot, 2011). 
 
1.4.4.1 – Intrahelical and intracellular allosteric antagonists 
Allosteric antagonists typically bind a site within the transmembrane bundles 
of the receptor. Examples of antagonists binding in this fashion include the CCR1 and 
CCR3 antagonist UCB36526 (de Mendonça et al., 2005; Wise et al., 2007), the CCR1 
antagonist BX471, and the CCR5 antagonist Maraviroc (Dorr et al., 2005; Watson et 
al., 2005). These antagonists typically contain a positively charged amine group that 
binds a conserved glutamine in helix VII of the receptors. Within the transmembrane 
bundle exists a major and minor binding pocket for the antagonists; the former is 
defined by helices I, II, III and VI while the latter is defined by helices III, IV, V, VI 
and VII. The functional groups of the antagonists then bind to other amino acids that 
line these binding pockets. It is through binding to this site that the antagonists 
prevent receptor activation, specifically by preventing helix VI from rotating 
outwards to facilitate ligand binding. This prevents the breakage of the ionic lock that 
exists between the DRYLAIV motif and a glutamic acid in helix VI in many GPCR 
structures; this then prevents subsequent G protein activation (Nygaard et al., 2009; 
Thiele et al., 2011). 
Figure 1-10 shows the diversity of antagonist-binding pockets of GPCRs, 
based on crystal structures. Despite the preservation of the seven transmembrane 
domain structures of these receptors, the ligand binding pockets can vary quite 
significantly, due to variations in amino acid side chains that line the pockets and also 
the relative shifts in helix and extracellular loop conformations. For example, the 
adenosine A2A receptor has a much shallower pocket than the adrenergic receptors, 
while the histamine H1 receptor has an even deeper binding pocket. 
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Interestingly, it has been shown that the ligand-binding pockets are relatively 
inflexible. Analysis of GPCR structures suggests that these pockets have restricted 
conformational rearrangements; for example, the β2-adrenergic receptor ligand-
binding pocket was largely similar when crystallised with different antagonists and 
inverse agonists. While some ligands, such as CVX15 bound to CXCR4 shown in 
figure 1-9, induce larger helix shifts, small molecules generally do not lead to large 
conformational rearrangements. This therefore suggests that small molecule 
antagonists inhibit function by subtly affecting receptor conformation, and that 
different antagonists for a receptor would each occupy a largely similar binding 
pocket rather each binding to a specific portion of the receptor (Katritch et al., 2012). 
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Figure 1-9 – Antagonist binding pockets of GPCRs 
Diversity of the shape of the ligand-binding pocket of different GPCRs, based on crystal 
structures. Adenosine A2A receptor (a) forms a channel with the antagonist ZM241385 
positioned vertically. The β1- and β2-adrenergic receptors (b and c) have similar and 
highly accessible pockets that share the same residues for cyandopindolol and carazolol. 
CXCR4 has a large and open pocket than can bind the small molecule IT1t (d) and the 
large peptide CVX15 (e). Dopamine D3 receptor (f) has distinct extracellular and core 
sub-pockets; the latter is occupied by eticlopride. The histamine H1 receptor (g) has a 
deeper pocket than the other receptors. Rhodopsin (h) has a small, hydrophobic, and 
enclosed retinal-binding pocket. All pockets are shown in the same orientation. From 
Katritch et al., 2012. 
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Seven allosteric antagonists of CCR4 have been supplied by 
GlaxoSmithKline. Four of these are hypothesised to target the intrahelical site 
between the transmembrane domains of CCR4. Their structures are shown in figure 
1-10. These are believed to act via the classical mode of allosteric antagonism, in 
which the antagonist binds within the transmembrane bundle and prevents the 
receptor from shifting into an active conformation, thus blocking its activation. 
In addition to the antagonists that target the classical intrahelical site of the 
receptor, a novel class of antagonists was developed that bound the C-terminus of 
CCR4. Based on C-terminus exchanges of CCR4 and CCR5, it was found that the 
antagonists were specific for the C-terminus of CCR4. The compounds were 
modified to ester and carboxylic forms in order to test this; the more lipophilic esters 
could pass through the membrane and antagonise the receptor while the less 
lipophilic carboxylic acids could not do so and thus had reduced efficacy. Treatment 
of cells with saponin to permeabilise the membrane or using membrane-based assays 
gave similar results, indicating that these compounds did indeed bind the CCR4 C-
terminus (Andrews et al., 2008). 
GlaxoSmithKline has supplied three antagonists that are hypothesised to bind 
to this novel intracellular site of CCR4. The structures of these antagonists are also 
shown in figure 1-10. 
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Compound Source patent 
1 US7144903B2 (Amgen) 
2 WO2003051870A1 (Astra Zeneca) 
3 WO2004020584A2 (Bristol-Myers-Squibb) 
4 WO2004020584A2 (Bristol-Myers-Squibb) 
5 WO2003059893A1 (Astra Zeneca) 
6 US20060004010A1 (Ono) 
7 WO2007111227A1 (Astellas) 
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Figure 1-10 – Structures of CCR4 antagonists 
Seven allosteric CCR4 antagonists were supplied by GlaxoSmithKline, the structures of 
which are shown in panel A. Antagonists 1, 3, 4, and 7 are hypothesised to bind to the 
site within the transmembrane helices. Antagonists 2, 5 and 6 are hypothesised to bind 
to the novel site identified in the C-terminus of CCR4. Panel B shows the source patent 
for each of the antagonists. 
A 
B 
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1.5 – Project hypotheses and aims 
The three hypotheses of this project are as follows: 
 
 There is a structural basis for the CCL17 and CCL22 selectivity seen in 
ligand-induced endocytosis and desensitisation assays. 
 The ‘site 1’ group of allosteric CCR4 antagonists bind to a site within the 
transmembrane domains of the receptor. 
 The ‘site 2’ antagonists bind to a site on the C-terminus of CCR4. 
 
The first aim of this project was to investigate the biology of the chemokine 
receptor CCR4. This was performed using different CCR4 antibodies to explore the 
differences reported in receptor expression between these antibodies, and to compare 
the differing effects of the two ligands CCL17 and CCL22 on receptor internalisation 
and function. Mutation of amino acids within the seventh transmembrane domain and 
C-terminus was also performed in order to determine their contribution to receptor 
expression, chemokine binding, and receptor function. 
GlaxoSmithKline has supplied seven allosteric antagonists of CCR4, four of 
which are hypothesised to bind to the intrahelical site within the transmembrane 
bundle of the receptor, while the remaining three are hypothesised to bind the novel 
C-terminal site. 
The second and third aims of the project were to investigate the intrahelical 
and intracellular antagonists to validate the hypotheses that they bind the two 
allosteric sites. This was performed by mutating regions of the receptor that were 
predicted to bind the antagonists. The mutants were then tested for cell surface 
expression, chemokine binding, and functional abilities. Functional mutants were 
investigated for their ability to be inhibited by the antagonists, the rationale being that 
a mutant of a key antagonist-binding region would confer sensitivity of the receptor 
to the compound. Radiolabelled antagonists were also used to directly test the 
interaction of the antagonists with the mutant receptors. 
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2 – Materials and Methods 
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2.1 – Materials 
2.1.1 – Reagents 
All reagents unless otherwise stated were purchased from Sigma-Aldrich 
(Poole, UK). Media, PBS, and media additives were from Gibco (Invitrogen, Paisley, 
UK). Chemokines were from Peprotech (London, UK). The anti-HA ascites fluid was 
from Covance (Crawley, UK), the IgG1 antibody from Sigma-Aldrich, and the FITC-
conjugated polyclonal goat anti-mouse immunoglobulins (Fab’2 fragments) from 
Dako (Glostrup, Denmark). Radiolabelled chemokines were from Perkin-Elmer Life 
Sciences (Waltham, MA, USA). CCR4 antagonists and radiolabelled antagonists 
were synthesised by GlaxoSmithKline (Stevenage, UK). Restriction enzymes, DNA 
ladders, R buffer, and Pfu polymerase were from Fermentas (Glen Burnie, MD, 
USA). 
 
2.1.2 – Kits 
The Fast Plasmid Mini Kit was from Eppendorf (Stevenage, UK). The 
HiSpeed Plasmid Maxi Kit was from Qiagen (Crawley, UK). The QuikChange site-
directed mutagenesis kit was from Stratagene (Santa Clara, CA, USA). The Pierce 
BCA Protein Assay Kit was from Thermo Scientific (Rockford, IL, USA). 
 
2.1.3 – Media, buffers and solutions 
“Complete” RPMI:  500 ml RPMI 1640+GlutaMAX+HEPES 
    10% heat-inactivated certified FCS (50 ml) 
    50,000 units penicillin (5 ml 10,000 units/ml) 
    50 mg streptomycin (5 ml 10 mg/ml) 
    50 µM β-mercaptoethanol (500 µl 50 mM) 
    1 mM sodium pyruvate (5 ml 100mM) 
    1x non-essential amino acids (5ml 100x) 
Ampicillin:   100 mg/ml in H2O 
LB broth:   1 litre dH2O 
10 g LB powder 
100 mg ampicillin (1ml 100 µg/ml) after autoclaving 
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LB agar:   1 litre H2O 
10 g LB broth powder 
15 g agar powder 
100 mg ampicillin (1ml 100 µg/ml) after autoclaving 
50xTAE:   242 g Tris base 
750 ml deionised water 
57.1 ml glacial acid 
100 ml 0.5M EDTA 
FACS buffer:   PBS (500 ml) 
0.25% BSA (1.25 g) 
    0.01% sodium azide (500 µl of 10%) 
HEPES buffer:  50 mM HEPES 
    1 mM EDTA 
    in water, pH=7.4 using KOH 
A2 buffer:   50 ml HEPES buffer 
    1 tablet protease inhibitor cocktail (Roche, UK) 
SPA buffer:    20 mM HEPES 
    100 mM NaCl 
    10 mM MgCl2 
    in water, pH 7.4 (NaOH) 
Filtration agonist buffer: 20 mM HEPES 
    100 mM NaCl 
    10 mM MgCl2 
10 µg/ml saponin 
    0.1% BSA 
    in water, pH=7.4 (KOH) 
Filtration antagonist buffer: 20 mM HEPES 
    100 mM NaCl 
    10 mM MgCl2 
10 µg/ml saponin 
    in water, pH=7.4 (KOH) 
Whole-cell binding buffer: 0.1% BSA (0.2 g) 
    0.05% NaN3 (1 ml/10%) 
    in RPMI 1640 (200 ml), pH 7.4 (NaOH) 
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2.2 – Methods 
2.2.1 – Cell biology 
2.2.1.1 – Culture of L1.2 cells 
The murine L1.2 pre-B lymphoma and Hut78 T cell lines were cultured in 
liquid suspension in complete RPMI. Cells were kept in a humidified incubator, at 
37°C, 5% CO2. The cells were maintained at a density between 0.5 x 10
6
/ml and 1 x 
10
6
/ml, to ensure that they were in a log growth phase, as higher cell densities often 
resulted in suboptimal transfection efficiencies. Cell density was determined by 
mixing 10 μl trypan blue with 10 μl cells and counting using a haemocytomer and 
inverted microscope (Zeiss, Cambridge, UK). Trypan blue selectively stained dead 
cells blue, allowing them to be factored in when assessing viability. Complete RPMI 
was stored at 4°C. 
 
2.2.1.2 – Transient transfection of L1.2 cells with CCR4-containing plasmid DNA 
All steps were performed in a tissue culture cabinet, with the exception of the 
electroporation step. L1.2 cells were counted using a haemocytometer. 1.5 x 10
7
 cells 
were transferred to a sterile 50 ml tube, and centrifuged at 310 g, 21°C, for 5 minutes. 
50 μl (10.5 mg/ml) tRNA and 1 μg DNA per 1x106 cells were added to the bottom of 
a sterile cuvette with a 0.4 cm electrode gap (BTX Harvard Apparatus, Holliston, 
MA, USA). The supernatant of the centrifuged cells was decanted, and the pelleted 
cells resuspended in 800 μl RPMI, transferred to cuvette, and incubated at room 
temperature for 20 minutes. The cuvette was placed in a BioRad Gene-pulser 
(BioRad, Hercules, CA, USA), electroporated at 330 volts, 975 μF, and incubated at 
room temperature for 20 minutes. The contents of the cuvette were transferred to a T-
75 tissue culture flask containing 15 ml complete RPMI, and incubated for 5 hours at 
37°C. 150 μl 1M sodium butyrate was added to the flask to give a final concentration 
of 10 mM, and the cells incubated overnight at 37°C. The number of cells transfected 
could be varied depending on assay requirements; the maximum recommended per 
cuvette was 4 x 10
7
 cells. 
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2.2.2 – Molecular biology 
2.2.2.1 – Primer design 
Individual primer pairs were designed to generate CCR4 mutants, and 
synthesised by Invitrogen. Primers were approximately 35bp in length, and 
corresponded to the target residue and flanking regions. The codon of the target 
residue was altered in the primer sequence. For example, mutation of glutamic acid 
290 to alanine (E290A) involved changing the codon from GAA to GCA. Reverse 
complementary primers were also designed. Primer length was varied by several base 
pairs to ensure a higher percentage of cytosine and guanine compared to adenine and 
thymine. This gave the primers a higher melting temperature (Tm). The Tm was 
determined by using the formula supplied by the Stratagene QuikChange Site-
Directed Mutagenesis Kit: 
 
Tm = 81.5 + 0.41(%GC) – 675/N - %mismatch 
 
Where N is primer length in bases, and values for %GC and %mismatch are whole 
numbers. 
 
2.2.2.2 – Site-directed mutagenesis of WT CCR4 DNA template 
A 50 μl reaction mixture was composed using the reagents from the kit and 
the custom-designed primers. It was made in a 250 μl thin-walled PCR tube and 
placed in the thermal cycler (MJ Research, Waltham, MA, USA): 
 
5 μl 10X buffer 
1 μl dNTPs 
1 μl Pfu DNA polymerase 
1 μl forward primer (10 μM) 
1 μl reverse primer (10 μM) 
40 μl sterile water 
 
The reaction mixture was run on this programme: 
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1) 95°C for 30 seconds 
2) 55°C for 1 minute 
3) 68°C for 6 minutes 
4) Go to step 2, repeat 15 times 
5) 4°C indefinitely 
 
1 μl DpnI (10 units/µl) (Invitrogen) was added to the reaction mixture. 
Incubation at 37°C for one hour digested parental DNA. This was used to transform 
E. coli. The resulting DNA from a mini-prep was sent for sequencing to Eurofins 
(Germany); once the mutation of CCR4 was confirmed, a maxi-prep culture was 
seeded using the previously transformed bacteria. This was then used to generate a 
larger volume of mutant CCR4 DNA. 
 
2.2.2.3 – Transformation of Escherichia coli with CCR4 DNA 
DH5α One-Shot supercompetent E. coli (Invitrogen) were removed from -
80°C storage and thawed on ice. A 50 μl E. coli aliquot and 1 μl (10 ng/µl) plasmid 
DNA were pipetted into a 15 ml tube, swirled to mix, incubated on ice for 30 
minutes, heat shocked in a 42°C water bath for 45 seconds, and incubated on ice for 2 
minutes. 0.5 ml SOC medium (Invitrogen) was added, and the tube placed in a 37°C 
shaker at 200 RPM for one hour. An ampicillin agar plate was left to dry in a 37°C 
incubator during the incubation. 250 μl of the bacterial culture was pipetted onto the 
plate, and spread evenly using a sterile glass rod. The plate was incubated overnight 
at 37°C. 
 
2.2.2.4 – Bacterial culture 
2 ml LB broth and 2 μl 100 mg/ml ampicillin (Boehringer Ingelheim, 
Ingelheim am Rhein, Germany) were added to a sterile 15 ml tube. A single bacterial 
colony from an agar plate was picked using a sterile pipette tip, and the tip ejected 
into the 15 ml tube, which was incubated in a 37°C Innova 4000 shaker (New 
Brunswick Scientific, Enfield, CT, USA) at 200 RPM overnight. 
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2.2.2.5 – Mini-prep of bacterial culture 
 
The Eppendorf Fast Plasmid Mini Kit (Eppendorf, UK) was used to obtain 20 
μl purified DNA from 2 ml bacterial culture, with a typical yield of approximately 
200 ng/μl. 
 
2.2.2.6 – Restriction digest of purified plasmid DNA 
Purified plasmid DNA from a mini-prep was digested to ensure the presence 
of the CCR4 insert. The following were added to a tube, mixed, and incubated for 1 
hour at 37°C: 
 
1 μl Hind III (10 units/µl) 
1 μl Xho I (10 units/µl) 
2 μl R buffer 
5 μl DNA 
11 μl H2O 
 
2.2.2.7 – Agarose gel electrophoresis of restriction digest product 
A stock of 1% agarose in 1xTAE was composed by dissolving 5 g of agarose 
powder (Helena Biosciences, Gateshead, UK) in 500 ml of 1xTAE by heating in a 
microwave. 
This mixture was then adjusted to 1 litre in volume by adding deionised water. 
7 μl ethidium bromide (10 mg/ml) was added to the molten agarose. This was used to 
fill a gel mould fitted with a comb. Once cooled, the comb was removed and the gel 
placed in a horizontal electrophoresis tank and submerged in 1xTAE. 5 μl 1kb DNA 
ladder (Fermentas) was loaded into the leftmost well. 4 μl loading dye (Fermentas) 
was added to the restriction digest, mixed, and loaded in the well adjacent to the 
ladder. The electrophoresis machine was set at 100V for approximately 40 minutes. A 
UV transilluminator was used to visualise the bands. 
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2.2.2.8 – Maxi-prep of bacterial culture 
Once the authenticity of the CCR4 insert was confirmed by sequencing 
(Eurofins, Ebersberg bei München, Germany), 0.5 ml of culture was added to a flask 
containing 100 ml LB broth and 200 μl of 100 mg/ml ampicillin, and incubated in a 
37°C Innova 4430 shaker (New Brunswick Scientific) at 200 RPM overnight. This 
culture was used to generate 1.5 ml plasmid DNA, using the Qiagen HiSpeed Plasmid 
Maxi Kit. A typical yield was approximately 1000 ng/µl. 
 
2.2.2.9 – Measurement of CCR4 surface expression using flow cytometry 
16 hours following transfection of CCR4 DNA, the cells were counted and 
transferred to a 50 ml tube and centrifuged at 310 g for 5 minutes. The supernatant 
was discarded, and the cells resuspended in simple RPMI at a density of 10
7
 cells/ml. 
2 x 100 μl of cells were pipetted into FACS tubes and centrifuged at 4ºC at 
310 g for 5 minutes. The supernatant was discarded. The cell pellets were 
resuspended in 100 μl of 5 μg/ml anti-HA ascites fluid or IgG1 antibody. They were 
then incubated on ice for 30 minutes, and centrifuged at 310 g for 5 minutes. The 
supernatant was discarded, and both pellets resuspended in 100 μl of 2 μg/ml FITC-
conjugated polyclonal goat anti-mouse immunoglobulins (Fab’2 fragments), and 
incubated on ice for 30 minutes. 500 μl FACS buffer was added to the tubes, which 
were centrifuged at 310 g for 5 minutes. The supernatant was then discarded, the 
pellet resuspended in 450 μl FACS buffer and analysed using a FACSCalibur or 
FACSFortessa flow cytometer (BD Biosciences, San Jose, CA, USA). 
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2.2.3 – Functional assays 
2.2.3.1 – Chemotaxis of CCR4-transfected cells to increasing chemokine 
concentrations 
The chemotaxis assay was performed on transfected cells. Once expression 
had been confirmed by staining and flow cytometry, a 96 well chemotaxis plate 
(Neuroprobe, Gathersburg, MD, USA) was blocked by adding 30 μl 1% BSA (0.1 g 
in 10 ml simple RPMI) to each well, and incubating at room temperature for 30 
minutes. Solutions of 0.1 nM, 1 nM, 10 nM and 100 nM chemokine (CCL17 and 
CCL22 (Peprotech, London, UK) from 10 μM stocks) in RPMI containing 0.1% BSA 
were prepared. The 1% BSA was removed from the plate and 31 µl chemokine 
solution added to the wells in duplicate, in addition to 0.1% BSA as a buffer control. 
The membrane of the chemotaxis plate was attached on top of the wells, and 20 μl 
cell droplets (at 10
7
/ml) were pipetted onto this contact point. The lid of the plate was 
attached, and the plate was placed in a humidified box and incubated for 5 hours at 
37°C. After incubation, the lid and membrane were removed, and the cell droplets 
scraped off of the top of the membrane. A well-funnel was placed over the 
chemotaxis plate, and a 96 well OptiPlate (Perkin Elmer) was placed on top. The 
plates were inverted and centrifuged at 310 g for 5 minutes, to transfer the chemotaxis 
plate well contents into the wells of the OptiPlate. 20 μl CellTiter-Glo (Promega, 
Southampton, UK) was added to each well, and the plate sealed with an adhesive 
TopSeal covering. The OptiPlate was placed on a shaking table for 10 minutes, to 
lyse the cells. The plate was analysed by detecting luminescence levels, using a 
TopCount NXT (Perkin Elmer). The results from this were used to determine the 
chemotactic index (CI), which is the mean of the duplicates divided by the mean of 
the buffer duplicates. 
 
2.2.3.2 – Dose-dependent inhibition of chemotaxis 
A chemotaxis assay was set up using a fixed concentration of chemokine and 
an increasing concentration of antagonist. A chemotaxis plate was blocked and the 
transfectants prepared as described previously. A solution of 1 nM CCL17 or CCL22 
(10 nM in the case of mutants that showed a reduced chemotactic potency) was made 
in RPMI containing 0.1% BSA. Serial dilutions of 10 mM antagonist stocks were the 
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made using this chemokine solution, at concentrations of 1 nM, 3 nM, 10 nM, 30 nM, 
100 nM, 300 nM, 1 µM, 3 µM, 10 µM and 30 µM. After the plate was blocked, these 
were pipetted into the wells in duplicate, along with negative buffer controls and 
positive chemokine-only controls. Following the 5 hour incubation, the cells were 
stained with CellTiter-Glo and luminescence detected, as described previously. The 
values of the mean of the buffer duplicates were subtracted from the remaining 
means, which were then expressed as percentage of the positive controls. These data 
were then analysed with non-linear regression using the GraphPad Prism statistical 
package to generate a logIC50. The logIC50 values for the mutant and WT 
transfectants were compared using an unpaired two-tailed t-test. 
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2.2.4 – Receptor binding assays 
2.2.4.1 – Preparation of cell membranes for filtration and scintillation proximity 
binding assays 
1-1.2 x 10
8
 L1.2 cells were transfected with WT or mutant CCR4 and assayed 
the following day for receptor expression, as described previously. Once expression 
was confirmed, the cells were centrifuged at 310 g for 5 minutes, resuspended in 10 
ml simple RPMI, and centrifuged again. The supernatant was discarded and the pellet 
snap-frozen in liquid nitrogen. The frozen pellet was stored at -80°C if required. 
The pellet was resuspended in 10 volumes of buffer A2; typically the cell 
pellet measured 1 ml in volume, therefore 10 ml of A2 was added. The cells were 
then homogenised by 3 x 45 second bursts in a pre-chilled blender (Waring, 
Torrington, CT, USA), with 2 minutes on ice between each burst and 5-10 minutes on 
ice after the final burst, to allow foam to dissipate. 
The homogenised cells and washings from the blender (with A2 buffer) were 
then transferred to 50 ml falcon tubes, which were spun at 500g for 20 minutes in a 
pre-chilled 4°C centrifuge. The supernatant was withdrawn and spun at 48,000g for 
30 minutes in a pre-chilled 4°C ultracentrifuge. The resulting pellet from the 
centrifuged supernatant was resuspended in 50 mM HEPES buffer, at 4x the volume 
of the original cell pellet. The pellet was resuspended by vortexing for 5 seconds, 
forcing it through a 10 ml syringe against the tube base, then forcing through a 0.6 
mm needle using a 10 ml syringe. The membrane suspension was then distributed 
into 200 µl aliquots and stored at -80°C until use. The same process was repeated for 
naïve L1.2 cells. 
 
2.2.4.2 – BCA (bicinchoninic acid) assay to determine membrane suspension 
concentration 
An aliquot of membrane suspension was removed from -80°C storage and 
thawed on ice. BSA standards were composed in PBS at the following 
concentrations: 0.1, 0.2, 0.4, 0.5, 0.6, 0.8, 1, 1.25, 1.5, 1.75, and 2 mg/ml. 10 µl 
duplicates were pipetted into a 96 well plate. 10 µl duplicates of membrane 
suspension were then added to the plate, in addition to 1:3, 1:6 and 1:9 dilutions of 
the suspension. The CuSO4 and BCA reagents from a Pierce BCA Protein Assay Kit 
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(Thermo Scientific, Rockford, IL, USA) were mixed at a ratio of 1:50, and 200 µl 
added to each well. The plate was incubated at 37°C for 30 minutes. Absorbance was 
read at 562 nm (540 nm reference), using a Safire microplate reader (Tecan, 
Männedorf, Switzerland). The absorbance values from the BSA standards were 
analysed using linear regression, and from this the concentration of the membrane 
suspension was determined. 
 
2.2.4.3 – Scintillation proximity assay (SPA) using cell membranes 
SPA involved incubating membranes with radiolabelled antagonist, scintillant 
beads, and either vehicle to measure total binding or unlabelled antagonist to measure 
non-specific binding. This assay was performed in 96 well polypropylene assay 
blocks (Coring, USA), with a final assay volume of 101 µl. 
The two radiolabelled antagonists, 
3
H-3 and 
3
H-5, required two different types 
of SPA beads; 
3
H-3 required wheatgerm agglutinin beads (WGA; GE Healthcare, 
Chalfont St Giles, UK) whereas 
3
H-5 required washed yttrium silicate beads (YSi; 
GE Healthcare). The beads were resuspended in SPA buffer along with thawed 
membrane suspension to give a final assay concentration of 10 mg/ml. Membrane 
suspension concentration varied from 5 µg/well to 40 µg/well. After a 30 minute 
incubation, 50 µl of the bead/membrane mixture was added to the wells along with 50 
µl radiolabelled ligand solution at a final assay concentration of 1 nM. To total 
binding wells, 1 µl DMSO was added. To non-specific binding wells, 1 µl unlabelled 
antagonist was added; from the 10 mM stocks this gave a final assay concentration of 
100 µM. The assay was incubated at room temperature for 30 minutes, after which 
the assay plate was read using a MicroBeta 1450 Trilux scintillation counter (Perkin 
Elmer). 
 
2.2.4.4 – Filtration binding assay using cell membranes 
Filtration binding involved incubating membranes, radiolabelled antagonist 
and either buffer (total binding) or unlabelled antagonist (non-specific binding) and 
then using a filter under vacuum pressure to separate the membranes. This assay was 
performed in 96 well propylene assay blocks, with an assay volume of 500 µl. 
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The membrane suspension was thawed on ice. 50 µl of a 10% DMSO in 
buffer solution was added to the TB wells, and a 100 µM antagonist/10% DMSO in 
buffer solution was added to the NSB wells (antagonist stocks at 10 mM); these 
resulted in 1% DMSO and 10 µM antagonist final assay concentration. 50 µl 
radiolabelled antagonist solution (
3
H-3 stocks at 27 µM, 
3
H-5 stocks at 19 µM) was 
added to the wells to give a final assay concentration of 1 nM, after which 400 µl 
membrane solution was added to mix. The membrane solution was composed at a 
concentration 1.25x that of the final assay concentration, to account for the dilution 
factor. 
The plate was sealed and shaken at room temperature for 2 hours, after which 
the contents on the wells were filtered through glass fibre mats under vacuum 
pressure using a Brandel harvester. 
3
H-3 wells were filtered through GF/C-type mats 
(Brandel Inc, Gathersburg MD, USA) pre-soaked in 0.3% polyethylenimine (PEI) for 
2 hours. 
3
H-5 wells were filtered through GF/B-type mats pre-soaked with pure H2O. 
The filter mats were dried for 30 minutes at 60ºC, after which the filter pieces placed 
in scintillation vials. 4ml liquid scintillant (Perkin Elmer) was added to each tube, 
which were then read on a Tri-Carb 2900 TR liquid scintillation counter (Canberra 
Packard, Pangebourne, UK). The resulting data were recorded as disintegrations per 
minute (DPM). Radioactive counts from free ligand were measured by adding 3 x 50 
µl aliquots to scintillation vials along with scintillation fluid. This was used to 
accurately determine the concentration of radiolabelled ligand added to each well. 
 
2.2.4.5 – Whole-cell radiolabelled chemokine binding assay 
L1.2 cells transfectants were incubated in 96 well round-bottomed 
polypropylene plates with 0.1 nM 
125
I-chemokine and either buffer (total binding) or 
100 nM unlabelled chemokine (non-specific binding). Chemokine and cell dilutions 
were composed in whole-cell binding buffer. Assay volume was 50 µl. 
20 µl buffer was added to the total binding wells, and 20 µl of 250 µM 
chemokine solution was added to the non-specific binding wells to give a final assay 
concentration of 100 nM. 5 µl 1 nM radiolabelled chemokine solution was added to 
each well to give a final assay concentration of 0.1 nM. Cells were resuspended in 
buffer at 6 x 10
7
/ml; 25 µl (1.5 million cells) was added to each well and the contents 
of the well mixed by pipetting. 
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The plate was incubated for 90 minutes at room temperature, during which 
time a 0.5 M NaCl in buffer salt wash was composed (5 g NaCl in 10 ml RPMI). 
Tubes were prepared for centrifugation by pipetting 100 µl of Nyosil M-25 oil (TAI 
Lubricants, Hockessin DE, USA) into 0.5 ml capped tubes. After incubation, 50 µl 
salt wash was added to each well, mixed, and 80 µl removed and layered on top of the 
Nyosil oil. The lids were closed and the tubes centrifuged at 10,000 g for 3 minutes. 
This resulted in the cells collecting at the bottom of the tube with the supernatant 
remaining on top of the oil. After centrifugation, canine nail clippers were used to cut 
off the base of the tube containing the cell pellet into LP3 tubes for use in a Canberra 
Packard Cobra 5010 gamma counter (Canberra Packard). 
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2.3 – Statistical analyses 
Unless otherwise stated, data are presented as the mean ± standard error of the 
mean (SEM). Data were plotted using Prism v4.03 (GraphPad, CA, USA). Statistical 
analyses were performed using Microsoft Excel (CA, USA) and Prism. Statistical 
thresholds of 0.05, 0.01 and 0.001 are denoted as *, ** and ***, respectively for the 
results of the t-tests. 
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3 – The biology of CCR4 
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3.1 – Introduction 
CCR4 is a chemokine receptor in the Rhodopsin GPCR family (Power et al. 
1995; Murphy et al. 2000) notably expressed by TH2 and Treg cells (Bonecchi et al., 
1998; Iellem et al., 2001). CCR4 has also been shown to be expressed on mast cells 
(Juremalm et al., 2005; Kaur et al., 2005), platelets (Abi-Younes et al., 2001) and 
monocytes (Katschke et al., 2001). CCR4 has two ligands, CCL17 (TARC) and 
CCL22 (MDC), which bind the receptor and induce migration of CCR4-expressing 
cells (Imai et al., 1997, 1998; Andrew et al., 1998). 
CCR4 can act as both a homeostatic and inflammatory chemokine receptor. In 
terms of its homeostatic capacity, the CCR4 ligand CCL22 has been shown to play a 
role in the migration of thymocytes, haematopoetic progenitor cells, during 
development in the medulla of the thymus (Chantry et al., 1999; Campbell et al., 
1999b). Both CCL17 and CCL22 are produced by dendritic cells, which attract 
various T cell populations in the lymphoid organs (Tang and Cyster, 1999; Sallusto et 
al., 1999). As for its inflammatory role, CCR4-directed migration of TH2 cells has 
been widely documented in diseases such as asthma and atopic dermatitis 
(Vijayanand et al., 2010; Saeki and Tamaki, 2006). CCR4 is strongly implicated in 
cancers such as leukaemia and lymphoma; CCR4-positive cells are involved in the 
pathogenesis of Hodgkin lymphoma (Ishida et al., 2006) and adult T-cell leukaemia 
(Yoshie, 2005). 
Chemokine receptors, like all GPCRs, depend on various structural motifs in 
order to function. In various studies, regions of interest were mutated and the 
resulting effects on receptor trafficking, expression, signalling, function and ligand 
binding were investigated. In addition to mutational studies, receptor chimeras were 
created in which specific domains of receptors were swapped, allowing dissection of 
the function of a particular motif. 
As described in section 1.3.2, the N-terminus and extracellular loops of the 
receptor are responsible for chemokine binding. These regions can be modified by 
glycosylation and sulphation, which has been shown in many receptors to be required 
for both receptor trafficking and function (see section 1.3.2.1). Mutations of the N-
terminus and extracellular loops of the receptor have been used to identify motifs that 
are critical for chemokine binding. For example, the amino acid glutamic acid 3 (E3) 
at the distal end of the CXCR6 N-terminus was shown to be important for receptor 
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expression; mutation of this to glutamine reduced cell-surface expression of CXCR6 
by 25%. The N16A mutation of CXCR6, in which an N-terminal asparagine was 
mutated to alanine, showed significantly reduced cell-surface expression, chemokine 
binding and migration compared to WT CXCR6. N16 of CXCR6 was identified as a 
site of N-linked glycosylation; tunicamycin, an inhibitor of this process, had the same 
effect on receptor expression, function and binding (Petit et al., 2008). 
The chemokine receptor US28 is encoded by human cytomegalovirus 
(HCMV). It shows strong homology with CCR1 and CCR2 and binds a large number 
of chemokines, including CCL5, CCL3, CCL4, CCL2, and CX3CL1 (Kuhn et al., 
1995; Kledal et al., 1998), indicating that it may function as a scavenger of 
chemokines. Truncation of 14 amino acids of the N-terminus of US28 removed the 
ability of the receptor to bind chemokines. Further investigation by point mutagenesis 
of specific amino acids to alanine revealed that phenylalanine 14 of US28 is 
important for interaction with the N-loop of CCL4. In addition, mutation of tyrosine 
16 of US28 to alanine resulted in significantly reduced cell-surface expression and 
chemokine binding, likely due to the removal of sulphation sites (Casarosa et al., 
2005). These studies on CXCR6 and US28 show that regions within the N-termini of 
chemokine receptors are critical for chemokine binding, both due to direct interaction 
and through the effects of post-translational modifications such as glycosylation and 
sulphation. 
 
The extracellular loops of chemokine receptors are also involved in 
chemokine binding, and mutational studies have been performed to examine these 
regions in detail. These loops contain cysteine residues which are thought to be 
involved in structural stabilisation of the receptor by forming disulphide bonds; two 
cysteines, located in the first and second extracellular loops of many chemokines 
receptors are known to form a disulphide bond (Ji et al., 1998). Substitution of these 
cysteines for serine removes the ability for bond formation due to the lack of sulphur 
in serine. Cysteine to serine substitution in CCR6 resulted in significantly reduced 
receptor expression, and confocal microscopy revealed that the majority of mutant 
receptors were unable to leave the cytoplasm and reach the cell surface, indicating a 
defect in intracellular trafficking. Further analysis showed that mutant receptors were 
insensitive to CCL20-induced migration except at high concentrations, and were less 
able to bind the chemokine (Ai and Liao, 2002). Mutation of glutamate 254 in the 
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third extracellular loop of CX3CR1 to alanine resulted in significantly reduced 
CX3CL1 binding, demonstrating the importance of this acidic residue in the 
chemokine-chemokine receptor interaction. Mutation of aspartic acid 266, also in the 
third extracellular loop, did not affect chemokine binding but did affect receptor 
activation; mutant transfectants migrated to 1 nM CX3CL1 at half the level of WT 
transfectants despite showing normal cell-surface expression (Chen et al., 2006). 
These data demonstrate that the extracellular loops of chemokine receptors have 
important roles in both chemokine binding and receptor activation. This fits with the 
two-step model of chemokine binding, described in section 1.3.2.2, which states that 
chemokine first binds the N-terminus of the receptor with high affinity, and then the 
extracellular loops with lower affinity (Monteclaro and Charo, 1997). 
 
The transmembrane domains of chemokine receptors also serve important 
functions in chemokine binding, receptor activation and signalling. Chemokines have 
been shown to interact with the transmembrane bundle; mutations of phenylalanine 
85 in helix II and leucine 104 and phenylalanines 109 and 122 in helix III 
significantly reduced CCL3 binding to CCR5 (Blanpain et al., 2003). The 
transmembrane domains are important in maintaining receptor tertiary structure, and 
are thus required for maintaining receptor signalling, since coupling to signalling 
partners is dependent on receptor conformation. Thus, disruption of stabilising 
interactions by mutagenesis has revealed several important domains required for 
receptor activation. 
The TXP motif is a highly conserved motif, located in the second 
transmembrane domain of many chemokine receptors. The amino acid proline, due to 
its cyclic side chain structure, causes a kink in a helical structure when it is present. 
Because of this, it was hypothesised that this highly conserved amino acid, along with 
the conserved threonine upstream, was involved in receptor function and chemokine 
binding. The mutation of these two amino acids in CCR5 resulted in significantly 
reduced binding of CCL3 and CCL4 to the receptor, in addition to reduced 
chemotactic ability. Interestingly, CCL5 binding was not as drastically affected by the 
mutations, indicating that this mode of receptor activation is dependent on specific 
chemokine structures (Govaerts et al., 2001). While in CCR5 this motif is involved in 
chemokine binding, the TXP motif was shown in CCR1 to instead be involved in 
receptor activation. Leucine 87 of CCR1 lies within the TXP motif, and when this 
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amino acid was mutated to alanine the chemokine CCL3 was still able to bind the 
receptor. However, the L87A mutant did not induce chemotaxis, despite the normal 
binding of the chemokine (de Mendonça et al., 2005). Therefore, the role of this 
conserved motif varies between different chemokine receptors. 
E290 is a highly conserved glutamic acid located near the top of the seventh 
transmembrane domain of CCR4. Following the Baldwin numbering scheme, this 
residue is referred to as GluVII:06, since it is the sixth amino acid in the seventh 
transmembrane in many receptors (Kledal et al., 1998; Nygaard et al., 2009). 
GluVII:06 acts as a major contact point for chemokines, and its mutation often results 
in the inability of the receptor to bind its ligand. For example, following mutation of 
GluVII:06 (E286) of CCR8 to glutamine the cell-surface expression of the receptor 
was significantly reduced along with its ability to induce chemotaxis to the 
chemokine CCL1 (Fox et al., 2006). The same mutation of GluVII:06 (E287) in 
CCR3 gave a similar phenotype (Wise et al., 2007). However, this mutation in CCR5 
did not abolish chemotaxis of mutant receptor-transfected cells to CCL3 (de 
Mendonça et al., 2005). Interestingly, mutation of GluVII:06 (E274) in CXCR6 
rendered the receptor unable to bind the soluble form of CXCL16 but still able to 
bind the membrane-bound from. This suggests that the receptor discriminates 
between different forms of the chemokine and that only the soluble form required 
GluVII:06 (Petit et al., 2008). 
The intracellular loops of chemokine receptors also play an important role in 
receptor function. One region in particular is the conserved DRYLAIV motif, located 
in the second intracellular loop. This motif consists of either a glutamic acid or an 
aspartic acid, followed by an arginine and then a tyrosine. This motif is highly 
conserved amongst chemokine receptors, indicating a potential role in function 
(Murphy et al., 2000; Rovati and Neubig, 2007). Mutation of the DRYLAIV motif in 
CCR3 resulted in a receptor that was non-functional; both an alanine triple mutation 
and individual point mutants of this region rendered the receptor unable to induce 
migration to CCL11 (Auger et al., 2002). As described in section 1.3.1, the intial 
glutamic acid/aspartic acid of the DRYLAIV motif forms an ‘ionic lock’ with 
residues in transmembrane helix VI. Ligand binding, inducing conformational 
changes in receptor structure, disrupts this lock and allows G protein coupling (Rovati 
and Neubig, 2007). The arginine of this motif, in addition to contributing to the 
previously described salt bridge, is believed to function as a micro-switch in receptor 
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activation, forming part of a binding pocket for Gα proteins (Nygaard et al., 2009). 
Therefore, the mutation of DRYLAIV motif residues disrupts these interactions and 
hinders receptor activation. 
The cytoplasmic end of transmembrane helix VII and the C-terminal helix 
VIII are also required for receptor function. The conserved NPXXY motif in helix 
VII functions as another micro-switch, similar to the DRYLAIV motif. The tyrosine 
of this motif interacts with a phenylalanine in helix VIII when the receptor is in an 
inactive state, forming pi-stacking interactions. Upon ligand binding the tyrosine 
rotates outward to interact with helix VI and stabilise its conformational shift. 
Mutations of this region in rhodopsin reduced levels of receptor activation (Fritze et 
al., 2003; Nygaard et al., 2009), and mutation of the tyrosine of this region in CCR5 
significantly reduced the chemotactic response of transfected cells to CCL5 (Kraft et 
al., 2001). 
Deletion of portions of the C-terminus of the helix VIII region of the viral 
chemokine receptor ORF74 caused reduced activity of the receptor, while complete 
C-terminal truncation resulted in an inactive receptor. The ORF74 receptor is 
constitutively active, and CXCL8 binding was shown to require the receptor to be 
coupled to Gαq proteins. By removing the C-terminus, coupling could not occur, and 
CXCL8 binding was ablated. However, CXCL10 retained the ability to bind since it 
did not require G protein coupling (Verzijl et al., 2006). These data indicate that this 
region mediates chemokine binding in addition to being involved in receptor 
activation. While it is well established that N-terminal binding of ligand influences 
receptor conformation to recruit C-terminal proteins, this finding is interesting as it 
shows that C-terminal coupling to G protein is required for N-terminal chemokine 
binding. 
 
This chapter describes experiments in which CCR4 expression and function 
was assayed on cells expressing CCR4 endogenously, or on L1.2 cells transfected 
with a plasmid containing the CCR4 gene. Due to the previous research highlighting 
the importance of key amino acids, mutants of CCR4 were made. Lysine 310, within 
the conserved C-terminal region helix VIII, was mutated to asparagine. GluVII:06 
(E290), a highly conserved amino acid within the seventh transmembrane domain 
was mutated to alanine, aspartic acid, and glutamine. These mutants were then 
compared to the WT receptor with respect to chemokine binding and function.  
93 
 
3.2 – Results 
3.2.1 – CCR4 cell-surface expression 
In order to study the expression and function of CCR4, the CCR4 gene needed 
to be transfected into a cell line and the protein subsequently expressed. CCR4 was 
previously cloned into the pcDNA3 vector. This was used to transiently transfect the 
L1.2 cell line. 
The pcDNA3 vector contains the sequence for the HA epitope tag upstream of 
the gene insert. Epitope tags are often used in molecular biology assays to label 
proteins without adversely affecting tertiary structure or function. While these tags 
can be placed anywhere within the protein sequence, they are usually placed at either 
the carboxy or amino terminus of the protein, in order to minimise effects on the 
target protein. The HA tag was derived from the haemagglutinin epitope of the 
influenza virus (protein sequence YPYDVPDYA). Tagged proteins can be used as 
normal in various assays such as flow cytometry, immunohistochemistry and Western 
blotting. 
Antibodies for CCR4 are commercially available, which rely on the presence 
of epitopes on the receptor which are currently unmapped. In this project, several 
mutants of CCR4 were generated, and many of the sites of mutation were within the 
transmembrane helices and extracellular loops of the protein. The mutations could 
have potentially affected receptor structure, and as such altered or masked the 
epitopes required for anti-CCR4 antibodies to bind. Therefore, using an antibody 
against the HA tag allowed for detection of the receptor without the mutation 
compromising binding of a conformationally sensitive antibody. 
The L1.2 cells into which the CCR4-containing pcDNA3 vector was 
transfected have previously been used for similar studies (Meiser et al., 2008; Pease 
et al., 1998; Wise et al., 2007). These cells serve well as a transfection system; they 
double in 16 hours, which allows the culture of large numbers in a relatively short 
amount of time compared to other cell lines; they grow in liquid suspension, which 
allows for a greater speed of manipulation; they are derived from a leukocyte line, 
and are therefore a suitable system in which to express chemokine receptors; they are 
easy to transfect by electroporation, and can be treated with sodium butyrate to 
increase gene expression and thus functional responses. 
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The cell-surface expression of transfected WT CCR4 is shown in figure 3-1. 
This figure shows the result of flow cytometry performed using anti-HA antibodies 
and an IgG1 isotype control. The isotype stain in figure 3-1 (filled curve) had a 
median fluorescence of 6.9, indicating a low degree of staining. The HA antibody 
however showed high receptor staining, as signified by the right-shift of the 
histogram (solid line). This had a median of 75.6. Subtracting the non-specific value 
from the HA value gave a median specific fluorescence value of 68.7. From this it 
can be concluded that L1.2 cells express CCR4 on their surface following transient 
transfection, and that this can be detected with the HA antibody. 
The Hut78 human T-cell line was also assessed by flow cytometry for CCR4 
expression. Since Hut78 cells express the receptor endogenously, CCR4 is contained 
within genomic DNA rather than the pcDNA3 vector. Therefore the protein does not 
possess the HA tag used for antibody staining in the transient transfection system. 
Two CCR4 antibodies, 1G1 and 10E4, were used in place of the HA antibody to 
detect the receptor on these cells. Figure 3-2 shows the results of antibody staining of 
Hut78 cells with these antibodies; panel A shows 1G1 staining while panel B shows 
10E4 staining. 1G1 staining shows a much lower CCR4 levels compared to 10E4; it 
had a median specific fluorescence of 6.6 whereas 10E4 had a median specific 
fluorescence of 175.9. 
The phenomenon of differing CCR4 expression with the 1G1 and 10E4 
antibodies was also apparent after chemokine-induced receptor internalisation. 
Following chemokine binding, receptors can undergo endocytosis via caveolae or 
clathrin-coated pits (see section 1.3.2.2). This removal of the receptor from the cell 
surface is believed to act as a form of regulation, preventing over-stimulation of the 
cell (Neel and Richmond, 2005; Borroni et al., 2010). CCL22 has previously been 
reported to induce CCR4 internalisation, when assayed with the mAb 1G1. CCL17 
however induced no CCR4 internalisation (Mariani et al., 2004). To investigate this 
whether this phenomenon was also apparent after 10E4 staining, Hut78 cells were 
incubated with 100 nM CCL17 or CCL22 for 30 minutes to induce receptor 
internalisation. The cells were then washed and stained with either 1G1 or 10E4, and 
CCR4 cell-surface levels analysed by flow cytometry and compared to untreated 
cells. The results of this are shown in figure 3-3. 1G1 staining showed a significant 
reduction in CCR4 cell-surface levels after CCL22 treatment, to 20% of untreated 
levels. CCL17 treatment showed a trend towards a reduction, however this was not 
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significant. 10E4 staining however showed a significant reduction in CCR4 cell-
surface levels for both CCL17 and CCL22 treatment; levels were 60% and 50% of 
WT, respectively. 10E4 thus detected significant CCR4 internalisation after both 
CCL17 and CCL22 treatment, whereas 1G1 only detected significant internalisation 
on the CCL22-treated cells. 
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Figure 3-1 – L1.2 cells transfected with HA WT CCR4 DNA express the 
receptor on their surface 
The histogram shows the cell surface expression of WT CCR4. The filled 
curve shows the isotype control IgG1 stain. Mean fluorescence – 6.9. The 
solid line shows the HA stain. Mean fluorescence – 75.6. Mean specific 
fluorescence – 68.7. Data are from a typical experiment and representative of 
at least three independent experiments. 
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Figure 3-2 – The 10E4 antibody detects a greater level of CCR4 
expression than the 1G1 antibody 
Cell-surface expression of CCR4 on the Hut78 human T cell line. Panel A 
shows the isotype IgG1 control stain (filled curve) and anti-CCR4 1G1 stain 
(solid line). Median specific fluorescence - 6.6. Panel B shows the isotype 
IgG2a (filled curve) and anti-CCR4 10E4 stains (solid line). Median specific 
fluorescence – 175.9. A FITC-conjugated secondary antibody was used in 
both A and B. Data are from a typical experiment and representative of at 
least three independent experiments. 
A 
B 
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Figure 3-3 – Detection of CCL17-induced internalisation of CCR4 is 
dependent upon the use of the 10E4 antibody 
Hut78 cells were stained with 1G1 (black bars) or 10E4 (grey bars) after 
treatment with 100 nM CCL17 or CCL22 for 30 minutes, and compared to 
untreated cells. Data are shown as a percentage of the untreated control, and 
are the mean ± SEM of three independent experiments, which were analysed 
by two-way ANOVA. Significance stars *, ** and *** represent p values of 
0.05, 0.01, and 0.001 respectively. 
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3.2.2 – Chemotaxis of CCR4-expressing cells 
After confirmation of cell-surface expression, WT CCR4-transfectants were 
then tested for their ability to undergo chemotaxis to soluble CCL17 and CCL22, the 
two ligands of the receptor. The chemotaxis assay was used to investigate this. This 
employed a membrane that was designed to mimic the endothelium; it had pores of 5 
µm in diameter through which the cells had to actively transmigrate. This assay was 
useful for determining the functionality of the transfected receptor, in that it 
discriminated between cells that were able to migrate and those that were not. 
Figure 3-4 shows the results of this chemotaxis assay. Data are expressed as 
chemotactic index (CI), which is the ratio of the response relative to buffer. The 
CCR4-expressing cells migrated to both chemokines in the 0.1 nM – 100 nM range, 
but did not migrate to buffer alone. Maximal migration was observed at 1 nM for 
CCL17 and CCL22. While both chemokines were of the same potency, CCL22 was 
the more efficacious of the two ligands, a larger CI was induced at 1 nM than CCL17 
(CIs of 60 and 45, respectively). Concentrations higher than 1 nM elicited a reduction 
in migration, giving the typical bell-shaped curve observed previously in chemotaxis 
assays (James Pease, personal communication). 
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Figure 3-4 – CCL17 and CCL22 have similar potencies and efficacies 
in chemotaxis assays 
WT CCR4 transfectants were tested for their ability to migrate towards 
buffer (B on the x-axes) and increasing concentrations of the two 
chemokines CCL17 (panel A) and CCL22 (panel B). Data are the means ± 
SEM of three independent experiments. 
A 
B 
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3.2.3 – Binding of CCL17 and CCL22 to CCR4 
CCR4-transfected cells were assessed for their ability to bind soluble CCL17 
and CCL22. Figure 3-5 shows total and non-specific binding of 
125
I-CCL17 and 
125
I-
CCL22 to WT CCR4 transfectants. A higher number of counts per minute (CPM) 
was observed for 
125
I-CCL17 binding when compared to 
125
I-CCL22; means of 3260 
and 1070, respectively. 
125
I-CCL22 however had a higher level of non-specific 
binding. 
To investigate the affinity of the chemokines for the receptor, saturation 
assays using increasing concentrations of radiolabelled chemokine would have been 
performed. These assays determine the Kd, which is the dissociation constant. The Kd 
indicates the strength of binding between the ligand and its receptor; if a high 
concentration is required to bind ligand and receptor, it shows that the strength of 
binding is low, which means that the Kd value is high. If a low concentration is 
required, it shows a strong binding affinity, giving a low Kd value. Therefore, the 
smaller the Kd, the stronger the binding affinity of the ligand for the receptor.  
Due to practical limitations, assays were performed in which binding of 0.1 
nM radiolabelled chemokine was inhibited with increasing concentrations of 
unlabelled chemokine. The results of this are shown in figure 3-6, in which CCL17 
and CCL22 were used to inhibit 
125
I-CCL17 and 
125
I-CCL22 binding, respectively. 
Figure 3-7 shows the inhibition of 
125
I-CCL17 (A) and 
125
I-CCL22 (A) binding with 
both unlabelled CCL17 and CCL22. 
The dose-response curves from figures 3-6 and 3-7 were initially used to 
calculate IC50 values, which is the concentration at which binding is inhibited to 50% 
of maximum. The Cheng-Prussof equation allows the Ki, the equilibrium dissociation 
constant for the binding of the unlabelled ligand, to be calculated from the IC50 
(Cheng and Prusoff, 1973): 
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Under the assumption that radiolabelled and unlabelled chemokine have the 
same binding affinity, (Motulsky and Christopoulos, 2004), the Kd and Ki are equal. 
This therefore converts the equation to: 
 
                       
 
However, the assumption that the radiolabelled and unlabelled chemokine had 
the same affinity was not true in this case. The specific activities of both 
125
I-CCL17 
and 
125
I-CCL22 were similar – 2200 and 2110 Ci/mmol, respectively. Despite this 
similarity in specific activities, 
125
I-CCL17 had higher specific binding that 
125
I-
CCL22 (3000 counts versus 300 counts; figure 3-6). This suggests that 
125
I-CCL17 
has a higher affinity for CCR4 than 
125
I-CCL22. However, figure 3-7 shows that both 
CCL17 and CCL22 inhibit 
125
I-CCL17 and 
125
I-CCL22 binding with similar potency. 
This therefore indicates that the affinities of the radiolabelled and unlabelled 
chemokines are not the same; if they were, similar specific binding values would 
have been observed for both 
125
I-CCL17 and 
125
I-CCL22. Because of this, figures 3-6 
and 3-7 cannot be considered as homologous competition assays, meaning that the Kd 
and Bmax for each ligand could not be calculated. 
A concentration of 0.1 nM radiolabelled chemokine was used in figures 3-5, 
3-6 and 3-7. This value is likely well below the Kd concentration of these ligands. 
This therefore allows for the approximation that the IC50 equals Ki. The Ki, the 
inhibitor constant, is the binding affinity of the inhibitor, which in this case is the 
unlabelled chemokine. IC50 values cannot be compared to one another, whereas Ki 
values can be compared. Ki values were thus generated for figures 3-6 and 3-7. 
Figure 3-6 shows that 
125
I-CCL17 binding was inhibited by unlabelled CCL17 
with a logKi of -7.89 ± 016 (A), while 
125
I-CCL22 binding was inhibited by 
unlabelled CCL22 with a logKi of -8.18 ± 0.31 (B). 
Figure 3-7 shows the inhibition of both 
125
I-CCL17 and 
125
I-CCL22 with 
unlabelled CCL17 and CCL22. This was performed on CEM-4 cells, a human T cell 
line that endogenously expresses CCR4 (Cronshaw et al., 2004; Viney et al., in 
preparation). Since the competing ligands were different, this assay could be used to 
determine whether the two occupy the same binding site on the receptor (Swillens et 
al., 1995). If both ligands bound the same site, they would have been able to displace 
each other, leading to a sigmoidal dose-response curve similar to those seen for figure 
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3-6. If the two ligands occupied different sites, then there would be no dose-
dependent competition with the radiolabelled ligand. Figure 3-7A shows that CCL17 
and CCL22 inhibit 
125
I-CCL17 binding with similar potencies; the log Ki values were 
-8.67 and -8.76 respectively. These values were not significantly different when 
analysed using a t-test (p = 0.91). The two chemokines also inhibited 
125
I-CCL22 
binding with similar potencies; the log Ki values were -8.50 and -8.57, respectively (p 
= 0.99). 
Despite this similarity in potency, 
125
I-CCL22 binding could not be fully 
inhibited. Panel A shows that CCL17 and CCL22 fully competed with 
125
I-CCL17; 
binding was reduced to 6% and 5% of maximum by 100 nM CCL17 and CCL22, 
respectively. Panel B however shows that CCL17 could not fully compete with 
125
I-
CCL22; while 100nM CCL22 reduced binding to 12.8% of maximum, 100 nM 
CCL17 reduced binding to only 33.5% of maximum. This difference was statistically 
significant when analysed using a t-test (p=0.01). 
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Figure 3-5 – Both CCL17 and CCL22 bind CCR4 transfectants 
WT-CCR4 transfectants were tested for their ability to bind 
125
I-CCL17 (A) or 
125
I-
CCL22 (B) in the presence/absence of unlabelled chemokine. Data are the means ± 
SEM of three independent experiments, which were analysed by one-way ANOVA. 
A 
B 
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Figure 3-6 – 125I-CCL17 and 125I-CCL22 can be dose-dependently competed with 
unlabelled chemokine for binding to CCR4 transfectants 
Increasing concentration of unlabelled chemokine was competed with radiolabelled 
chemokine in order to investigate the ability of the chemokines to bind CCR4 on 
transfected L1.2 cells. Panel A: 
125
I-CCL17 binding competed with increasing 
concentrations of CCL17 (logKi = -7.89 ± 0.16). Panel B: 
125
I-CCL22 binding 
competed with increasing concentrations of CCL22 (logKi = -8.18 ± 0.31). Data are the 
mean ± SEM of three independent experiments. 
A 
 
B 
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Figure 3-7 – CCL17 is unable to fully displace 125I-CCL22 from CEM-4 
cells in homologous competition assays 
Homologous and heterologous binding curves on CEM-4 cells. Panel A: 
125
I-
CCL17 was competed with increasing concentrations of CCL17 (logKi = -8.67 ± 
0.07) or CCL22 (logKi = -8.76 ± 0.09). Panel B: 
125
I-CCL22 was competed with 
increasing concentrations of CCL17 (logKi = -8.50 ± 0.12) or CCL22 (logKi = -
8.57 ± 0.15). Data are mean ± SEM of three independent experiments. From 
(Viney et al., in preparation). 
A 
 
B 
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3.2.4 – Mutation of GluVII:06 (E290) ablates binding and chemotactic 
ability of CCR4-transfected cells 
GluVII:06 of CCR4 (E290) is located in the seventh transmembrane domain. 
It is conserved among other GPCRs, including chemokine receptors, and has been 
shown to play an important role in receptor function. Fox et al. (2006) demonstrated 
that GluVII:06 in CCR8 (E286) was critical for cell-surface expression and receptor 
function. When mutated to glutamine, expression levels and chemotactic responses 
were abolished. An analogous mutation in CCR3 produced the same effect (Wise et 
al., 2007). However, similar mutation of GluVII:06 in CCR1 (E287) did not perturb 
chemokine binding of functional responses of the receptor (de Mendonça et al., 
2005). 
GluVII:06 (E290) of CCR4 was mutated to alanine (E290A), aspartic acid 
(E290D) and glutamine (E290Q). Glutamic acid is a negatively charged amino acid. 
Glutamine is uncharged, but with a side chain of similar size to glutamic acid. 
Aspartic acid is similarly charged and has a smaller side chain. Alanine is uncharged 
and has an even smaller side chain. By mutating glutamic acid to these three amino 
acids, the contribution of both size and charge of E290 to receptor function could be 
determined. 
Once the three CCR4 mutants had been generated, they were transfected into 
L1.2 cells. Their cell surface expression was assessed and compared to WT (figure 3-
8A). The three mutations affected surface expression to varying degrees. E290A and 
E290D were expressed at lower levels that WT, E290D significantly so at 
approximately 50% of WT levels. E290Q was expressed at higher levels than WT. 
When the mutants were assessed for chemotactic ability, it was found that none of 
cells expressing the three mutants migrated to either CCL17 or CCL22 (panels B and 
C); two way ANOVA showed that the chemotaxis responses for all three mutants 
were significantly reduced compared to WT transfectants. WT transfectants migrated 
to CCL17 and CCL22 with chemotactic indices of 10 and 30, respectively. However, 
all three of the E290 mutants did not migrate to either CCL17 or CCL22, since the 
response did not significantly increase above background levels. 
 Following this, the cells were assayed for chemokine binding, to investigate 
whether the lack of chemotaxis was due to the inability of the chemokine to bind to 
the mutated receptors. As described previously, transfected cells were incubated with 
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radiolabelled ligand and either buffer or excess unlabelled chemokine to provide a 
measure of total and non-specific binding. WT transfectants showed significant 
differences between both CCL17 and CCL22 total and non-specific binding, 
indicating that chemokine binding occurred. Non-specific binding for 
125
I-CCL17 and 
125
I-CCL22 binding was approximately 7% and 40%, respectively. All three E290 
mutant transfectants had reduced total binding values approximating the level of non-
specific binding, such that there was no significant difference between the two values. 
This indicated that all three E290 mutants did not bind 0.1 nM of the radiolabelled 
chemokine; this could be explained by a reduction in affinity for ligands, and also 
explains the inability of the mutant receptors to induce chemotaxis to the chemokines. 
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Figure 3-8 – Mutation of GluVII:06 (E290) ablates chemokine binding and 
functional responses of transfected cells. 
CCR4 transfectants were analysed for cell-surface expression (panel A) and then 
assessed for their chemotactic ability in response to CCL17 (B) and CCL22 (C). Total 
and nonspecific binding was then assessed with 0.1 nM 
125
I-CCL17 (D) and 
125
I-CCL22 
(E). Data are mean ± SEM of three independent experiments, which were analysed with 
a two-tailed t-test or two-way ANOVA. Significance stars *, ** and *** represent p 
values of 0.05, 0.01, and 0.001 respectively. 
E D 
A 
B C 
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3.2.5 – Mutation of K310N does not affect chemokine binding, but ablates 
chemotactic ability toward CCL17 
The amino acid lysine 310 (K310) in the C-terminus of CCR4 was mutated to 
asparagine (K310N). K310 is located in helix VIII, an important structural motif in 
the C-terminus that is highly conserved across several GPCRs. Helix VIII has been 
implicated in receptor signalling, ligand activity and antagonist activity (see section 
1.3.2.3). The mutation to asparagine was chosen because lysine and asparagine have 
different ionisation states at physiological pH (Salchow et al., 2010), but do not differ 
enough structurally for a mutation to adversely affect helical structure. The fact that 
the side chain of asparagine is not a proton donor or acceptor under physiological 
conditions means that any ionic interactions with other amino acids would be 
disrupted. Therefore the lysine to asparagine mutation allowed study of the ionic 
interactions involved in receptor activity without causing a breakdown in the structure 
of helix VIII. 
K310N mutation did not significantly affect expression of the receptor; 
expression levels of the mutant were comparable to WT when assayed by flow 
cytometry (figure 3-9 A). Panels B and C show the migration of transfectants to 
CCL17 and CCL22. WT transfectants migrated to increasing concentrations of 
CCL17 and CCL22, with peak chemotactic indices at 1 nM of 45 and 60, 
respectively. K310N transfectants did not migrate dose-dependently to CCL17, and 
the chemotactic index for 1 nM was 4.6, which was not significantly different to 
migration to buffer alone. K310N transfectants did however migrate dose-
dependently to CCL22, albeit with reduced efficacy. The chemotactic index for these 
transfectants for 1 nM CCL22 was 30, which was significantly lower than the 
chemotactic index for WT transfectants. 
To determine whether the lack of chemotactic response to CCL17 and the 
reduced chemotactic response to CCL22 was due to a loss of binding, K310N 
transfectants were incubated with radiolabelled chemokine and an increasing 
concentration of unlabelled chemokine. Panel D shows WT and K310N transfectant 
binding to 
125
I-CCL17, and panel E shows binding to 
125
I-CCL22. In both cases, WT 
CCR4 transfectants bound higher levels of radiolabelled chemokine; WT 
transfectants bound 2250 counts of 
125
I-CCL17 whereas K310N bound 1500 counts; 
this difference was statistically significant when analysed using a t-test (p=0.02). WT 
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bound 300 counts of 
125
I-CCL22, K310N bound 200 counts; this difference was not 
statistically significant (p=0.1). 
In the same manner as figures 3-6 and 3-7, the logKi values were calculated 
for the inhibition of 
125
I-CCL17 and 
125
I-CCL22 binding by unlabelled CCL17 and 
CCL22. CCL17 inhibited binding of 
125
I-CCL17 to both WT and K310N CCR4 with 
similar potencies; the logKi values were -7.89 and -7.93, respectively. These values 
were not significantly different, with a p value of 0.62 when analysed using a t-test. 
The difference between CCL22 inhibition of 
125
I-CCL22 binding to WT and K310N 
was also not significantly different (p = 0.73). 
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Figure 3-9 – K310N mutation ablates chemotactic response to CCL17 but not CCL22. 
WT and K310N CCR4 transfectants were analysed for cell-surface expression by flow 
cytometry (panel A), then assessed for their ability to induce chemotaxis toward the ligands 
CCL17 (B) and CCL22 (C). Homologous competition curves were generated to compare 
chemokine binding of WT and K310N. CCL17 (D) – WT: logKi
 
= -7.89 ± 0.16. K310N: 
logKi = -7.93 ± 0.17. CCL22 (E) – WT: logKi = -8.18 ± 0.31. K310N: logKi = -7.93 ± 0.42. 
Data are the means ± SEM of three independent experiments. Significance stars *, ** and 
*** represent p values of 0.05, 0.01, and 0.001 respectively. 
A 
B C 
D E 
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3.3 – Discussion 
3.3.1 – L1.2 and T cell lines express functional CCR4 
CCR4, a chemokine receptor normally expressed on TH2 cells and Treg cells, 
was transiently transfected into L1.2 cells and successfully expressed on the cell 
surface (figure 3-1). The L1.2 cells, a pre-B cell lymphoma line, have previously been 
used in similar studies to investigate other chemokine receptors (Mueller et al., 2008; 
Pease et al., 1998; Wise et al., 2007). CCR4 has been transfected into 300-19 cells, a 
human pre-B cell line (Sebastiani et al., 2005), as well as HEK293 cells (Wang et al., 
2006). 
Compared to previous studies, CCR4 is expressed at reduced levels compared 
to other receptors; CXCR3 transfected into L1.2 cells and gave a much higher degree 
of cell-surface expression than seen here with CCR4 (Nedjai et al., 2012). Similar 
results have been observed for other chemokine receptors, such as CXCR1 and 
CXCR2, when transfected into the same cells (James Pease, personal 
communication). The reasons for this disparity between chemokine receptor cell-
surface expression levels are unclear; the L1.2 cells may not possess the full 
repertoire of cellular machinery necessary to express the receptor at a level normally 
seen on cells that endogenously express it. Hut78 cells, which are a T cell line, 
express CCR4 at a higher level (figures 3-1 and 3-2). It has been previously 
demonstrated that different chemokine receptors are expressed at different levels on 
the same cells; for example, lung CD4+ cells were shown to have higher expression 
levels of CCR5, CCR6 and CXCR4 compared to CCR4 and CCR7 (Campbell et al., 
2001). When a specific CD4+ T cell subtype was examined, TH2 cells were shown to 
have relatively low levels of CCR1, CXCR2 and CCR3 compared to CCR4 and 
CCR5 (Sebastiani et al., 2005). Eosinophils also had varying expression levels of 
different chemokine receptors; CCR3 being the most highly expressed compared to 
others such as CCR1, CCR2 and CCR4 (Nagase et al., 2001). The data in this chapter 
that show L1.2 cells express CCR4 relatively poorly compared to other receptors such 
as CXCR3 (personal communication) or compared to T cell lines that endogenously 
express it, may be indicative of general variation in expression levels between 
receptors. 
Sodium butyrate was used to increase cell-surface expression levels; addition 
of this short-chain fatty acid has been shown to increase transfection efficiency and 
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resulting protein expression in several cell lines; HeLa cell transcription was 
increased by a factor of 30 (Gorman and Howard, 1983). The improved efficiency 
was the result of increased enhancer-dependent transcription through the SV40 
promotor present on the transfected plasmid. 
 
In agreement with previous findings, CCR4 was also shown to be 
endogenously expressed on Hut78 cells, a T cell line (figure 3-2). Whereas L1.2 
transfectant CCR4 expression was determined using an antibody specific to the HA 
tag on the N-terminus of the receptor, detection of CCR4 on Hut78 cells was 
performed with CCR4-specific antibodies 1G1 and 10E4. 1G1 was commercially 
available, whereas 10E4 was developed by Millennium Pharmaceuticals (Jopling et 
al., 2002) and is no longer in production. 
The 10E4 epitope was mapped to N-terminus of CCR4 (Jopling et al., 2002), 
whereas information regarding the epitope of 1G1 was unavailable. However, when 
considering the difference in CCR4 expression that was observed when staining the 
same cells with the two antibodies (figures 3-2A and B); it is likely that they bound 
different epitopes. This difference in CCR4 expression was also observed by Jopling 
et al. (2002) in the original identification of the 10E4 antibody, and later in CEM-4 
and L1.2 cells (Viney et al., in preparation). 
The antibody-dependent difference in CCR4 cell-surface expression was also 
observed after treatment with chemokine. Figure 3-3 shows CCR4 expression on 
Hut78 cells after CCL17 or CCL22 treatment when assayed with either 1G1 or 10E4. 
While 10E4 showed a significant reduction in CCR4 levels after treatment with both 
CCL17 and CCL22, 1G1 only showed a significant reduction after treatment with 
CCL22. CCL22 has previously been described as ‘dominant’ over CCL17 with 
respect to CCR4 internalisation (Mariani et al., 2004); CCL22 treatment of TH2 cells 
induced a 62.6% level of CCR4 internalisation, whereas CCL17 only induced a 4.5% 
level of internalisation. However these results were obtained by staining the cells with 
the 1G1 antibody; figure 3-3 shows that when stained with 10E4 CCL17 can also 
internalise a significant proportion of CCR4. These results suggest that 10E4 detects a 
larger population of CCR4 than 1G1, which would account for the increased 
expression seen here on Hut78 cells in figure 3-2, as well as in the original 10E4 
identification report (Jopling et al., 2002). Taken together, it could be surmised that 
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10E4 is binding a major CCR4 population that is internalised by both CCL17 and 
CCL22. 
Transfected CCR4 was shown to be functional; L1.2 transfectants migrated to 
soluble CCL17 and CCL22 (figure 3-4). The classic bell-shaped dose-response 
showed that as concentration of chemokine increased, the number of cells migrating 
also increased. However this response peaked at 1 nM chemokine, after which cell 
migration decreased. This type of response generally believed to be due to saturation 
of chemokine receptors across the cell membrane, leading to a loss of directionality 
of the cells. Since a cell can sense as little as a 2% difference in concentration 
between its anterior and posterior ends, an overabundance of chemokine would lead 
to a loss of response (Devreotes and Zigmond, 1988). Both CCL17 and CCL22 
chemotactic responses peaked at 1 nM, indicating that both chemokines were equally 
potent. The maximal responses however were not identical for the two chemokines. 1 
nM CCL17 induced a chemotactic index of 45, whereas 1 nM CCL22 induced a 
chemotactic index of 61. This shows that CCL22 was a more efficacious ligand, 
inducing a greater degree of cell migration compared to CCL17. Similar findings 
have previously been reported in CCR4; in chemotaxis assays, 500 ng/ml CCL22 
induced migration of 10,000 L1.2 cells compared to the same concentration of 
CCL17 inducing migration of L1.2 4000 cells (Mariani et al., 2004). CCL22 was also 
shown to induce full arrest of rolling cells under shear conditions, whereas CCL17 
only induced partial arrest of cells (D’Ambrosio et al., 2002). 
 
Following confirmation of CCL17- and CCL22-induced chemotaxis, the 
binding properties of these chemokines were investigated. 0.1 nM chemokine labelled 
with radioactive iodine 125 (
125
I) was incubated with CCR4 transfectants and either 
buffer or 100 nM unlabelled chemokine. Figure 3-5 shows the results of this. 
To determine receptor affinity (Kd) and density (Bmax), the ideal assay to 
perform would have been a saturation binding assay. This would have involved 
measuring total and non-specific binding at several radiolabelled ligand 
concentrations. Due to the large volumes of radiolabelled ligand required for 
saturation binding assays, homologous competition assays can be used as an 
alternative in order to estimate Kd and Bmax. These involve using a fixed 
concentration of radiolabelled ligand and an increasing concentration of unlabelled 
chemokine. These assays require several assumptions: that there was no 
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cooperativity; that radiolabelled ligand was not depleted; that non-specific binding 
was proportional to radiolabelled ligand concentration; and that the unlabelled and 
radiolabelled ligands had identical affinity for the receptor. 
Cooperativity is the phenomenon in which the affinity of a ligand for its 
receptor changes dependent on ligand concentration (Motulsky and Christopoulos, 
2004). Since, there is no published evidence for CCR4 or other chemokine receptors 
exhibiting cooperative binding, it is assumed that no cooperativity occurred in the 
binding assays presented here. 
Ligand depletion is a phenomenon that occurs when more than 10% of the 
added radiolabelled ligand binds during the assay incubation. This means that the free 
concentration of ligand is not equal to the added concentration (Daugherty et al., 
2000). Ligand depletion can be tested by measuring the radioactivity emitted from 
free ligand; in the case of the whole-cell binding assay, after centrifugation the 
radiation emitted from the free ligand was measured. This was then compared to the 
counts measured from ligand incubated without cells, in which no binding would 
have occurred. The two values were identical, indicating that no depletion had 
occurred in the CCR4 binding assays.  
The third assumption, that non-specific binding was proportional to ligand 
concentration, has been shown to be true in multiple systems (Motulsky and 
Christopoulos, 2004). 
The final assumption - that the ligands had identical affinity - is quite a major 
one since it assumes that the iodinated chemokine has not been structurally altered. 
Since the iodination process attached iodine molecules to tyrosine residues within the 
protein, it would be unlikely if this did not have some degree of an effect on 
chemokine-receptor interaction. However, the chemokines were iodinated through the 
use of the enzyme lactoperoxidase, which is considered a more gentle way of 
achieving iodination than by other methods; as such, protein function is more likely 
to remain conserved than if another method was used (Bennett and Horuk, 1997).  
Despite this, the data in the CCR4 binding assays shown in figures 3-5, 3-6 
and 3-7 indicate that the radiolabelled chemokines do not bind CCR4 with the same 
affinity as unlabelled chemokines, as described in section 3.2.3. The Kd of the ligands 
could therefore not be determined. The Ki was therefore used to compare the potency 
of 
125
I-chemokine inhibition by the unlabelled chemokines. It was shown that both 
unlabelled ligands inhibited 
125
I-CCL17 and 
125
I-CCL22 binding with similar 
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potencies. This indicates that the two ligands occupied the same binding site on 
CCR4, as they were both able to displace the radiolabelled chemokines. It was shown 
however that CCL17 could not fully displace 
125
I-CCL22, suggesting that a 
population of receptors may exist that only bind CCL22. 
The data also suggest that the addition of radioactive iodine to the chemokines 
significantly perturbs their structure enough to cause a change in affinity for CCR4. 
This finding has implications for future assays performed with the radiolabelled 
chemokines, since it is often assumed that the labelled and unlabelled ligands bind the 
receptor in the same manner. 
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3.3.2 – GluVII:06 (E290) within transmembrane domain 7 is critical for 
CCR4 function 
Mutation of the GluVII:06 (E290) at the top of transmembrane domain 7 was 
carried out due to its conservation in other receptors and the important role it plays in 
chemokine-induced signalling. In the data shown here, mutation of this residue in 
CCR4 to alanine, aspartic acid or glutamic acid removed the ability of the receptor to 
bind either chemokine, and thus prevented chemotaxis (figure 3-8). These results 
clearly show that the charge and shape of the side group is necessary for chemokine 
binding and thus receptor function. 
Mutations of GluVII:06 in other receptors had similar effects; this residue in 
CCR2, E291, was shown to be important for chemokine function. When mutated to 
alanine and glutamine, CCL2 binding was significantly reduced in potency 
(Mirzadegan et al., 2000). The acidic side chain of GluVII:06 was believed to interact 
with basic residues in CCL2. Mutation to alanine and glutamine, amino acids with 
uncharged side chains, would have removed this acid-base interaction, leading to the 
loss of binding. 
However, mutation of GluVII:06 of CCR1 and CCR5 to alanine and 
glutamine did not perturb chemotaxis of transfectants; the CCR1 and CCR5 mutants 
were still able to induce chemotaxis to the chemokine CCL3 (Hall et al., 2009; de 
Mendonça et al., 2005). GluVII:06 of CCR1 was believed to interact with the basic 
lysine and arginine side chains of CCL3, however the data show that this residue is 
not essential for chemokine binding (de Mendonça et al., 2005). CCR1 and CCR5 
thus seem to differ to other chemokine receptors in that GluVII:06 is not an essential 
interaction point for chemokines. 
Mutation of GluVII:06 (E287) of CCR3 induced a less efficacious 
chemotactic response to CCL11 than WT CCR3; approximately half the number of 
cells migrated in a chemotaxis assay (Wise et al., 2007). Receptor modelling 
implicated GluVII:06 (E287) of CCR3 in the binding of proline 2 (P2) of CCL11; 
disruption of this interaction may explain the reduced efficacy of the chemokine. 
However, since some function was retained, it can be concluded that chemokine 
binding was not fully ablated in the CCR3 mutant, unlike data shown here for CCR4. 
Again this demonstrates that the same conserved residues have differing roles in 
different receptors. 
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When placed in context with other chemokine receptor mutants, it is likely 
that the CCR4 GluVII:06 mutations presented here have disrupted a network of bonds 
that are required for receptor conformations that can recognise chemokine, leading to 
the receptor being unable to bind either ligand. Since the binding assays were carried 
out with 0.1 nM radiolabelled chemokine, it may be the case that binding is only 
perturbed at this particular concentration. The mutations may have just removed high-
affinity binding of the chemokines, and an increased concentration may reveal some 
degree of binding occurring due to the retention of low-affinity binding. A two-step 
binding model has been previously been proposed, and mutation of GluVII:06 may 
have removed the ability of the chemokine to bind in the second higher affinity stage 
(Monteclaro and Charo, 1997). 
Other point mutants on the extracellular end of transmembrane domains and 
in the extracellular loops also have been shown to prevent the receptor from binding 
ligand. In most Rhodopsin-type GPCRs, a disulphide bond is formed between two 
highly conserved cysteines, one located in ECL2 and the other at the top of 
transmembrane helix III (Palczewski, 2000). This bond provides structural 
stabilisation of the receptor; in the rat M1 muscarinic receptor, mutation of these 
cysteines to serines prevented ligand binding (Savareses et al., 1992). Mutation of 
these to alanine in the M3 receptor as well as the β2-adrenergic receptor had a similar 
effect; ligand binding affinity and receptor expression were significantly reduced, 
suggesting reduced stability of receptor conformation (Zeng et al., 1999; Noda et al., 
1994). Two acidic residues within the second extracellular loop of CXCR3, D195 and 
E196, were postulated to form a salt bridge and provide structural stabilisation of 
ligand-binding conformations of the receptor. Interestingly, when mutated the 
receptor had impaired CXCL10 binding but not CXCL11 binding, indicating that 
certain receptor motifs and thus conformations are chemokine-specific (Nedjai et al., 
2012). The studies demonstrate that several key amino acids within the receptor, 
when mutated, perturb ligand binding. 
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3.3.3 – CCL17 and CCL22 stabilise distinct conformations of CCR4 
Since many chemokine receptors bind more than one ligand, and some 
chemokines bind to multiple receptors, the chemokine system has often been 
described as redundant or promiscuous (Lukacs et al., 1999; Power 2003). It was also 
postulated that this apparent redundancy made the chemokine system robust, in that 
genetic mutations or other factors reducing one chemotactic signal would result in 
compensation by another signal (Mantovani, 1999). However, these descriptions were 
used before some of the complexities of the chemokine network were fully realised. 
As previously described in section 1.3.2, mixed populations of cells were assayed for 
chemotactic function and the resulting responses to multiple ligands were interpreted 
as evidence of redundancy (Schall & Proudfoot, 2011). 
Since it can be argued that chemokines and their receptors may not be 
performing redundant functions, that instead the chemokine network is highly 
complex, it could also be argued that multiple ligands for the same receptor have 
distinct roles. Indeed, chemokines that bind the same receptor have been shown to 
induce different effects. CCL19 and CCL21, the two ligands for CCR7, have similar 
binding affinities and induce chemotaxis with the same potency (Sullivan et al., 2000; 
Yoshida et al., 1998; Ott et al., 2004). However only CCL19 induced receptor 
internalisation, whereas CCL21 treatment had no effect on receptor levels (Bardi et 
al., 2001). Subsequent research showed that this internalisation is coupled with 
receptor desensitisation. Receptor desensitisation involves the phosphorylation of the 
C-terminus of the GPCR by GPCR kinases (GRKs), leading the recruitment of 
arrestins, which then allow attenuation of GPCR signalling by way of G protein 
decoupling and recruitment of other binding partners. CCR7 was shown to be 
desensitised by CCL19 but not CCL21; CCR7-expressing membranes showed a 
reduced ability to signal through G proteins after treatment with CCL19, whereas 
CCL21 signalling was unaffected. A greater level of receptor phosphorylation was 
shown to occur after CCL19 treatment when compared to CCL21 treatment, 
indicating that the two ligands induce different effects upon the receptor (Kohout et 
al., 2004). Subsequent research showed that arrestin 3 co-localised with CCR7 
following CCL19-induced internalisation, whereas arrestin 3 was not associated with 
CCL21 (Byers et al., 2008). Since the two ligands are differentially expressed, 
CCL19 within the high endothelial venules and CCL21 within the T-cell zones 
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(Campbell and Butcher, 2000), their differing effects upon the receptor likely reflect 
distinct biological roles. 
Another chemokine receptor, CCR5, was also shown to be differentially 
phosphorylated and internalised by its ligands; CCL5 induced a greater degree of 
receptor phosphorylation and internalisation than CCL3, which itself was more 
effective at doing so than CCL4. As with CCR7, this receptor phosphorylation was 
carried out by GRKs acting on C-terminal serine residues (Oppermann et al., 1999). 
These data on chemokine receptors show that the activity of different ligands 
through the same receptor is not redundant; each induce different effects on the 
receptor which likely have in vivo significance. Therefore, considering these findings 
in context with the data presented here on CCR4 may suggest that it too is 
differentially activated by its ligands. 
 
It has been reported that CCL22 induces a greater degree of receptor 
activation and desensitisation than CCL17; in both TH2 cells and CCR4-transfected 
L1.2 cells CCL22 induced a greater degree of calcium mobilisation than CCL17. In 
addition to this, CCL22 treatment of cells desensitised the calcium response to 
subsequent CCL17 treatment, whereas treatment of CCL17 followed by CCL22 did 
not produce the same magnitude of receptor desensitisation (Ambrosio et al., 2002; 
James Pease, personal communication). This may indicate that the different binding 
potencies and chemotactic efficacies of CCL22 and CCL17 demonstrated here are not 
solely due to receptor-chemokine interactions; downstream G protein signalling is 
likely differentially activated by the two chemokines, which may explain the larger 
efficacy of CCL22-induced chemotaxis seen in figure 3-4. 
Figure 3-7 shows heterologous competition assays of CCR4-expressing CEM-
4 cells. While CCL17 and CCL22 could fully compete with 
125
I-CCL17, only CCL22 
could fully compete with 
125
I-CCL22, suggesting that a population of receptors exists 
that is unable to bind CCL17. These data are reminiscent of those previously reported 
regarding CXCR3 and its ligands, CXCL9, CXCL10 and CXCL11. These three 
chemokines exhibited different potencies when competed with the radiolabelled 
chemokines. CXCL10 and CXCL11 could displace 
125
I-CXCL10 with equal potency; 
however CXCL9 did so with a lower potency. CXCL11 could fully displace 
125
I-
CXCL11, but CXCL9 and CXCL10 could not; as well as showing lower potency, 
these chemokines did not fully displace the 
125
I-CXCL11 even at micromolar 
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concentrations (Nedjai et al., 2012; Cox et al., 2001; Xanthou et al., 2003). It was also 
shown that CXCL11 bound to uncoupled CXCR3, unlike CXCL9 and CXCL10. It 
was concluded that CXCL11 bound to a different, allotopic, site on the receptor and 
thus was not binding in a classical competitive manner (Cox et al., 2001). 
Since the allotopic binding of CXCR3 ligands is dictated by coupling to G 
proteins (Cox et al., 2001), the same was hypothesised to be true of CCR4 and its 
differential ligand binding. When treated with Pertussis toxin to uncouple the 
receptor from G proteins, the same phenomenon was observed; despite a reduction in 
125
I-chemokine binding, there existed a population of receptors that still bound 
125
I-
CCL22 despite being uncoupled and incubated with excess CCL17 (James Pease, 
personal communication). Therefore it can be concluded that the results shown in 
figure 3-7 regarding the differential binding of CCL17 and CCL22 signify that the 
ligands bind different receptor states; CCL22 may be able to bind both coupled and 
uncoupled receptors while CCL17 only binds coupled receptors. 
Figure 3-9 shows the effect of the K310N mutation on CCR4 expression, 
chemotaxis, and binding. Since the lysine to asparagine mutation did not affect 
receptor expression when compared to WT CCR4 (figure 3-9A), it can be surmised 
that any ionic interactions dependent on the lysine side group were not essential for 
receptor expression. The mutation did however affect the functionality of the 
receptor; the chemotactic response to CCL17 was ablated (figure 3-9B). Despite the 
lack of response to CCL17, responses to CCL22 were intact (figure 3-9C). While 
efficacy to this ligand was significantly reduced by the mutation, a large response was 
still observed. 
Our initial conclusion regarding these data was that the mutation had 
disrupted chemokine binding, leading to the loss of chemotaxis to CCL17 and the 
reduced response to CCL22. However it was shown that the K310N mutants retained 
the ability to bind chemokine. CCL17 and CCL22 showed similar logKi values in 
binding assays, indicating that the mutation had not affected chemokine binding 
affinity, although this would need to be confirmed by performing saturation binding 
assays. 
This result was interesting for several reasons. The first reason is that such a 
mutation does not normally lead to a receptor capable of responding to one ligand and 
not the other; data presented in chapters 4 and 5 show that most point mutations either 
render the receptor completely non-functional or have no affect on chemotaxis. Many 
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receptor point mutants of CCR4 did not induce chemotaxis to ligand, and after 
investigation it was determined that was due to a lack of binding (see chapters 4 and 
5). For example, the GluVII:06 (E290) mutants shown in figure 3-8 were unable to 
bind chemokine, rendering them non-functional. This phenomenon is discussed in 
section 3.3.2. 
The K310N mutant however retained the ability to bind both chemokines but 
did not induce chemotaxis to CCL17. Therefore, signalling in response to CCL17 
binding had been disrupted by the mutation. The fact that the logKi values were not 
affected by the mutation despite a reduction in total 
125
I-chemokine binding suggests 
that K310 is involved in receptor activation. 
Receptor mutations have previously been reported to prevent ligand-induced 
signalling while not affecting ligand binding. As described in section 1.3.1, the highly 
conserved DRYLAIV motif located at the end of transmembrane helix II of most 
GPCRs plays a critical role in receptor signalling and is believed to form an ‘ionic 
lock’ (Rovati and Neubig, 2007; Palczewski, 2000). When this region is mutated, 
receptor signalling can be drastically affected. For example, mutation of this region in 
somatostatin receptor 5, a hormone-responsive GPCR, led to markedly reduced 
calcium signalling and cAMP production (Peverelli et al., 2009). Mutation of the 
arginine in this region to asparagine in CCR5 did not affect CCL4 binding - the 
affinity of the chemokine for the mutant was unaltered compared to the WT receptor - 
but signalling was lost, indicated by the lack of G protein coupling and chemotaxis 
(Lagane et al., 2005). 
These findings indicate that the interaction between the DRYLAIV motif and 
transmembrane helix VI is an important and conserved one that plays a major role in 
receptor activation. Since these mutations can affect receptor function, it is not 
unimaginable that a mutation such as K310N in CCR4 could also do the same. Since 
the DRYLAIV mutations disrupted ionic interactions between helices and prevented 
G protein coupling, the mutation of K310 within the highly conserved helix VIII 
region could feasibly disrupt recruitment of other signalling partners. 
 
The C-termini of other GPCRs, including chemokine receptors, have been 
implicated in receptor function. The conserved helix VIII region in particular has 
been shown to have an important role. A truncation mutant of CCR7, in which the C-
terminus was removed, removed the ability of the receptor to activate G proteins and 
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thus induce chemotaxis, implying that a G protein activation motif lies within this 
region. Further analysis narrowed down this region to an 11 amino acid motif at the 
proximal end of the C-terminus, directly after the seventh transmembrane domain 
(Otero et al., 2008), which is the location of the putative helix VIII (see section 
1.3.2.3). Similar truncations of these regions in CCR3, CCR5 and CXCR3 gave 
similar results, including poor cell migration and calcium mobilisation (Sabroe et al., 
2005; Kraft et al., 2001; Dagan-Berger, 2006; Colvin et al., 2006). Non-chemokine 
receptor GPCRs also rely on signalling through helix VIII; for example, mutations of 
residues within the eighth helix of the thrombin receptor PAR1 disrupted ionic 
interactions with residues in transmembrane helix VII and intracellular loop 1, and 
prevented signalling through Gαq proteins (Swift et al., 2006). 
Analysis of the crystal structure of squid rhodopsin adds weight to the 
hypothesis of helix VIII signalling via G proteins, and in particular implicates the 
homolog of K310 in CCR4. Several residues of squid rhodopsin, including D132 and 
R133 of the DRYLAIV motif as well as K321 of helix VIII, interacted with the 
amphiphilic compound octylglucoside; a detergent used in the preparation of protein 
crystals. This binding was believed to mimic Gαq binding and provide stabilization of 
the cytoplasmic domain of the receptor, thus facilitating signalling (Murakami and 
Kouyama, 2008). These studies suggest that K310 of CCR4 may also be involved in 
G protein signalling. However the results presented here, that mutation of an eighth 
helix residue leads to differential ligand activity, are novel. No references to single 
mutations having this effect on GPCR function could be found in the literature; 
however these data may support the notion of biased agonism. 
Biased agonism is the term given to the observation that different ligands for a 
receptor do not activate the same repertoire of downstream signalling partners. 
Rather, each agonist stabilises distinct receptor conformations that in turn activate 
pathways specific to that ligand (Kenakin, 2009). The β2-adrengergic receptor, like 
other GPCRs, is conformationally flexible when not bound to an agonist. The model 
proposes that the catechol ring of norepinephrine first stabilises interactions between 
transmembrane helices V and VI. This allows an amine nitrogen to interact with an 
aspartic acid in helix III, which then allows the receptor to bind the β-hydroxyl group 
of norepinephrine (Swaminath et al., 2004). 
 As described previously, GPCRs couple to G proteins in order to signal, as 
well as binding arrestins and other proteins. It has been demonstrated that different 
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receptor agonists induce different levels of G protein and arrestin recruitment; some 
agonists show a G protein or arrestin bias. The β2-adrenergic receptor shows identical 
activation of G proteins and recruitment of arrestins when bound to most ligands, 
however three ligands in particular induced a biased phenotype; isoetharine, CPB (N-
cyclopentylbutanephrine) and ethyl-norepinephrine induced a greater degree of 
arrestin recruitment relative to G protein activation (Drake et al., 2008). Also, as 
previously described, CCL19 and CCL21 both induce G protein signalling through 
CCR7 while only CCL19 induces receptor phosphorylation and arrestin recruitment 
(Kohout et al., 2004). 
When the data shown here regarding CCR4 are placed in context with the 
research described above regarding biased agonism and ligands inducing unique 
receptor conformations, we hypothesise that CCR4 is stabilised into two distinct 
conformations by the chemokines CCL17 and CCL22. Figure 3-10 shows this model. 
We propose that there are two distinct CCR4 populations. The major species (R1) 
signals in response to both CCL17 and CCL22 while the minor species (R2) signals 
only in response to CCL22. This model accounts for the data shown in this chapter 
and those in unpublished data (Viney et al., in preparation); a second population of 
receptors able to respond to CCL22 alone would explain why CCL17 treatment 
cannot desensitise the receptor against subsequent CCL22 treatment. Also, the 
inability of the CCL17 to fully compete with CCL22 for binding (figure 3-7) would 
again by explained by this model. Since this incomplete displacement left 20% of 
125
I-CCL22 bound, we propose that R2 compromises the same proportion of total 
receptor numbers. 10E4 detected a larger level of CCR4 than 1G1 (figure 3-2), and 
was able to detect CCL17-induced internalisation (figure 3-3), again implying that it 
can recognise different receptor conformations. Since K310 mutation removed 
chemotactic responsiveness of the receptor to CCL17 but not CCL22, while still 
maintaining binding, we propose that this residue is required for functionality of R1; 
when mutated R2 is still able to respond to CCL22 and induce chemotaxis. 
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Figure 3-10 – Two-population model of CCR4 
Two species of CCR4 are proposed to exist; one that responds to CCL17 and CCL22 
(R1; left) and another that only responds to CCL22 (R2; right). R1 is the major species, 
comprising 80% of receptors. It is detected by the 10E4 antibody and its function is 
mediated by K310 in the C-terminus. R2 comprises 20% of receptors, is not detected by 
10E4, and does not require K310 for function. 
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3.3.4 – Summary 
In summary, L1.2 cells serve as a platform for functional CCR4 expression. 
The 10E4 and 1G1 antibodies were shown to detect different levels of cell-surface 
CCR4 on Hut78 cells, and different levels of chemokine-induced internalisation. The 
C-terminal K310N mutation of CCR4 ablated chemotactic responses to CCL17 but 
not CCL22. These data, along with unpublished data (Viney et al., in preparation), 
suggest that CCL17 and CCL22 stabilise distinct conformations of CCR4. In 
addition, the conserved residue GluVII:06 (E290) located with transmembrane 
domain 7 was shown to be critical for chemokine binding and thus receptor function. 
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4 – Investigation of intrahelical CCR4 antagonists by 
receptor point mutation 
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4.1 – Introduction 
In the preceding chapter, CCR4 was shown to be expressed on the surface of 
L1.2 cells after transient transfection. CCR4 was shown to bind both CCL17 and 
CCL22, and induce migration toward these chemokines. The K310N, E290A, E290D 
and E290Q point mutants were investigated for their effects on receptor function. In 
this chapter, the activities of several CCR4 antagonists will be discussed in relation to 
other point mutants of CCR4. 
Since GPCRs comprise such a large family of cell-surface receptors and bind 
a huge array of ligands, they unsurprisingly are involved in the pathogenesis of many 
diseases, and as such are important targets for therapeutic intervention. Current 
GPCR antagonists in therapeutic use include beta blockers, which antagonise β-
adrenergic receptors. Upon stimulation these receptors can cause increases in heart 
rate and blood pressure. As such, beta blockers are used to antagonise these receptors 
to treat conditions such as angina or high blood pressure (Frishman, 2003). As 
described in section 1.1, histamine release by mast cells and basophils leads to the 
swelling and redness associated with an allergic reaction. A common treatment for 
this reaction is through the use of histamine H1 receptor inverse agonists; these reduce 
the functional output of the receptor and thus limit histamine-associated effects such 
as swelling (Leurs et al., 2002). 
Agonists or antagonists for GPCRs thus have the potential to ameliorate 
disease states by counteracting the signalling pathways associated with them. For 
example, in diseases such as asthma and atopic dermatitis, CCR4-expressing TH2 
cells contribute to pathology by secreting the cytokines IL-4, IL-5 and IL-13, which 
lead to eosinophil recruitment and antibody production. By developing antagonists 
against CCR4 it is hoped that symptoms associated with CCR4
+
 cells could be 
reduced (see section 1.4.3). As previously described, antagonists can be classified as 
either orthosteric or allosteric. Orthosteric antagonists bind to the endogenous agonist 
binding site on the receptor, and therefore compete with the receptor ligand. 
Allosteric antagonists however bind to a site distinct from the agonist, preventing 
receptor activation without competing with the ligand (see section 1.4.4). 
Seven allosteric CCR4 antagonists have been supplied by GlaxoSmithKline 
(GSK). Four of these antagonists - denoted antagonists 1, 3, 4, and 7 - are 
hypothesised to bind to a site within the transmembrane bundle of the receptor known 
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as site 1. The remaining three antagonists are hypothesised to bind to an intracellular 
site, known as site 2, which will be discussed in chapter 5. The binding of antagonists 
to the transmembrane bundle, referred to as intrahelical or ‘classical’ binding, is the 
principal mechanism by which receptor antagonists were believed to act and inhibit 
receptor function. The adenosine, dopamine, neurokinin, opiod and serotonin 
receptors are all examples of GPCRs that have had allosteric modulators for them 
identified or developed (reviewed in Conn et al., 2009). Several allosteric antagonists 
for chemokine receptors have also been identified that also bind this site, for targets 
including CCR1, CCR3 and CCR5 (de Mendonça et al., 2005; Wise et al., 2007; 
Vaidehi et al., 2006; Dorr et al., 2005; Dragic et al., 2000). 
The four intrahelical antagonists described here are lipophilic amines. The 
structures of the antagonists are shown in figure 4-1. The compounds all contain 
several simple aromatic rings. Antagonist 3 is a derivative of antagonist 4, while 
antagonists 1 and 7 are of different structural classes. 
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Figure 4-1 – Site 1 antagonists 
The structures of the four site 1 (intrahelical) allosteric antagonists are shown. These 
were supplied by GlaxoSmithKline (GSK), and were hypothesised to bind within the 
transmembrane bundle of CCR4. 
133 
 
Molecular modelling performed by scientists at GlaxoSmithKline identified 
several amino acids of CCR4 potentially involved in antagonist binding. Figure 4-2A 
shows a cartoon of CCR4, with its extracellular N-terminus and three extracellular 
loops (ECL), seven transmembrane (TM) domains, and intracellular C-terminus and 
three intracellular loops (ICL). Seventeen amino acids were predicted to be points of 
contact for the site 1 antagonists; these are highlighted in green. Eight of these were 
located within transmembrane helix III, indicating its potential importance in 
antagonist activity. Four were located in the second extracellular loop, while the rest 
were in transmembrane domains 2, 4, 5 and 7. Panel B of this figure shows a 
molecular model of the predicted interaction of the site 1 compounds with the 
transmembrane domains of CCR4. 
The seventeen highlighted amino acids were comprised of seven different 
types; leucine, isoleucine, serine, tyrosine, phenylalanine, lysine and glutamic acid. 
Lysine is positively charged and glutamic acid negatively charged, due to their 
respective amino and carboxyl side groups. Serine and tyrosine are weakly polar, due 
to the presence of electronegative groups causing an uneven distribution of electrons 
in their side chains. Leucine, isoleucine and phenylalanine are strongly hydrophobic 
due to their non-polar side chains, explaining their positions in or near the 
transmembrane domains of the receptor. 
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Figure 4-2 – Model of site 1 antagonist binding 
(A) A cartoon of CCR4 showing the extracellular N-terminus and 3 extracellular loops, 
seven transmembrane domains, and the intracellular C-terminus and 3 intracellular 
loops. Highlighted in green are the seventeen predicted contact points of site 1 
antagonists, located in transmembrane domains 2, 3, 4, 5 and 7, as well as extracellular 
loop 2. (B) Molecular modelling performed by GSK, showing the predicted interactions 
of the site 1 compounds with the transmembrane domains of CCR4. From Nick Barton 
(personal communication).  
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To investigate the contribution of these amino acids to antagonist binding and 
thus antagonist activity, point mutants of these residues were made. The rationale 
behind this method was that by mutating the particular side chain of an amino acid of 
interest, the properties that lent it to antagonist binding were removed. For example, 
tyrosine 117 (Y117) within the 3
rd
 transmembrane domain was predicted to be a point 
of contact for the site 1 antagonists. The structure of tyrosine is shown in figure 4-3A; 
it contains a phenol group, which is fairly bulky compared to other amino acid side 
chains. In order to determine the contribution of this tyrosine to antagonist binding, it 
was mutated to alanine (Y117A). Functional studies were then performed on Y117A 
and compared to WT CCR4 in which the tyrosine remained. The structure of alanine 
is shown in figure 4-3B; it has a CH3 group, which compared to tyrosine’s phenol 
group is much smaller in size. In addition to size, the side chains of the amino acids 
also affect charge and polarity. Alanine is neutral and non-polar, whereas tyrosine is 
neutral and polar. This polarity is due to the hydroxyl group present in the side chain. 
Another mutation, Y117F, was also made; this involved mutation of tyrosine 
to phenylalanine, the structure of which is shown in figure 4-3C. Phenylalanine, like 
tyrosine, also contains a large benzene ring in its side chain. However the lack of the 
hydroxyl group in phenylalanine renders this amino acid neutral and non-polar. These 
two mutations allowed dissection of the relative contribution of size and polarity to 
antagonist binding; by performing assays on both and comparing them to WT CCR4 
it could be ascertained which property, if any, was important for antagonist binding. 
Glutamic acids 205 (E205) and 290 (E290) were mutated to alanine, aspartic acid and 
glutamine in order to dissect the contribution of size and charge of the side chain of 
this amino acid. Mutation to aspartic acid maintained the charge while removing the 
bulk associated with the glutamic acid. Mutation to glutamine retained the bulk of 
glutamic acid while removing the charge. Mutation to alanine removed both the bulk 
and charge of glutamic acid. 
 
Previous studies have used receptor mutation to investigate antagonist binding 
and activity as well as receptor function, the latter described in section 1.1. The 
antagonist UCB36526 was predicted to bind several amino acids within the 
transmembrane domains of CCR1, analogous to the site 1 CCR4 compounds 
presented here. The E287Q, Y113A, and Y41A CCR1 mutants showed resistance to 
UCB36526 in chemotaxis assays; 100 nM of the compound completely inhibited the 
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wild-type response to CCL3 but did not inhibit the mutant responses. Molecular 
modelling of the receptor-antagonist interaction suggested the formation of a salt 
bridge between E287 and the quaternary nitrogen of the compound (de Mendonça et 
al., 2005). The same antagonist was shown to inhibit CCR3 responses, and as with 
CCR1, the conserved E287 and Y113 residues were required for its activity (Wise et 
al., 2007). Y113A of CCR1 was also critical for the activity of another antagonist, 
BX 471 (Vaidehi et al., 2006). 
Figure 4-3G shows the site 1 residues implicated in antagonist binding along 
with the mutations of these residues. Most mutations were to alanine, which as 
described is small, neutral, and non-polar. This mutation therefore removed any 
specific effects of size, charge or polarity of that amino acid. Tyrosines 117, 122 and 
258 were mutated to both alanine and phenylalanine. In addition to this, glutamic acid 
205 (E205) was mutated to alanine (E205A), aspartic acid (E205D), and glutamine 
(E205Q), the structures of which are shown in figure 4-3D-F. In section 3.2.4 the 
rationale for this strategy was explained in reference to the three E290 mutants; 
mutation to these three amino acids allowed the relative contribution of side chain 
size and charge on antagonist binding to be determined. 
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Location TM2 TM3 TM4 ECL2 TM5 TM6 TM7 
Mutation 
L92A I113A F173A K188A L209A Y258A I286A 
 S114A  S202A  Y258F E290A 
 Y117A  E205A   E290D 
 Y117F  E205D   E290Q 
 L118A  E205Q    
 F121A  I206A    
 Y122A      
 Y122F      
 I125A      
 F126A      
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Figure 4-3 – Site 1 amino acid point mutations 
Structures of amino acids; tyrosine 117 (A) was mutated to alanine (B) and 
phenylalanine (C). Glutamic acid 290 (D) was mutated to alanine, glutamine (E), and 
aspartic acid (F) and glutamine. Side chains of the amino acids are shown in boxes. 
Panel G shows a summary table of the site 1 point mutants along with their location in 
the receptor. 
 
G 
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4.2 – Results 
4.2.1 – Cell-surface expression of site 1 CCR4 point mutants 
Since the intrahelical CCR4 antagonists were believed to contact sites within 
the transmembrane bundle, point mutants of these residues were made by performing 
site-directed mutagenesis on the CCR4 insert within the pcDNA vector. These 
mutants were then transiently transfected into L1.2 cells and the following day their 
cell-surface expression measured using antibody staining and flow cytometry. In 
total, 25 point mutants were made of 18 residues. Figure 4-4 shows the cell surface 
expression of the various CCR4 point mutants after transfection. Receptor mutation 
had a wide variety of effects on cell-surface expression. L92A and L118A showed 
significantly increased levels of expression, with L92A expressed at 150% of WT 
CCR4 levels. Most of the point mutants showed no difference in expression; F121A, 
I113A, K188A, S202A, I206A, Y117A, Y117F, I125A, Y122F, F126A, E205A, 
E205D, E205Q and I286A all had expression levels comparable to WT, although 
Y117F, I125A and E290Q showed a trend to an increase. The remaining mutants 
S114A, Y122A, Y258A, Y258F, F173A, L209A, E290A and E290D were expressed 
at lower levels than WT. Y122A, Y258A and E290A showed the most marked 
reduction, expressing at 50% of WT levels. These data are summarised in table 4-5, 
which shows the change in cell-surface expression of a mutant relative to WT CCR4. 
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Figure 4-4 – CCR4 point mutants show variability in cell-surface expression levels 
L1.2 cells were transiently transfected with WT and mutant CCR4 pcDNA and the 
following day analysed for cell surface expression by flow cytometry. The black bar 
shows WT CCR4, grey bars show individual point mutants. Data are presented as 
percentage of WT expression, and as the mean ± SEM of three independent 
experiments. Data were analysed by one-way ANOVA. Significance stars *, ** and *** 
represent p values of 0.05, 0.01, and 0.001 respectively. 
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Mutant Relative expression Mutant Relative expression 
L92A ↑ S202A - 
I113A - E205A ↓ 
S114A ↓ E205D ↓ 
Y117A - E205Q - 
Y117F - I206A - 
L118A ↑ L209A ↓ 
F121A - Y258A ↓ 
Y122A ↓ Y258F ↓ 
Y122F - I286A - 
I125A - E290A - 
F126A - E290D ↓ 
F173A ↓ E290Q - 
K188A -   
 
 
  
Table 4-5 – Changes in cell-surface expression of CCR4 site 1 point mutants 
A summary table of the relative cell-surface expression changes from figure 4-4. - = no 
change relative to WT, ↑ = increase relative to WT, ↓ = decrease relative to WT. 
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4.2.2 – Migratory potential of site 1 CCR4 point mutant transfectants to 
CCL17 and CCL22 
After cell-surface expression was determined, the point mutant transfectants 
were assessed for their ability to migrate to soluble CCL17 and CCL22 in chemotaxis 
assays. These assays used concentrations of CCL17 and CCL22 ranging from 0.1 to 
100 nM; it was previously shown in WT CCR4 L1.2 transfectants that the typical 
response observed during chemotaxis assays peaked at 1 nM (figure 3-4). The 
mutants were compared to WT across this concentration range. 
Figure 4-6 shows the results of the chemotaxis assays of the mutants 
compared to WT CCR4. Some mutants, such as I113A, showed no difference in 
terms of migration to both CCL17 and CCL22 when compared to WT CCR4. Other 
mutants that exhibited this behaviour were K188A, S202A, Y258F, F173A, and 
E205Q. Other mutants showed no chemotactic response to either ligand; L29A, 
Y117A, Y122A, Y258A and the three E290 mutants did not induce migration above 
baseline levels. Another effect of receptor mutation was to decrease the potency of 
the chemokine relative to the WT response; for example, F121A mutation shifted the 
peak response of both CCL17 and CCL22 rightwards to 10 nM rather than its normal 
peak at 1 nM. The chemotactic responses of the mutants E205D, I206A, Y117F, 
I125A, Y122F, F126A, I286A, and E205A all showed a reduction in potency to one 
or both chemokines. The chemotactic response of I268A to CCL22, while reduced in 
potency compared to the WT response, showed an increase in efficacy; the 
chemotactic index at 1 nM was 15 for WT CCR4, compared to 65 at 10 nM for 
I286A. These results are summarised in table 4-7; the table shows what effects each 
mutation had on the efficacy and potency of each chemokine response. 
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Figure 4-6 – CCR4 point mutation affects chemotaxis of transfectants to both 
CCL17 and CCL22 
Following analysis of cell-surface expression, WT and mutant CCR4 transfectants were 
assessed for their ability to migrate to soluble CCL17 (left-hand column) and CCL22 
(right-hand column). WT responses are shown as filled squares; mutants as open circles, 
squares and triangles. Data are the mean ± SEM of three independent experiments, and 
were analysed by two-way ANOVA. Significance stars *, ** and *** represent p values 
of 0.05, 0.01, and 0.001 respectively. 
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 CCL17 CCL22  CCL17 CCL22 
CCR4 
mutant 
Efficacy Potency Efficacy Potency 
CCR4 
mutant 
Efficacy Potency Efficacy Potency 
L92A NR NR NR NR S202A - - - - 
I113A - - - - E205A ↓ ↓ ↓ ↓ 
S114A ↓ - - - E205D ↓ ↓ ↓ ↓ 
Y117A NR NR NR NR E205Q - - - - 
Y117F ↓ ↓ - ↓ I206A - ↓ - ↓ 
L118A - - ↑ - L209A ↓ - - - 
F121A - ↓ ↓ ↓ Y258A NR NR NR NR 
Y122A NR NR NR NR Y258F - - - - 
Y122F ↓ - - ↓ I286A ↓ ↓ ↑ ↓ 
I125A ↓ ↓ - ↓ E290A NR NR NR NR 
F126A ↓ ↓ - ↓ E290D NR NR NR NR 
F173A - - - - E290Q NR NR NR NR 
K188A - - - -      
 
 
  
Table 4-7 – Changes in chemotactic response of site 1 point mutant transfectants 
A summary table of the data from figure 4-6; the effect of point mutations on efficacy 
and potency of the chemotactic response. - = no change, NR = no response, ↑ = increase 
in efficacy/potency, ↓ = decrease in efficacy/potency. 
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4.2.3 – Binding of radiolabelled chemokines to site 1 CCR4 point mutant 
transfectants 
After functional assays had been performed, the ability of chemokine to bind 
WT and mutant CCR4 was assessed. Cells expressing the receptor were incubated 
with radiolabelled ligand and either buffer or unlabelled ligand, after which they were 
centrifuged through oil. This separated the cells from the free ligand, and the counts 
from the resulting cell pellet measured. To investigate chemokine binding, 
radioactive iodinated CCL17 and CCL22 (
125
I-CCL17 and 
125
I-CCL22) were used in 
these assays. 
Figure 4-8 (panels A and B) shows the total and non-specific binding of WT 
CCR4 and the Y117A, Y122A and Y258A mutants. WT CCR4 bound both 
chemokines; there was a significant difference between the total and non-specific 
binding values for 
125
I-CCL17 and 
125
I-CCL22. The 
125
I-CCL22 binding window was 
smaller than for 
125
I-CCL17; there was 45% non-specific 
125
I-CCL22 binding 
compared to 20% for 
125
I-CCL17. The three mutants did not bind chemokine, as there 
was no significant difference between the total and non-specific binding values. In 
addition, the values for these were similar to the non-specific WT values, indicating 
that only non-specific binding was being detected. Similar results were observed for 
the mutants E205A, E205D and Y117F in panels C and D, and mutants L92A and 
I286A in panels G and H. These mutants had no significant difference between total 
and non-specific binding, indicating that they did not bind chemokine. E205Q and 
Y122F (panels C and D) however did bind chemokine, along with L118A (panels E 
and F). E205Q and L118A showed a significant difference between total and non-
specific binding for both chemokines, with a window comparable to WT CCR4 in 
that total binding reached 100%. Y122F however had a smaller binding window; the 
total binding value was 58% for 
125
I-CCL17 and 62% for 
125
I-CCL22. Panels I and J 
show the E290 mutants, which as previously described in figure 3-9, did not bind 
either 
125
I-CCL17 or 
125
I-CCL22. 
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Figure 4-8 – Whole-cell chemokine binding of CCR4 point mutant transfectants 
CCR4 transfectants were incubated with 
125
I-CCL17 (left-hand column) or 
125
I-CCL22 
(right-hand column) and buffer (total binding; black bars) or excess unlabelled 
chemokine (non-specific binding; grey bars). Panels A and B show binding of Y117A, 
Y122A, and Y258A. Panels C and D show binding of E205A, E205D, E205Q, Y117F 
and Y122F. Panels E and F shows the binding of L118A. Panels G and H show binding 
of L92A and I286A. Panels I and J show binding of E290A, E290D and E290Q. Data 
are the mean ± SEM of three independent experiments and analysed with two-way 
ANOVA, with the exception of panels C and D, which are from two experiments. 
Significance stars *, ** and *** represent p values of 0.05, 0.01, and 0.001 respectively. 
I J 
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4.2.4 – Inhibition of WT and mutant CCR4-induced chemotaxis to CCL17 
and CCL22 by the site 1 antagonists 
The allosteric antagonists were hypothesised to bind the receptor and prevent 
it from shifting into an active conformation, inhibiting its functional response. Since 
the primary response of chemokine receptors is to induce cell migration, assaying the 
ability of the antagonist to inhibit this migration would provide a measure of the 
antagonists’ activity. To investigate the ability of the CCR4 antagonists to block 
CCL17- and CCL22-induced migration, chemotaxis assays were performed. In these 
assays, cells were tested for their ability to migrate to solutions of a fixed 
concentration of chemokine and an increasing concentration of antagonist. For mutant 
transfectants that migrated to chemokine with a reduced potency, the fixed chemokine 
dose in the antagonist assays was changed accordingly. For example, the most 
efficacious chemokine concentration for E205A transfectants was 10 nM, which was 
used as the fixed chemokine concentration in the antagonist assays. By comparing the 
total migration for each antagonist concentration against the migration to chemokine 
without antagonist, the ability of the antagonist to inhibit chemotaxis could be 
determined. 
This dose-response of antagonist was used to determine its potency; at a low 
concentration of antagonist we would expect to see minimal inhibition compared to 
chemokine alone, whereas a high concentration would be expected to fully inhibit 
chemokine-induced migration. By plotting a non-linear regression curve using the 
results of this dose response, the IC50 could be measured to give a measure of the 
potency of the antagonist. The IC50 is the concentration causing half of the maximal 
inhibitory response, in this case half maximal migration. A lower IC50 would show 
that the compound is more potent as half maximal migration is reached at a lower 
concentration. IC50 values can be expressed in the concentration units of the data they 
are calculated from - in this case nM - or alternatively, in logarithmic form as a 
logIC50. An IC50 of 1 nM would be -9 when expressed as a logIC50. Antagonist 
potencies are shown here as logIC50 values. 
Figure 4-9 shows the results of inhibition of chemotaxis of L1.2 transfectants 
expressing WT CCR4 to 1 nM CCL17 and CCL22. The four site 1 compounds are 
used to antagonise the migration of these cells. The antagonists were used at 
increasing concentrations, from 1 nM to 30 µM. Migration to chemokine alone was 
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set at 100% and the inhibition of migration calculated relative to this value. Panel A 
shows that antagonists 3 and 7 inhibited CCL17-induced migration with similar 
potency; their logIC50 values were -8.00 and -8.06, respectively. Complete inhibition 
of migration occurred at 100 nM of antagonists 3 and 7. Antagonist 4 was less potent 
at inhibiting the response, with a logIC50 of -7.09, and complete inhibition occurring 
at 1 µM. Antagonist 1 was the least potent, with a logIC50 of -6.23, and full inhibition 
of the response not occurring even with 30 µM of antagonist 1. 
Panel B shows the inhibition of CCL22 migration by the antagonists. In 
contrast to panel A, antagonists 3 and 7 inhibited the response with different 
potencies; they had logIC50 values of -7.43 and -7.97, respectively. Antagonist 4 was 
poorer at inhibiting CCL22-induced migration compared to CCL17-induced 
migration, with a logIC50 of -6.06. Similarly, antagonist 1 was poorer at inhibiting 
CCL22-induced migration, with a very low logIC50 of -5.43. Even at 30 µM 
antagonist 1, there was still 25% migration occurring. 
Thus, antagonist 1 was shown to be the least potent at inhibiting CCL17- and 
CCL22-induced migration. Antagonists 3 and 7 were the most potent at inhibiting 
CCL17-induced migration. Antagonists 1, 3, and 4 were all less potent at inhibiting 
CCL22-induced migration. 
 
Of the CCR4 point mutants that were functional - those that showed a 
functional chemotactic response in figure 4-6 – several were then tested for their 
sensitivity to antagonist in the same manner as described above. Figure 4-10 shows 
the responses of L1.2 transfectants expressing WT CCR4 and L118A CCR4 to 1 nM 
CCL17 and CCL22 in the presence of three of the site 1 antagonists; antagonists 3, 4, 
and 7. Antagonist 1 is not shown due to variability in the datasets arising from the 
poor solubility of the compound. Rather than compare the response of each mutant to 
the original dose-response curves shown in figure 4-9, separate WT response curve 
were generated for each independent assay. 
Table 4-11 shows the logIC50 values from figure 4-10. Antagonist 3 logIC50 
values were not significantly different for WT or L118A for both inhibition of 
CCL17- and CCL22-induced migration. The same was true for antagonist 4 inhibition 
of migration, with the exception of a small reduction in potency against I125A-
induced migration to CCL17. Antagonist 7 however showed a large and significantly 
reduced potency against L118A CCR4 transfectants. WT CCL17 and CCL22 
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responses were inhibited with logIC50 values of -8.19 and -7.66 respectively, while 
L118A responses were inhibited with logIC50 values of -6.20 and -5.34 respectively. 
These reductions in potency were statistically significant when analysed with a t-test, 
with p values of 0.0059 and 0.000023, respectively. 
This comparison of mutant versus WT chemotaxis inhibition was then 
repeated for many of the other CCR4 point mutants. The inhibition of Y122F and 
I125A migration by site 2 antagonists is shown in figure 4-12. The effectiveness of 
the site 1 antagonists at inhibiting point mutant-induced migration was compared to 
WT by testing the significance of the differences between logIC50 values. The logIC50 
values from all of the chemotaxis assays are summarised in table 4-13 along with the 
data from figure 4-10. Table 4-13 shows that along with L118A, two other site 1 
point mutants showed reduced sensitivity to antagonist 7 in chemotaxis assay; both 
Y122F and I125A showed significantly reduced antagonist potency in the inhibition 
of CCL22-induced migration compared to WT. I125A also showed a reduction in 
potency to the CCL17 response. These two mutations are of amino acids in 
transmembrane domain 3, in close proximity to L118. The other mutants that were 
tested did not show a reduction in antagonist potency. 
The remaining site 1 mutants were also tested against antagonist 7, however 
no loss of potency was observed. The F173A, K188A and Y258F mutants were also 
tested against antagonist 4; however these experiments were only performed twice 
rather than three times. As such, statistical analyses were not performed on the 
logIC50 values. 
 
Chapter 5 discusses a class of antagonists that are hypothesised to bind to the 
CCR4 C-terminus. In chapter 5, C-terminal truncation mutants of CCR4 were made 
to dissect the role of successive portions of the C-terminus in antagonist binding. The 
Δ40 CCR4 mutant had the terminal 40 amino acids of its C-terminus truncated, 
leaving only the short helix VIII region at the end of the transmembrane helix VII. 
Since this truncation mutant did not contain any mutated site 1 amino acids, it was 
tested against the site 1 antagonists in this chapter to confirm that the C-terminus was 
not required for their function. As can be seen from the table of logIC50 values in 
table 4-13, the Δ40 truncation mutants did not significantly differ in their response to 
antagonists 3, 4, and 7 compared to WT transfectants. 
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Figure 4-9 – Antagonism of WT CCR4-induced migration of L1.2 transfectants 
CCR4 transfectants were tested for their sensitivity to the four site 1 antagonists by 
measuring migration toward 1 nM CCL17 (A) or CCL22 (B) and increasing 
concentrations of antagonist, and expressing the data as a percentage of migration to 
chemokine alone. logIC50 values for panel A - 1: -6.23 ± 0.21. 3: -8.00 ± 0.08. 4: -7.09 ± 
0.13. 7: -8.06 ± 0.07. Panel B – 1: -5.43 ± 0.23. 3: -7.43 ± 0.10. 4: -6.06 ± 0.09. 7: -7.97 
± 0.05 (B). logIC50s were calculated using non-linear regression analysis. Data points 
and logIC50s are the mean ± SEM of three independent experiments. 
A 
B 
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Figure 4-10 – L118A transfectants are less sensitive to chemotactic inhibition by 
antagonist 7 
The sensitivity of L118A transfectants to the site 1 antagonists in chemotaxis assays 
was compared to WT transfectants. Increasing concentrations of antagonists 3 (A), 4 
(B), and 7 (C) inhibited migration to 1 nM CCL17 and CCL22. Data are the mean ± 
SEM of three independent experiments. 
A 
B 
C 
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 CCL17 CCL22 
CCR4 
construct 
Antagonist 
3 logIC50 
Antagonist 
4 logIC50 
Antagonist 
7 logIC50 
Antagonist 
3 logIC50 
Antagonist 
4 logIC50 
Antagonist 7 
logIC50 
WT 
-7.98 ± 
0.06 
-6.68 ± 
0.10 
-8.23 ± 
0.04 
-7.71 ± 
0.27 
-6.16 ± 
0.13 
-7.64 ±  
0.06 
L118A 
-8.13 ± 
0.12 
-7.39 ± 
0.27 
-6.19 ± 
0.20 
-7.82 ± 
0.29 
-6.22 ± 
0.03 
-5.31 ±  
0.06 
(p=0.000012) 
 
 
  
Table 4-11 – Potency of site 1 antagonist inhibition of WT and L118A transfectants 
logIC50 values from the inhibition of WT and L118A CCR4 transfectants from figure 4-
10. logIC50 values were calculated using non-linear regression analysis, and two-tailed 
t-test used to compare values. Blue shaded columns indicate statistically significant 
differences between logIC50 values; p values of 0.007 and 0.000012 for CCL17 and 
CCL22, respectively. logIC50s are the mean ± SEM of three independent experiments. 
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Figure 4-12 – Inhibition of Y122F and I125A transfectant migration by antagonists 
3, 4 and 7 
The sensitivity of Y122F and I125A transfectants to the site 1 antagonists in chemotaxis 
assays was compared to WT transfectants. Increasing concentrations of antagonists 3 
(A), 4 (B), and 7 (C) inhibited migration to 1 nM CCL17 and CCL22. Data are the 
mean ± SEM of three independent experiments. 
A 
B 
C 
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CCR4 
Construct 
Antagonist 3 
logIC50 
Antagonist 4 
logIC50 
Antagonist 7 logIC50 
WT -7.94 ± 0.08 -6.84 ± 0.13 -8.23 ± 0.04 
I113A -8.03 ± 0.03 -7.29 ± 0.10 -8.31 ± 0.08 
WT -7.97 ± 0.16 -7.71 ± 0.46 -8.04 ± 0.21 
Y117F -7.35 ± 0.38 -7.57 ± 0.23 -7.86 ± 0.24 
WT -7.98 ± 0.06 -6.68 ± 0.10 -8.23 ± 0.04 
L118A -8.13 ± 0.12 -7.39 ± 0.27 -6.19 ± 0.20 (p=0.007) 
WT -7.74 ± 0.12 ND ND 
F121A -8.03 ± 0.23 ND ND 
WT -7.97 ± 0.16 -7.71 ± 0.46 -8.04 ± 0.21 
Y122F -7.51 ± 0.48 -6.80 ± 0.18 -7.09 ± 0.39 (p=0.12) 
WT -7.97 ± 0.16 -7.71 ± 0.46 -8.04 ± 0.18 
I125A -6.97 ± 0.50 -5.81 ± 0.07 
(p=0.05) 
-7.16 ± 0.25 (p=0.007) 
WT ND ND -7.30 ± 0.38 
F126A ND ND -7.83 ± 0.18 
WT ND -7.03 ± 0.03 -7.45 ± 0.47 
F173A ND -6.70 ± 0.38 -7.66 ± 0.50 
WT ND -7.03 ± 0.03 -7.45 ± 0.47 
K188A ND -7.19 ± 0.08 -7.91 ± 0.30 
WT ND ND -7.30 ± 0.38 
S202A ND ND -7.72 ± 0.33 
WT ND ND -7.30 ± 0.38 
I206A ND ND -7.40 ± 0.28  
WT ND -7.03 ± 0.03 -7.45 ± 0.47 
Y258F ND -6.48 ± 0.14 -7.85 ± 0.37 
WT -8.04 ± 0.11 -7.15 ± 0.24 -8.06 ± 0.01 
Δ40 -7.76 ± 0.34 -7.50 ± 0.15 -7.54 ± 0.17 
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CCR4 
Construct 
Antagonist 3 
logIC50 
Antagonist 4 
logIC50 
Antagonist 7 logIC50 
WT -7.50 ± 0.10 -6.37 ± 0.08 -7.64 ± 0.06 
I113A -7.41 ± 0.12 -6.28 ± 0.10 -7.70 ± 0.18 
WT -7.45 ± 0.27 -5.79 ± 0.07 -8.04 ± 0.24 
Y117F -7.16 ± 0.66 -6.68 ± 0.13 -7.65 ± 0.21 
WT -7.71 ± 0.27 -6.16 ± 0.13 -7.64 ± 0.06 
L118A -7.82 ± 0.29 -6.22 ± 0.03 -5.31 ± 0.06 (p=0.000012) 
WT -7.25 ± 0.10 ND ND 
F121A -7.30 ± 0.13 ND ND 
WT -7.45 ± 0.27 -5.79 ± 0.07 -8.04 ± 0.24 
Y122F -7.25 ± 0.26 -6.12 ± 0.08 -6.41 ± 0.11 (p=0.01) 
WT -7.45 ± 0.27 -5.79 ± 0.07 -8.04 ± 0.24 
I125A -6.56 ± 0.66 -5.30 ± 0.13 
(p=0.04) 
-6.51 ± 0.17 (p=0.009) 
WT ND ND -6.92 ± 0.33 
F126A ND ND -7.71 ± 0.17 
WT ND -6.16 ± 0.10 -7.45 ± 0.47 
F173A ND -5.87 ± 0.05 -7.25 ± 0.54 
WT ND -6.16 ± 0.10 -6.92 ± 0.44 
K188A ND -6.24 ± 0.11 -7.10 ± 0.57 
WT ND ND -6.92 ± 0.33 
S202A ND ND -6.95 ± 0.32 
WT ND ND -6.92 ± 0.33 
I206A ND ND -6.93 ± 0.40 
WT ND -6.16 ± 0.10 -7.45 ± 0.47 
Y258F ND -5.05 ± 0.21 -7.19 ± 0.60 
WT -7.45 ± 0.21 -6.05 ± 0.11 -7.97 ± 0.05 
Δ40 -7.16 ± 0.32 -6.50 ± 0.15 -7.64 ± 0.17 
 
 
  
Table 4-13 – Antagonist 7 has reduced potency against three site 1 mutants in 
inhibition of chemotaxis assays 
Non-linear regression was used to calculate the logIC50 values for the site 1 antagonist 
inhibition of CCR4 point mutant migration to CCL17 (A) and CCL22 (B). Mutant logIC50 
values that were significantly different to WT are highlighted in blue, and the p-values of 
the t-tests shown in brackets. Data are the mean ± SEM of three independent experiments. 
Italicised logIC50 values are two independent experiments, upon which statistical analyses 
were not performed. ND = not done. 
B 
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4.2.5 – Inhibition of 125I-chemokine binding to WT and mutant CCR4 
transfectants by site 1 antagonists 
In section 4.2.4 it was shown that L118A transfectants had reduced sensitivity 
to antagonist 7 in chemotaxis assays. Following this, the ability of the antagonist to 
antagonise chemokine binding was tested, in order to ascertain whether the reduction 
in functional potency was due to the antagonist inhibiting ligand binding. Whole-cell 
binding of chemokine was performed in a similar manner to that described previously 
(section 4.2.3). L118A transfectants were incubated with a fixed concentration of 0.1 
nM 
125
I-CCL17 or 
125
I-CCL22 and an increasing concentration of antagonist 7. Data 
were presented as a percentage of binding without antagonist, after subtraction of 
non-specific binding (100 nM unlabelled chemokine). 
Figure 4-14 shows the inhibition of 
125
I-CCL17 (panel A) and 
125
I-CCL22 
(panel B) binding to WT and L118A transfectants with antagonist 7, after 
confirmation of cell-surface expression of the receptors. Binding of 
125
I-CCL17 to 
WT CCR4 was inhibited with a logIC50 of -6.34, while binding to L118A was 
inhibited with a logIC50 of -5.77. This reduction was statistically significant 
(p=0.00022). Inhibition of CCL22 binding appeared to be reduced in potency by the 
L118A mutation; however there was no significant reduction, possibly due to 
variation in the data. 
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Figure 4-14 – Antagonist 7 inhibition of chemokine binding is less potent against 
L118A transfectants 
Binding of 
125
I-CCL17 (A) and 
125
I-CCL22 (B) to WT and L118A transfectants was 
inhibited by increasing concentrations of antagonist 7. Non-specific binding - 100 nM 
unlabelled chemokine - was subtracted from each value. logIC50 values for panel A – 
WT: -6.34 ± 0.1. L118A: -5.77 ± 0.16. logIC50 values for panel B – WT: -7.92 ± 0.19. 
L118A: -6.27 ± 0.21. Data are expressed as a percentage of binding without antagonist, 
and are the mean ± SEM of three independent experiments. 
A 
B 
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4.3 – Discussion 
4.3.1 – The effect of site 1 CCR4 point mutation on cell-surface expression 
In this chapter, the amino acids of CCR4 predicted by molecular modelling to 
be points of site 1 antagonist contact were individually mutated and the effects of 
these mutations upon receptor function and antagonist activity were measured. The 
CCR4 site 1 point mutations had a wide variety of effects on receptor cell-surface 
expression, chemotactic responses and binding of the chemokines CCL17 and 
CCL22. Some mutations had no effect on receptor phenotype, while others 
completely removed the ability of the receptor to bind or respond to chemokine. 
 
Following synthesis, proteins are exported via the endoplasmic reticulum and 
the Golgi apparatus to the cell membrane. The mechanisms by which GPCRs such as 
chemokine receptors are exported to the cell-surface are not well understood. 
However, it is believed that various chaperone proteins aid in the trafficking of 
receptors from the endoplasmic reticulum to the cell membrane, and ensure that the 
receptors are correctly folded. For example, heat shock proteins have been shown to 
aid in protein folding, stabilise misfolded proteins, and protect against heat-induced 
degradation of protein structure. Other accessory proteins have also been 
demonstrated as important mediators of GPCR expression; for example, Drip78 and 
ninaA are examples of small proteins that aid the trafficking of the dopamine D1 
receptor and Drosophila rhodopsin, respectively. In general, these proteins bind 
specific motifs in the GPCRs and either stabilise structure or act as chaperones 
through export pathways (Cooray et al., 2009). The mutation or disruption of motifs 
or domains required for folding or chaperone interaction may therefore negatively 
affect cell-surface expression of proteins, such as CCR4. Mutation may have also 
grossly affected the conformation of the receptor, preventing it from being effectively 
trafficked and thus targeted for degradation. The mutants of CCR4 that had reduced 
cell-surface expression included S114A, Y122A, F173A, E205A, E205D, L209A, 
Y258A, Y258F, and E290D (figure 4-4). 
 
Fifteen site 1 point mutations had no significant effect on receptor cell-surface 
expression. These were: I113A, Y117A, Y117F, F121A, Y122F, I125A, F126A, 
K188A, S202A, E205A, E205Q, I206A, I286A, E290A, and E290Q (figure 4-4). The 
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first seven of these were mutants of amino acids located in transmembrane helix III, 
while I286A, E290A and E290Q were mutations of helix VII amino acids. The 
remaining mutants were of amino acids in the second extracellular loop. Since these 
mutations had no effect on receptor expression, it can thus be surmised that either 
these mutations were of amino acids not required for receptor trafficking, or that the 
particular mutation did not perturb an interaction that was necessary for trafficking. 
An example of the latter case is highlighted in the case of the E205Q mutant. 
While E205Q CCR4 retained full receptor expression levels, the E205D mutant 
showed significantly reduced expression, to approximately 70% of WT levels. 
Glutamic acid (E) and glutamine (Q) are of similar size but differ in their charge, 
while aspartic acid (D) is negatively charged like glutamic acid but has a shorter side-
chain. Any potential interactions necessary for folding or chaperone binding may 
have thus been disrupted by the shortening of the E205 side chain. The E205A mutant 
also showed a trend to reduced receptor expression, to approximately 80% of WT 
levels. Since the glutamic acid to alanine mutation is a more extreme one than to 
aspartic acid, it follows that any interactions based on the glutamic acid side chain 
would also be disrupted upon mutation to alanine. 
A similar phenomenon was observed for the mutations of E290, the conserved 
GluVII:06 amino acid in transmembrane helix VII. The E290D mutant showed a 50% 
reduction in cell-surface expression relative to WT CCR4, while the E290A and 
E290Q mutants showed trends to a decrease and increase in expression, respectively. 
The cause of the reduced cell surface expression of E290D is likely structural rather 
than related to accessory or chaperone proteins, since this amino acid is buried within 
helix VII and forms part of the ligand binding pocket and therefore would be 
inaccessible to other proteins. It is highly conserved and has been shown to be an 
important structural motif in many chemokine receptors; therefore it is likely that 
ionic interactions necessary for receptor conformation have been disrupted by the 
mutations (see chapter 3). In CCR2 and CCR5, an interhelical network of bonds was 
postulated to exist between conserved tyrosines in transmembrane helices I and III, a 
tryptophan in helix II and the conserved GluVII:06 in helix VII. Mutagenesis of these 
residues and validation using cell-surface expression, chemotaxis and chemokine 
binding assays showed that this network was required to maintain receptor 
conformation for both cell-surface expression and receptor function (Hall et al., 
2009). 
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In addition to effects upon cell-surface expression, some of the mutations of 
the various amino acids hypothesised to comprise site 1 had effects on the ability of 
the receptor to induce chemotaxis to the chemokine CCL17 and CCL22. The E205A 
and E205D mutants, which as described had reduced cell-surface expression, showed 
a reduction in efficacy and potency in migration assays using CCL17 and CCL22 
(figure 4-6). This implies that the size of the glutamic acid is a determinant of an 
interaction necessary for receptor function; due its position in the second extracellular 
loop E205 may be required for chemokine binding or for the formation of a salt 
bridge with another amino acid in another extracellular loop. The two-step model of 
chemokine binding describes high affinity binding of chemokines to the receptor N-
terminus followed by low affinity binding to the extracellular loops (Monteclaro and 
Charo, 1997). Mutation of glutamic acid 172 of CCR5 - analogous to E205 of CCR4 - 
to alanine rendered the mutant unable to bind the chemokine CCL3. It was suggested 
that this was due to the removal of the negative charge of the amino acid (Blanpain et 
al., 2003). However, an E172D mutant was not investigated in the course of this 
study to determine whether amino acid charge or shape was the critical factor in 
chemokine binding. Mutations of several glutamic acid residues of CCR3 showed 
that those in the second extracellular loop were required for receptor trafficking to the 
cell-surface and for binding of CCL26 due to their negative charge. Other charged 
residues in the third extracellular loop were also required for CCL11 binding to the 
receptor (Duchesnes et al., 2006). 
The ability of the E205 mutants to bind CCL17 and CCL22 was also 
investigated in this project, and the results mirror those of the expression and 
chemotaxis assays (figure 4-8). E205Q binding of 
125
CCL17 did not differ 
significantly to WT binding of the chemokine, however E205A and E205D showed 
significantly reduced total binding compared to CCR4. E205A and E205D also 
showed no significant difference between total and non-specific binding at the 0.1 nM 
125
I-CCL17 concentration used in the assay. Since these mutants responded to CCL17 
in chemotaxis assays with reduced potency, it can be concluded that binding was 
below the limits of detection in this assay since they likely bound the chemokine with 
a reduced affinity. Similar results were observed for the binding of 
125
I-CCL22, 
however this assay was performed twice and as such statistical analyses could not be 
carried out. 
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In conclusion, the E205A and E205D mutations significantly reduced the cell-
surface expression, chemotactic ability, and chemokine binding ability of CCR4, 
likely due to the shortening of the glutamic acid side chain. Since the E205Q mutant 
retained its cell-surface expression, functional and binding properties, the negative 
charge of glutamic acid is therefore not a critical requirement for the function of this 
amino acid. To investigate the precise effect of mutation on chemokine binding, 
saturation binding assays would need performed using both 
125
I-CCL17 and 
125
I-
CCL22 in order to determine how chemokine affinities for the mutant receptors may 
have changed. Saturation assays use increasing concentrations of radiolabelled 
chemokine in order to determine the binding affinity of the chemokine, the Kd, and 
also the number of chemokine binding sites, the Bmax. 
The I286A mutant would be another target for saturation binding assays. 
Transfectants of this mutant migrated to CCL17 at a significantly reduced efficacy 
and potency, and to CCL22 at a decreased potency and increased efficacy (figure 4-6, 
panels S and T). This result is interesting in that the mutation had differential effects 
on the responses of the receptor to the two chemokines. The position of I286 in 
transmembrane helix VII may signify a role in chemokine activity, since it lies on 
same side of the helix as the conserved GluVII:06 (E290). Despite the changes in 
migratory responses of the mutant, there was no detectable binding of 0.1 nM 
125
I-
CCL17 and 
125
I-CCL22 to the I286A mutant (figure 4-8, panels G and H). As with 
the E205A and E205D mutants, binding is likely below the limits of detection for this 
assay, and saturation binding assays would be required to fully investigate the loss of 
binding affinity that has likely occurred as a result of this mutation. 
 
The E290 mutations had similar effects as the E205 mutants on cell-surface 
expression; the aspartic acid mutation showed a reduction in cell-surface expression 
compared to the WT receptor, indicating that the shape of the glutamic acid rather 
than the charge was important for trafficking. The E290A mutant showed a trend 
toward a reduction in expression, while the E205Q mutant showed normal 
expression. As with the E205 mutants, it shows that restoration of side group shape in 
the form of the glutamine mutation rescued receptor expression. 
In addition, the mutation of this residue ablated chemokine binding and 
function of the receptor. As previously described in section 3.3.2, the conserved 
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GluVII:06 of CCR4, in this case E290, likely forms networks of bonds necessary for 
receptor conformations that recognise chemokine. 
 
Apart from the E290 mutants, the other transmembrane mutants that showed a 
decrease in surface expression were S114A, Y122A, F173A, L209A, Y258A, and 
Y258F. Like E290, these amino acids have been shown to be required for cell-surface 
expression of the receptor, possibly due to intramolecular interactions they form with 
other parts of the receptor. For example, π-stacking, the non-covalent interaction of 
aromatic rings, can occur between tyrosine and other aromatic amino acids such as 
phenylalanine. Tyrosines 120 and 124 in helix III of CCR2, analogous to Y117 and 
Y122 here in CCR4, have been shown to form these π-stacking interactions to 
stabilise receptor structure. Similar interactions between a tyrosine and a 
phenylalanine have been shown in CCR5 (Hall et al., 2009). Therefore, mutations of 
Y122, F173 and Y258 may have perturbed these interactions, leading to a detrimental 
shift in receptor conformation and ultimately reduced cell-surface expression. Serine 
is important due to the hydrogen-bonding capacity of its hydroxyl side-group 
interacting with other membranes of α-helices (Ballesteros et al., 2000). Leucine is 
commonly a component of transmembrane helices due to its hydrophobicity. This 
may explain why the S114A and L209A mutants also showed a reduction in cell-
surface expression. 
While some CCR4 mutants, such as E205A and E205D, showed a 
concomitant decrease in cell-surface expression, chemotaxis and binding ability, the 
effects of other mutations on receptor phenotype were more complex. The S114A 
mutant had reduced expression but only lost chemotactic efficacy to CCL17 but not 
CCL22, indicating that serine 114 was more important for CCL17-induced 
conformations of CCR4 than CCL22-induced conformations. This could also be 
explained by the lower efficacy of CCL17. A similar result was observed for the 
L209A mutant. The F173A mutant showed reduced expression, but chemotactic 
responses were normal. Taken together the various mutations show that some amino 
acids of CCR4 are required for expression, others for functional response to one 
chemokine and others to both, and some are also required for chemokine binding. 
This supports the results shown in chapter 3, which suggested that CCR4 has distinct 
conformations that are stabilised by CCL17 and CCL22 
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Three major determinants of CCR4 function were the two conserved tyrosines 
in helix III, Y117 and Y122, and Y258 in helix VI. All three tyrosine to alanine 
mutations resulted in non-functional CCR4. When these mutants were also tested in 
binding assays, they showed a lack of binding to 
125
I-CCL17 and 
125
I-CCL22, based 
on two experiments. These data show that the tyrosine side-chain is likely critical for 
binding of chemokine, and thus receptor function. This may be due to the previously 
described π-stacking of the aromatic rings of the tyrosine side-chain. This is 
supported by the fact that mutation to phenylalanine, which also contains an aromatic 
ring, restored chemotactic ability to all three mutants. However since this restoration 
was at a reduced level, it may suggest that the hydroxyl group of the tyrosine side 
chain, lacking in phenylalanine, is necessary for hydrogen bond formation. Binding 
studies also showed a trend toward restoration of the ability of the Y117 and Y122 
phenylalanine mutants to bind 
125
I-CCL17 and 
125
I-CCL22. 
Interestingly, mutations of the conserved tyrosine residues of helix III in other 
receptors do not have the same effect upon receptor phenotype. For example, Y113A 
CCR1 mutant transfectants responded in the same manner as WT transfectants to 
CCL3 in chemotaxis assays (de Mendonça et al., 2005). A similar mutation in CCR3 
was also still able to induce a normal chemotaxis response to CCL11 (Wise et al., 
2007). In summary, the CCR4 data demonstrate the importance of the aromatic side 
chain of these three tyrosines in receptor function, likely due to it forming stabilising 
interactions necessary for chemokine binding. When compared to the previous studies 
on CCR3 and CCR1, it may suggest that the importance of particular amino acids in 
receptor function and chemokine binding are receptor-specific. 
 
Another critical determinant of CCR4 function and chemokine binding was 
L92, located within the highly conserved TXP motif in transmembrane helix II. This 
motif is present in nearly all human and murine chemokine receptors; in most 
receptors the first amino acid is threonine, while in CCR4 and CCR8 it is serine. 
Leucine is commonly the second amino acid in this motif, while the third is always 
proline (Govaerts et al., 2001). The L92A mutant of CCR4, despite showing above 
normal cell-surface expression, was non-functional in chemotaxis assays. Further 
investigation of this mutant in chemokine binding assays revealed that it did not bind 
125
I-CCL17 or 
125
I-CCL22. Mutation of the threonine and proline residues of the TXP 
motif of CCR5 to alanine reduced the ability of the receptor to bind CCL3 and CCL4. 
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Mutation of the leucine of this motif was not investigated in this study (Govaerts et 
al., 2001). An L87A of CCR1 however showed normal binding of CCL3 but impaired 
receptor activation (de Mendonça et al., 2005). 
It was determined that the TXP motif of CCR5, potentially due to the helical 
kink introduced by the proline, orients the extracellular portion of transmembrane 
helix II. This portion of the helix is involved in the activation process of the receptor; 
the high concentration of aromatic residues at the extracellular ends of helices II and 
III suggest mediation of helical interactions necessary for activation (Govaerts et al., 
2001; Govaerts et al., 2003). Mutational studies of CCR5 also suggested an 
interaction between the N-terminus of chemokines with the TXP motif in the 
chemokine receptor transmembrane bundle (Blanpain et al., 2003). The L92A CCR4 
mutation is therefore likely disrupts this key TXP motif, leading to the observed loss 
of chemokine binding and receptor functionality. 
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4.3.2 – The effect of site 1 point CCR4 point mutation on antagonist activity 
Following the characterisation of the point mutants, several were then tested 
against the site 1 antagonists in chemotaxis and chemokine binding assays. The 
rationale for this was that a residue critical for antagonist activity would result in 
reduced antagonist effectiveness upon mutation. Since the chemotaxis assays 
involved the inhibition of migration, only mutants that exhibited a functional 
response could be antagonised in this manner. The highly conserved GluVII:06 of 
transmembrane helix VII has previously been implicated in the binding of intrahelical 
allosteric antagonists (see section 1.4.4.1). However the E290A, E290D and E290Q 
mutants of this amino acid were non-functional in chemotaxis assays, meaning that 
these mutant receptors could not be antagonised in chemotaxis assays. The Y117A, 
Y122A, Y258A and L92A mutants, which were also non-functional could not be 
tested for the same reasons. The GluVII:06 mutants were however directly tested for 
their ability to bind radiolabelled antagonist, shown in chapter 6. 
The majority of the mutants tested in chemotaxis antagonism assays did not 
differ significantly to WT CCR4 with respect to inhibition of migration; these were 
I113A, Y117F, F121A, F126A, F173A, K188A, S202A, I206A and Y258F. 
Transfectants of the Δ40 truncation, in which the last 40 amino acids of CCR4 were 
removed, were also tested for their sensitivity to the antagonists in chemotaxis assays. 
Since the site 1 antagonists were not hypothesised to contact the C-terminus, this 
truncation should not have resulted in a potency shift of the antagonists. The results 
of the chemotaxis assays confirmed this. 
The I125A mutant showed a significant reduction in potency to inhibition of 
migration to CCL17 and CCL22 by antagonist 7, indicating that isoleucine 125 within 
transmembrane helix III was involved in antagonist binding. The Y122F mutant, also 
in the same region, showed a large drop in potency when inhibition of CCL22 
chemotaxis by antagonist 7 was assessed, but interestingly not to migration of 
CCL17. This suggests that the removal of the hydroxyl group of the tyrosine hindered 
inhibition of the CCL22-induced response, possibly due to the removal of hydrogen-
bonding capacity of this amino acid. This result supports the idea described in chapter 
3 that CCL17 and CCL22 activate the receptor in different ways, since an interaction 
has been identified that inhibits CCL22 but not CCL17. 
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Modelling of the interaction of the allosteric antagonist BX 741 with CCR1 
predicted that strong hydrophobic and π-stacking interactions occurred between the 
conserved tyrosines of helix III and the piperazine and phenyl rings of the antagonist, 
and a possible weak hydrogen bond interaction with the urea group (Vaidehi et al., 
2006). Antagonist 7 contains three aromatic rings, which have the potential for 
stacking and hydrophobic interactions. Since the removal of hydrogen-bonding 
capacity of CCR4 with the Y122F mutant resulted in a reduction in antagonist 
potency, it may be the case that Y122A mutation removed the stronger hydrophobic 
and stacking interactions. However, the fact that Y122A was non-functional 
prevented confirmation of this. In the previously described study, alanine mutations 
of these tyrosines retained their functionality, which allowed dissection of the relative 
contribution of hydrogen-bonding and other interactions resulting from the tyrosine 
side chain (Vaidehi et al., 2006). 
The most significant loss of antagonist potency was against the L118A 
mutant. This mutation significantly reduced the ability of antagonist 7 to inhibit 
migration to CCL17 and CCL22, with approximately a hundred-fold reduction in 
potency in the dose-response curves. L118, like Y122 and I125, is located in the third 
transmembrane helix, which contains a cluster of amino acids predicted to be sites of 
antagonist binding. This leucine may be involved in hydrophobic interactions with 
the antagonist; analysis of antagonist binding pockets of β1- and β2-adrenergic 
receptors reveals the presence of a valine residue facing inwards to the pocket 
(Nygaard et al., 2009). Leucine and valine, along with isoleucine are hydrophobic 
aliphatic amino acids, meaning that they contain branched carbon chain side groups. 
Leucine and isoleucine contain four carbons in their side chains in different 
arrangements while valine contains three. 
The ability of antagonist 7 to inhibit 
125
I-CCL17 and 
125
I-CCL22 binding to 
L118A CCR4 was also investigated. Figure 4-8E and F showed that the mutant bound 
chemokine; in line with the increased cell-surface expression of the receptor, L118A 
CCR4 bound a higher level of chemokine than the WT receptor. Also in agreement 
with the chemotaxis inhibition assays, antagonist 7 showed reduced potency against 
the mutant receptor. Figure 4-14 showed that the antagonist was less able to inhibit 
binding of 
125
I-CCL17 and 
125
I-CCL22. When placed in context with the chemotaxis 
data these data suggest that antagonist 7 prevents chemokine binding, and that the 
mutation of leucine 118 to alanine hinders this to a significant degree. This is 
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consistent with the definition of allosteric modulators, which decrease the activity of 
the orthosteric ligand of the receptor (Bridges and Lindsley, 2008). 
 
The fact that inhibition only by antagonist 7 was affected by the site 1 CCR4 
mutations indicates that this compound has unique features that contact the mutated 
residues. Since the other antagonists were not affected, it suggests that these did not 
contain structural features that required the mutated amino acids. Figure 4-1 shows 
antagonist 7 is of a different structural class to antagonist 3 and 4; the latter are 
identical apart from the presence of the extra pyridine group in antagonist 3. As 
described in 4.2.4, the use of antagonist 1 was discontinued due to persistent 
difficulties regarding its solubility. Inhibition curves using this antagonist were very 
variable, and often produced inconsistent results. 
It is important to note that since the mutants L92A, Y117A, Y122A, Y258A, 
E290A, E290D, and E290Q were non-functional, it cannot be concluded that the 
antagonists do not contact that these residues. It may be the case that the effects on 
L118A, Y122F and I125A result from minor changes in antagonist binding and that 
the major contact points have yet to be determined. GluVII:06 is involved in the 
binding of several antagonists to many different chemokine receptors, as it acts as 
major point of contact for the quaternary nitrogen that is shared by many small 
molecule inhibitors of these receptors. For example, CCR5 inhibitor Maraviroc, 
which is clinically approved for the treatment of HIV, is an allosteric antagonist that 
contacts the conserved GluVII:06 residue (Dorr et al., 2005; Garcia-Perez et al., 
2011). Another CCR5 inhibitor, TAK-779, also contacts this residue (Dragic et al., 
2000). GluVII:06 of CCR4 is therefore likely a point of antagonist contact; assays 
investigating direct binding of a site 1 antagonist are presented in chapter 6. 
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4.3.3 – Summary 
In summary, the mutants of amino acids predicted by molecular modelling to 
be sites of antagonist contact were varied in their phenotype. Several mutants such as 
I113A, K188A, and S202A showed no difference to WT CCR4 in terms of cell-
surface expression and chemotactic ability. Others, such as Y117A, Y122A, Y258A 
and the GluVII:06 mutations E290A, E290D, and E290Q did not bind chemokine or 
induce chemotaxis to either ligand. This reflects the critical role these residues play in 
both chemokine binding and receptor activation, likely due to stabilising interactions 
they form with ligand and other regions of CCR4. 
Antagonism of chemotaxis induced by these mutants revealed that L118A, 
Y122F and I125A CCR4 responded with reduced potency to inhibition by antagonist 
7. Binding of radiolabelled chemokines to L118A CCR4 was poorly inhibited by 
antagonist 7. The non-functional mutants could not be antagonised in these assays, 
highlighting the need for further studies using direct methods of investigating the 
effect of mutations of antagonist activity. 
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5 – Investigation of intracellular CCR4 antagonists by 
receptor point mutation and truncation 
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5.1 – Introduction 
Chapter 4 focused on the effects on four intrahelical allosteric antagonists; 
these were hypothesised to bind within the transmembrane domains and inhibit 
receptor function. The remaining three antagonists will be investigated in this chapter 
in a similar manner, by using receptor mutations to identify potential antagonist 
binding sites. 
These three antagonists – denoted 2, 5 and 6 – are hypothesised to bind to an 
intracellular site on the C-terminus of CCR4 termed ‘site 2’. This intracellular mode 
of binding is relatively novel compared to the previously described intrahelical 
antagonist binding (section 4.1), as it was only recently that an intracellular site was 
described. 
As described in section 1.4.4.1, C-terminal exchanges of CCR4 and CCR5 
showed that some antagonists were specific to the CCR4 C-terminus. The CCR4-5 
chimera (CCR4 with a CCR5 C-terminus) was unable to respond to the antagonists, 
while the CCR5-4 chimera was able to do so. Carboxylic acid derivatives of the 
compounds were less able to pass through the membrane and antagonise the CCR4 C-
terminus, while ester derivatives were more lipophilic and as such had higher activity. 
The use of membranes or permeabilised cells also increased the activity of the 
carboxylic acid derivatives. These findings were therefore taken to shown that some 
antagonists bound an intracellular site (Andrews et al., 2008). Similar observations 
were noted regarding CXCR1 and CXCR2; a C-terminal swap between the two 
receptors transferred antagonist sensitivity, in addition to the fact that antagonists 
required properties such as lipophilicity and hydrogen bonding capacity in order to 
pass through the membrane (Nicholls et al., 2008). Further research on CXCR2 
showed that in intracellular residue, K320, was an important point of antagonist 
contact; a K320A mutant had reduced antagonist binding potency by a factor of 5 
compared to WT CXCR2 (Salchow et al., 2010). 
The three intracellular antagonists described here are pyrazinyl 
sulphonamides, the structures of which are shown in figure 5-1. The three structures 
share the same basic core; a sulphur atom bound to two oxygen atoms and two side-
groups, including the aromatic pyrazine. Antagonist 2 was previously used in the 
study that originally identified the intracellular CCR4 antagonists (Andrews et al., 
2008).  
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Figure 5-1 – Site 2 antagonists 
The structures of the three site 2 (intracellular) allosteric antagonists; denoted 2, 5 and 
6. These were supplied by GSK, and based on functional studies and the work by 
Andrews et al., 2008 were hypothesised to bind to the C-terminus of CCR4. Molecular 
modelling was performed to identify likely contact points on the receptor. 
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As in chapter 4, molecular modelling identified several amino acids 
potentially involved in antagonist binding to site 2; these amino acids were mutated in 
order determine their contribution to antagonist binding. Figure 5-2 shows a cartoon 
of CCR4 with the residues highlighted in green. Two amino acids, phenylalanine 305 
(F305) and leucine 307 (L307), were located at the end of transmembrane helix VII. 
Lysine 310 (K310) and leucine 318 (L318) were located in the C-terminus, within the 
conserved helix VIII region. 
Phenylalanine 305 was mutated to alanine, which as previously described in 
section 4.1 is a small, neutral and non-polar amino acid. Phenylalanine by contrast is 
much larger due to its benzene ring, but like alanine is hydrophobic. Therefore the 
mutation removed the bulk associated with phenylalanine but retained the 
hydrophobicity of the residue. Leucine 307 was mutated to valine, which was a 
relatively conservative mutation; both have branched aliphatic side-chains, leucine 
containing one extra carbon in the chain than valine. The differences in structure 
between leucine and valine are shown in figure 5-3, panels A and B. 
The C-terminal helix VIII residue lysine 310 was mutated to asparagine; these 
two amino acids have different ionisation states at physiological pH (Salchow et al., 
2010) but do not differ enough structurally for the mutation to adversely affect helical 
structure. These amino acids are shown in figure 5-3, panels C and D. Leucine 318 
was mutated to alanine. 
In addition to the point mutations, three truncations of the receptor were made 
by mutating the codon at the desired truncation position to a stop codon; the sites of 
these truncations are labelled in red in figure 5-2. Δ40 CCR4 had the last 40 amino 
acids of the C-terminus deleted, directly after the end of helix VIII. Δ45 and Δ50 
CCR4 were truncations that cut into helix VIII, with Δ50 CCR4 cutting almost to the 
end of transmembrane helix VII. Receptor truncations have been previously used to 
investigate receptor function. CCR5 truncations demonstrated that the proximal end 
of the C-terminus was required for receptor signalling (Gosling et al., 1997); this 
region is homologous to the helix VIII motif in CCR4, indicating the potential effects 
CCR4 truncations will have on receptor function. Truncation downstream of this 
region in CXCR4 resulted in reduced receptor phosphorylation and thus β-arrestin 
recruitment, leading to poor regulation of receptor-mediated signalling (Cheng et al., 
2000). Natural truncations of the distal C-terminus of CXCR4 lead to gain-of-
function mutations that result in the rare immunodeficiency disorder WHIM 
177 
 
syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) (Liu et al., 
2012b). 
Figure 5-3, panel E summarises the CCR4 mutants that were made to 
investigate site 2 antagonist binding, along with their location within the receptor. 
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Figure 5-2 – Amino acids and regions implicated in site 2 antagonist binding 
Cartoon of CCR4; highlighted in green are amino acids hypothesised to bind the site 2 
intrahelical antagonists. Shown in red are sites of three successive C-terminal 
truncations. 
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Figure 5-3 – Site 2 amino acid point mutations and receptor truncations 
Structures of amino acids; leucine 307 (A) was mutated to valine (B), and lysine 310 
(C) was mutated to asparagines (D). Amino acid side chains are highlighted. Panel E 
shows a summary table of the site 2 point mutants and truncations along with their 
location in the receptor. 
E 
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5.2 – Results 
5.2.1 – Cell-surface expression of site 2 CCR4 mutants 
Following site-directed mutagenesis of WT CCR4, the plasmids containing 
the CCR4 constructs were transfected into L1.2 cells, which were analysed the 
following day for surface expression by flow cytometry. 
Figure 5-4 shows the relative cell-surface expression of the CCR4 mutants 
compared to WT CCR4. Of the point mutants, F305A and L307V showed significant 
reduction in cell-surface expression relative to WT; 70% and 73% of WT levels, 
respectively. The other point mutants, K310N and L318A, did not show expression 
levels significantly different to that of WT. The Δ40 mutant also showed no 
difference compared to WT with respect to cell-surface expression. The Δ45 and Δ50 
mutants however, which were truncations into helix VIII, showed significantly 
reduced expression; 20% and 30%, respectively. The relative change of each mutant 
compared to WT is summarised in table 5-5. 
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Figure 5-4 – Cell-surface expression of site 2 CCR4 point mutants 
L1.2 cells were transiently transfected with WT and mutant CCR4 pcDNA and the 
following day analysed for cell surface expression by flow cytometry. The black bar 
shows WT CCR4, grey bars show individual point mutants. Data are presented as 
percentage of WT expression, and as the mean ± SEM of three independent 
experiments. Data were analysed by one-way ANOVA. Significance stars *, ** and *** 
represent p values of 0.05, 0.01, and 0.001 respectively. 
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Mutant Relative expression Mutant Relative expression 
F305A ↓ Δ40 - 
L307V ↓ Δ45 ↓ 
K310N - Δ50 ↓ 
L318A -   
 
 
  
Table 5-5 – Change in cell-surface expression of site 2 CCR4 point and truncation 
mutants 
Summary table of the relative expression changes from figure 4-4. - = no change 
relative to WT, ↑ = increase relative to WT, ↓ = decrease relative to WT. 
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5.2.2 – Migratory potential of site 2 CCR4 mutants transfectants to CCL17 
and CCL22 
Following analysis of cell-surface expression, L1.2 cells transfected with the 
CCR4 site 2 point mutants and truncations were assessed for their ability to migrate 
to CCL17 and CCL22 in chemotaxis assays. As before, these were performed with 
chemokine concentrations ranging from 0.1 nM to 100 nM. WT CCR4 transfectants 
were used as a reference in all cases. 
Figure 5-6 shows the results of the chemotaxis assays. F305A transfectants 
showed no difference to WT for either the CCL17 (A) or CCL22 (B) response in 
terms of efficacy or potency. L307V transfectants showed reduced efficacy to 
CCL17-induced migration; at 1 nM the chemotactic index was 19, compared to 33 for 
WT CCR4 transfectants (C). The potency of chemokine was unaffected by this 
mutation. The CCL22 response was also no different to WT (D). Interestingly the 
K310N mutant did not induce migration to CCL17 (E), but did induce migration to 
CCL22 (F); the chemotactic index for CCL17 was significantly reduced compared to 
WT, and not significantly different to the level of migration observed to buffer. 
Migration to CCL22 also showed a reduction in efficacy; at 1 nM a chemotactic 
index of 31 was observed for K310N, compared to 61 for WT. L318A showed a 
similar phenotype, in that CCL17-induced migration was significantly reduced (G) 
with CCL22-induced migration being less affected (H). However in this case, it still 
induced a small chemotactic response to CCL17, with a chemotactic index of 9 
compared to 43 for WT. 
For the receptor truncations, Δ40 showed a significant increase in chemotactic 
efficacy for both chemokines. The Δ40 transfectants migrated to CCL17 with a peak 
chemotactic index of 60, compared to 25 for WT transfectants (I). They migrated to 
CCL22 with a peak chemotactic index of 100, compared to 60 for WT (J). The Δ45 
and Δ50 truncations showed the most marked change in chemotaxis; both mutants did 
not show migration to either chemokine at any concentration. For all data points, the 
chemotactic indices were no different to those observed for migration to buffer alone 
(K and L). This may be explained in part by the poor truncation surface expression.  
Table 5-7 shows a summary table of the point mutants and truncations, 
indicating the relative changes in potency and efficacy of migration compared to WT 
CCR4.  
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Figure 5-6 – CCR4 point mutation and truncation affects chemotaxis of 
transfectants to both CCL17 and CCL22 
Panels A-L: Following analysis of cell-surface expression, WT and mutant CCR4 
transfectants were assessed for their ability to migrate to soluble CCL17 (left-hand 
column) and CCL22 (right-hand column). WT responses are shown as filled squares; 
mutants as open circles, squares and triangles. Data are the mean ± SEM of three 
independent experiments, and were analysed by two-way ANOVA and a Bonferroni 
post-test. Significance stars *, ** and *** represent p values of 0.05, 0.01, and 0.001 
respectively. 
I J 
K L 
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 CCL17 CCL22 
 Efficacy Potency Efficacy Potency 
F305A - - - - 
L307V ↓ - - - 
K310N NR NR ↓ - 
L318A ↓ - - - 
Δ40 ↑ - ↑ - 
Δ45 NR NR NR NR 
Δ50 NR NR NR NR 
 
 
  
Table 5-7 – Changes in chemotactic responses resulting from CCR4 site 2 point 
mutation and truncation 
Summary table of the effect of point mutations on efficacy and potency of the 
chemotactic response from figure 5-6. - = no change, NR = no response, ↑ = increase in 
efficacy/potency, ↓ = decrease in efficacy/potency. 
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5.2.3 – Binding of radiolabelled chemokine to site 2 CCR4 mutant 
transfectants 
After receptor cell-surface expression was confirmed, and chemotaxis assays 
had been performed, the K310N and Δ40 CCR4 mutants were investigated for their 
ability to bind 
125
I-CCL17 and 
125
I-CCL22. These mutants were chosen due to the 
distinct phenotypes they induced in chemotaxis assays. 
Figure 5-8 shows the results of a whole-cell binding assay in which WT and 
K310N transfectants were incubated with 0.1 nM 
125
I-CCL17 (A) or 
125
I-CCL22 (B) 
and either buffer or 100 nM unlabelled chemokine. The binding window for WT and 
K310N CCR4 was the same, indicating that the mutation did not affect chemokine 
binding. A t-test of the mean total binding values for both WT and K310N 
transfectants for both chemokines did not shown any significant difference. 
The Δ40 mutant showed increased chemotactic efficacy in response to CCL17 
and CCL22 (figure 5-6). When this truncation mutant was compared to WT CCR4 in 
binding assays, there was no observed increase in chemokine binding; in fact 
chemokine binding decreased compared to WT for both 
125
I-CCL17 (C) and 
125
I-
CCL22 (D). These data however are from one experiment, which must be taken into 
consideration when comparing them to the more robust chemotactic data. 
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Figure 5-8 – Whole-cell chemokine binding of CCR4 point mutant and truncation 
transfectants 
CCR4 transfectants were incubated with 
125
I-CCL17 (left-hand column) or 
125
I-CCL22 
(right-hand column) and buffer (total binding; black bars) or excess unlabelled 
chemokine (non-specific binding; grey bars). Panels A and B show binding of K310N 
CCR4, panels C and D shown binding of Δ40 CCR4. Panels A and B are the mean ± 
SEM of three independent experiments, panels C and D are from one experiment. 
Significance stars ** and *** represent p values of 0.01 and 0.001 respectively. 
A B 
C D 
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5.2.4 – Antagonism of site 2 mutant chemotaxis 
Following the investigation of site 2 mutant expression, function and 
chemokine binding, their sensitivity to antagonists was determined. As shown in 
figure 5-2, the site 2 antagonists were hypothesised to bind to an intracellular site on 
CCR4. This site included the C-terminal end of transmembrane domain 7 in addition 
to helix VIII, a highly conserved region located in the proximal portion of the C-
terminus. By mutating these regions, their importance in antagonist activity could be 
determined; if a mutant lost sensitivity to an antagonist it could be inferred that the 
mutated residue was required for the activity of the antagonist. 
Since figure 5-6 showed that the point mutants F305A, L307V, K310N and 
L318A were able to induce migration to chemokine, this chemotaxis was inhibited 
with the antagonists and the potency of the inhibition compared to WT. The Δ40 
truncation was also tested since it showed a functional response. The Δ45 and Δ50 
truncations however were not tested since they did not induce a functional response 
(figure 5-6 panels K and L). The K310N mutant only induced chemotaxis of 
transfectants to CCL22. Therefore, responses to CCL22 alone were subjected to 
antagonism with the compounds. 
Figure 5-9 shows the results of the antagonism of WT and L307V CCR4-
induced migration to CCL17 and CCL22. Increasing concentrations of the antagonists 
were used to inhibit maximal migration, and the data analysed using non-linear 
regression to generate logIC50 values. The values from the mutants were compared to 
those from the WT to determine whether antagonist potency was affected. This was 
performed with the three site 2 antagonists. Antagonist 7 was also tested against these 
transfectants as a control, since this antagonist was not hypothesised to bind the 
intracellular antagonist binding site. A summary table of the logIC50 values is shown 
in table 5-10. Antagonist 7 proved to be more potent that the others in inhibiting 
chemotaxis to both CCL17 and CCL22. Antagonist 2 was the least potent. 
The data show that compared to WT, antagonist 2 was less potent at inhibiting 
CCL17-induced migration; it had a logIC50 of -5.74, compared to -6.30 for WT. This 
difference was statistically significant, with a p-value of 0.005. Antagonist 5 was less 
potent at inhibiting CCL22-induced migration of the L307V mutant, with a logIC50 of 
-6.45 compared to -7.70 for WT. This difference was also significant, with a p-value 
of 0.00086. T-tests of the remaining logIC50 values did not show a statistical 
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difference between WT and L307V. There was no difference between the logIC50 
values for antagonist 7. 
This process was repeated for the other functional mutants, such as F305A, 
the results of which are shown in figure 5-11. The logIC50 values from these 
experiments are shown in table 5-12, along with the results from table 5-10. F305A 
CCR4 showed a significant decrease in potency in the antagonist 5 inhibition of 
CCL22; WT transfectant migration was inhibited with a logIC50 of -6.88 while 
F305A transfectant migration was inhibited with a logIC50 of -5.71. This difference 
was significant with a p-value of 0.0031. Both L318A and Δ40 CCR4 did not affect 
the activity of the antagonists. K310N transfectants also did not show a reduction in 
antagonist potency. 
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Figure 5-9 – Antagonism of L307V transfectant chemotaxis 
Chemotaxis of L307V transfectants to CCL17 or CCL22 was inhibited with increasing 
concentrations of the site 2 antagonists, and compared to WT. Increasing concentrations 
of antagonists 2 (A), 5 (B), 6 (C), and 7 (D) inhibited migration to 1 nM CCL17 and 
CCL22. Data are the mean ± SEM of three independent experiments. 
A B 
C D 
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 CCL17 
CCR4 
construct 
Antagonist 2 
logIC50 
Antagonist 5 
logIC50 
Antagonist 6 
logIC50 
Antagonist 7 
logIC50 
WT 
-6.30 ±  
0.10 
-7.72 ± 
0.32 
-7.97 ± 
0.16 
-8.11 ± 
0.12 
L307V 
-5.74 ± 
 0.08 
-6.79 ± 
0.24 
-7.03 ± 
0.42 
-8.30 ± 
0.05 
 CCL22 
CCR4 
construct 
Antagonist 2 
logIC50 
Antagonist 5 
logIC50 
Antagonist 6 
logIC50 
Antagonist 7 
logIC50 
WT 
-6.07 ± 
0.36 
-7.70 ± 
0.07 
-7.74 ± 
0.18 
-7.94 ± 
0.04 
L307V 
-5.29 ± 
0.15 
-6.45 ± 
0.10 
-6.77 ± 
0.47 
-8.20 ± 
0.12 
 
 
  
Table 5-10 – Potency of site 2 antagonist inhibition of WT and L307V transfectants 
logIC50 values are shown from figure 5-9. logIC50 values were calculated using non-
linear regression analysis, and two-tailed t-test used to compare values. Blue shaded 
columns indicate statistically significant differences between logIC50 values; p values of 
0.005 and 0.00086 for CCL17 and CCL22, respectively. logIC50 values are from three 
independent experiments. 
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Figure 5-11 – Antagonism of F305A transfectant chemotaxis 
Chemotaxis of F305A transfectants to CCL17 or CCL22 was inhibited with increasing 
concentrations of the site 2 antagonists, and compared to WT. Increasing concentrations 
of antagonists 2 (A), 5 (B), 6 (C), and 7 (D) inhibited migration to 1 nM CCL17 and 
CCL22. Data are the mean ± SEM of three independent experiments. 
A B 
C D 
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CCR4 
Construct 
Antagonist 
2 logIC50 
Antagonist 
5 logIC50 
Antagonist 
6 logIC50 
Antagonist 
7 logIC50 
WT -6.34 ± 0.09 -7.70 ± 0.17 -7.97 ± 0.16 -8.11 ± 0.12 
F305A -6.72 ± 0.25 -7.94 ± 0.28 -7.83 ± 0.10 -8.32 ± 0.19 
WT -6.30 ± 0.10 -7.72 ± 0.32 -7.97 ± 0.16 -8.11 ± 0.12 
L307V -5.74 ± 0.08 
(p=0.005) 
-6.79 ± 0.24 -7.03 ± 0.42 -8.30 ± 0.05 
WT ND ND ND ND 
K310N ND ND ND ND 
WT -6.34 ± 0.09 -7.70 ± 0.17 -7.97 ± 0.16 -8.06 ± 0.01 
L318A -6.42 ± 0.08 -7.77 ± 0.11 -7.55 ± 0.43 -8.30 ± 0.19 
WT -6.33 ± 0.28 -7.62 ± 0.33 -7.83 ± 0.24 -8.06 ± 0.01 
Δ40 -6.07 ± 0.18 -7.46 ± 0.21 -7.61 ± 0.11 -7.54 ± 0.17 
 
CCR4 
Construct 
Antagonist 
2 logIC50 
Antagonist 
5 logIC50 
Antagonist 
6 logIC50 
Antagonist 
7 logIC50 
WT -5.70 ± 0.34 -6.88 ± 0.15 -7.74 ± 0.18 -7.94 ± 0.04 
F305A -5.61 ± 0.44 -5.71 ± 0.09 
(p=0.0031) 
-7.64 ± 0.23 -7.94 ± 0.08 
WT -6.07 ± 0.36 -7.70 ± 0.07 -7.74 ± 0.18 -7.94 ± 0.04 
L307V -5.29 ± 0.15 -6.45 ± 0.10 
(p=0.00086) 
-6.77 ± 0.47 -8.20 ± 0.12 
WT -5.71 ± 0.49 -6.96 ± 0.35 ND ND 
K310N -6.15 ± 0.53 -7.44 ± 0.38 ND ND 
WT -5.35 ± 0.20 -6.88 ± 0.14 -7.74 ± 0.18 -7.97 ± 0.05 
L318A -5.66 ± 0.20 -6.92 ± 0.07 -7.25 ± 0.37 -8.29 ± 0.21 
WT -5.52 ± 0.76 -6.77 ± 0.27 -7.20 ± 0.10 -7.97 ± 0.05 
Δ40 -5.39 ± 0.07 -6.64 ± 0.16 -7.16 ± 0.07 -7.64 ± 0.17 
 
 
  
Table 5-12 – F305A and L307V CCR4 transfectant migration is inhibited with 
reduced potency by the site 2 antagonists  
Non-linear regression was used to calculate the logIC50 values for the site 2 antagonist 
inhibition of CCR4 point mutant migration to CCL17 (A) and CCL22 (B). Mutant 
logIC50 values that were significantly different to WT are highlighted in blue, and the p-
values of the t-tests shown in brackets. Data are the mean ± SEM of three independent 
experiments. 
A 
B 
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5.2.5 – Antagonism of chemokine binding to site 2 mutants 
Following the antagonism of CCR4 mutant chemotaxis, the site 2 antagonists 
were used to dose-dependently inhibit 
125
I-chemokine binding to the transfectants. 
L307V transfectants were investigated since they showed reduced sensitivity to the 
site 2 antagonists in chemotaxis assays. K310N transfectants were tested due to the 
unique functional phenotype they presented. 
Figure 5-13 shows the inhibition of radiolabelled chemokine binding to CCR4 
transfectants by increasing concentrations of the site 2 antagonists. Panel A shows 
inhibition of 
125
I-CCL22 binding to WT and L307V CCR4 transfectants by antagonist 
2. Binding to WT transfectants was inhibited with a mean logIC50 of -6.72 while 
binding to L307V transfectants was inhibited with a mean logIC50 of -5. This 
difference was statistically significant, with a p value of 0.034, showing that the 
L307V mutation made CCR4 less sensitive to inhibition of 
125
I-CCL22 binding by 
antagonist 2. 
Inhibition of chemokine binding to K310N transfectants was also 
investigated. Figure 5-13B shows inhibition of 
125
I-CCL22 binding to transfectants by 
antagonist 5, while figure 5-13C shows inhibition of 
`125
I-CCL17 binding by 
antagonist 2. Both experiments were performed twice, meaning that statistical tests of 
p-values could not be carried out; however the graphs show that the inhibition curves 
of the mutants are very similar to the WT curves, indicating that the K310N mutation 
likely had no effect on antagonist inhibition of chemokine binding to the receptor. 
The WT and K310N inhibition curves produced similar logIC50 values. 
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Figure 5-13 – Inhibition of chemokine binding to CCR4 transfectants by site 2 
antagonists 
Binding of 
125
I-CCL22 (A and B) and 
125
I-CCL17 (C) to CCR4 point mutant 
transfectants was inhibited with increasing concentrations of the site 2 antagonists 2 (A 
and B) and 5 (C) and compared to WT. Non-specific binding (100 nM unlabelled 
chemokine) was subtracted and the data presented as a percentage of binding without 
antagonist. Panel A is the mean ± SEM of four independent experiments; panels B and 
C are of two experiments. The logIC50 values of each dose-response curve are shown; 
panel A also shows the p value of the t-test of the WT and L307V values. 
A 
C 
B 
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5.3 – Discussion 
5.3.1 – Effect of site 2 mutations and truncations on receptor phenotype 
In this chapter, point mutations of CCR4 residues implicated in site 2 
antagonist binding were mutated. In addition three receptor truncations, Δ40, Δ45 and 
Δ50 were made. As in chapter 4, the receptor mutants were assessed for cell-surface 
expression, chemotactic and chemokine binding abilities. Following this, the potency 
of the antagonists in the inhibition of migration and chemokine binding was 
measured, in order to determine the contribution of each residue to antagonist 
activity. 
 
5.3.1.1 – Phenotype of site 2 CCR4 point mutants 
Four CCR4 C-terminal amino acids - F305, L307, K310 and L318 - were 
predicted by sequence comparison of the CCR4 and CCR5 C-termini to be points of 
contact for the site 2 antagonists. The mutants of these were F305A, L307V, K310N 
and L318A. The former two were located at the end of transmembrane helix VII, 
while the latter two were located in the highly conserved C-terminal helix VIII. 
The F305A and L307V CCR4 mutants both showed reduced cell-surface 
expression, at approximately 75% of WT levels. L307V transfectants showed a 
significant reduction in migration to CCL17 compared to WT; however there was still 
a robust response. Migration to CCL22 was unaffected by this mutation. F305A-
mediated migration to both chemokines was normal. These data show that despite the 
reduction in cell surface expression and migration of L307V transfectants to CCL17, 
both F305 and L307 are not critical for receptor function. 
 
The K310N mutation was previously described in chapter 3, in context of 
biased agonism through CCR4. This mutant had normal cell surface expression and 
chemokine binding, but only mediated chemotaxis to CCL22 and not CCL17. This 
suggested that CCL22 and CCL17 stabilised distinct conformations and that K310 
was required for the CCL17-induced conformation (see section 3.3.3). 
The mutation of L318 to alanine did not have an effect on receptor expression 
(figure 5-4), but did however affect chemotaxis. L318A-mediated chemotaxis to 
CCL17 was significantly decreased in efficacy, although a reduced response still 
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occurred. Chemotaxis to CCL22 showed a trend to a reduction but this was not 
significant (figure 5-6). These results were similar to the K310N data, in that 
chemotaxis to CCL17 was more adversely affected than chemotaxis to CCL22. 
However the K310N mutant showed a complete lack of response to CCL17 while 
L318A retained a reduced response, albeit reduced compared to WT. 
K310 and L318 lie within helix VIII, a highly conserved C-terminal region 
located in many receptors. Since the helix lies parallel to the membrane, one side 
faces the lipid membrane and the other faces the cytosol. Previous studies on helix 
VIII in other receptors have used helical wheel analysis to show that the helix is 
amphipathic, with hydrophobic residues of the helix clustered on one side, and polar 
and hydrophilic residues on the other. For example, helix VIII of rhodopsin was 
analysed using this tool and shown to have hydrophobic residues such as leucine and 
phenylalanine on the hydrophobic side, in contrast to hydrophilic and charged 
residues such as glutamic acid and lysine on the other (Krishna et al., 2002). Similar 
analyses were performed on the leukotriene B4 receptor 1 (Okuno et al., 2005; 
Aratake et al., 2012), the β2-adrenergic receptor (Katragadda et al., 2004) and the 
cannabinoid receptor 1 (Ahn et al., 2010). Mutational analysis of the cannabinoid 
receptor 1, in which the hydrophobic residues were replaced with alanine, showed 
that they were required for ligand binding due to their role in receptor conformation 
(Ahn et al., 2010). In many GPCRs, the tyrosine of the conserved NPXXY motif of 
transmembrane helix VII forms π-stacking interactions with a conserved 
phenylalanine on the hydrophobic side of helix VIII, and is required for receptor 
activation in the chemokine receptor CCR5 (Fritze et al., 2003; Nygaard et al., 2009; 
Kraft et al., 2001). 
Helical wheel analysis of the putative helix VIII region of CCR4 is shown in 
figure 5-14. A clear clustering of hydrophobic and charged/hydrophilic residues is 
present, indicating that the former likely faces the lipid membrane and the latter likely 
faces the cytosol. K310 is located on the hydrophilic side and L318 on the 
hydrophobic side. Helix VIII of CCR4 shares the conserved phenylalanine 311 that 
potentially interacts with the tyrosine of the NPXXY motif, meaning it too is likely 
required for receptor activation. 
The cytosolic face of helix VIII is also important for receptor function, since 
in other GPCRs it has been shown to bind G proteins. Modelling of helix VIII of the 
β1-adrenergic receptor along with mutational studies showed that G proteins 
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interacted with this region (Delos Santos et al., 2006). In addition, removal of the C-
terminus of the viral chemokine receptor ORF74 prevented coupling of the receptor 
to Gαq proteins (Verzijl et al., 2006). K321 of squid rhodopsin was shown to interact 
with the detergent octyl glucoside, believed to mimic Gαq binding (Murakami and 
Kouyama, 2008). Thus the hydrophilic face of helix VIII of CCR4, including the 
amino acid K310, are likely involved in coupling to signalling partners of the 
receptor. 
In summary, due to the importance of each side of the amphipathic helix VIII 
in other GPCRs, and the fact that helical wheel analysis of this helix VIII mirrors 
previous studies, the respective mutations of K310 and L318 have likely disrupted 
key regions involved in receptor function. L318 may be required for maintenance of 
helical structure due to its hydrophobicity, since hydrophobic residues would need to 
orient away from the cytosol and into the lipid membrane. L318 could also possibly 
stabilise an interaction of the tyrosine of the NPXXY motif with phenylalanine 311. 
Neighbouring aromatic resides such as this phenylalanine may also be required for 
anchoring of helix VIII to transmembrane helix VII. K310 on the other hand likely 
faces the cytosol along with other hydrophilic and charged residues on its side of the 
helix and is directly implicated in receptor signalling. 
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Transmembrane helix VII Helix VIII
310300 320
Figure 5-14 – Helical wheel projection of CCR4 helix VIII 
Panel A shows the sequence of the helix VII and the C-terminus of CCR4, including 
helix VIII. Panel B is a helical wheel projection of the thirteen predicted residues of 
helix VIII, based on sequence conservation and homology modelling. Hydrophobic 
residues are shown as diamonds, and hydrophilic residues as circles. Negatively 
charged residues are shown as triangles, and positive ones shown as pentagons. 
Hydrophobicity is also colour-coded green to yellow, indicating reducing levels of 
hydrophobicity. Red indicates hydrophilic residues, while charged residues are light 
blue. The line intersecting the projection indicates the likely divide between the 
hydrophobic and hydrophilic sides of the helix. Helical wheel program from Zidovetzki 
et al., 2003. 
B 
A 
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5.3.1.2 – Phenotype of CCR4 C-terminal truncations 
In addition to the four site 2 point mutants, three successive CCR4 C-terminal 
truncation mutants were made. The Δ40 mutant cut outside the conserved helix VIII 
after K320, Δ45 cut into helix VIII directly after I315, while the Δ50 mutant had most 
of helix VIII removed since it cut directly after K310 (figure 5-2). The Δ40 mutant 
showed normal cell-surface expression while the Δ45 and Δ50 mutants showed 
significantly reduced expression (figure 5-4). These data demonstrate that the last 40 
amino acids of CCR4 are not required for expression, while cutting into the 
conserved helix VIII region is severely detrimental to receptor trafficking. 
Previous studies that disrupted the C-terminal helix VIII produced similar 
defects in receptors trafficking. A cannabinoid receptor 1 mutant in which three helix 
VIII hydrophobic residues were substituted with alanine had reduced trafficking to 
the cell surface. Confocal microscopy revealed that the receptor localised within the 
endoplasmic reticulum, explaining its failure to export to the cell-surface (Ahn et al., 
2010). Earlier studies on the vasopressin V2 receptor showed that the hydrophobic 
residues of helix VIII were required to maintain folding of the receptor (Thielen et al., 
2005). Truncation mutants of the leukotriene B4 type-2 receptor, similar to those 
described here for CCR4, also showed that cutting into this region reduced receptor 
expression. This was determined to be due to incorrect folding of the receptor, 
causing it to fail to be exported from the endoplasmic reticulum following synthesis 
(Yasuda et al., 2009). In addition, disruption of the bradykinin B2 helix VIII structure 
also negatively impacted trafficking; mutation of lysine 315 of this receptor to proline 
introduced a kink in the helix and thus substantially disrupted the normal alignment 
of the helix, leading to its localisation within the cell rather than on the membrane 
(Feierler et al., 2011). 
Therefore, the Δ45 and Δ50 truncations of CCR4 have likely disrupted a key 
element required for receptor folding, significantly reducing the trafficking of the 
protein to the cell surface. Placed in context with these data, previously described 
K310N and L318A mutants have likely not impacted helix VIII structure due to their 
normal levels of cell-surface expression. Further point mutations of this region 
designed to disrupt helical structure, such as through the introduction of a proline, 
would likely result in similar defects in receptor trafficking. 
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In chemotaxis assays, Δ40 transfectants migrated with increased efficacy to 
both chemokines while Δ45 and Δ50 transfectants did not migrate to either 
chemokine (figure 5-6). Since the latter two truncations cut into helix VIII, and 
considering the impact they had on expression, the inability of the Δ45 and Δ50 
mutants to induce chemotaxis is hardly surprising. Several studies of other chemokine 
receptors have shown similar results. A truncation outside of helix VIII of CCR5 did 
not affect expression and had a modest effect on chemokine-induced calcium release, 
however a truncation within helix VIII significantly reduced both expression and the 
calcium response (Gosling et al., 1997). In a similar manner to data presented here on 
CCR4, a truncation into helix VIII of CCR3 rendered the receptor unable to mediate 
chemotaxis to CCL11, CCL13 or CCL5. This truncation exhibited a reduced ability 
to bind the chemokine CCL11 (Sabroe et al., 2005). 
In another chemokine receptor, CCR7, three truncations of the receptor were 
made; two of these were analogous to the Δ40 and Δ50 CCR4 truncations presented 
here while the third cut further down into the C-terminus. While all three of these 
mutants had normal cell-surface expression, the Δ50 analogue did not migrate to 
either of the CCR7 chemokines CCL19 or CCL21. This CCR7 truncation mutant had 
a lower level of G protein activation than WT CCR7 or the other truncations, again 
demonstrating that this region is required for receptor signalling (Otero et al., 2008). 
An interesting phenotype observed from the Δ40 CCR4 truncation was that it 
induced a more efficacious chemotactic response to both CCL17 and CCL22. This 
increase implies that a mechanism of attenuation had been removed, thus increasing 
the response induced by the receptor. Further replicates of the 
125
I-CCL17 and 
125
I-
CCL22 binding assays would need to be performed to determine whether the Δ40 
truncation affected chemokine binding of the receptor. If it was unaffected it would 
suggest
 
that the increase in chemotactic efficacy was due to another factor. 
The previously described paper on CCR3 also investigated similar truncations 
to the CCR4 Δ40 mutant and observed the same chemotactic increase; a truncation 
mutant of approximately 20 amino acids further down the C-terminus compared to 
CCR4 showed increased efficacy in chemotaxis assays to CCL11 and CCL13. The 
CCR3 truncation mutant internalised to a lesser degree after chemokine treatment; 
this failure to fully remove the receptor from the cell surface after stimulation may 
account for the observed increase in chemotactic efficacy (Sabroe et al., 2005). 
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The post-helix VIII portions of chemokine receptors, including CCR4, contain 
several serine and threonine residues. In CCR5, these residue were shown to be 
phosphorylated by GPCR kinases (GRKs), which subsequently caused the 
recruitment of β-arrestins and attenuation of chemokine receptor signalling 
(Oppermann et al., 1999). As described in section 1.3.2.2, β-arrestins prevent the 
receptor from further G protein coupling, and also act as a scaffold for recruitment of 
other proteins that in turn internalise the receptor. β-arrestins can also activate 
signalling pathways (Borroni et al., 2010; Vroon et al., 2006). The Δ40 CCR4 
truncation, lacking these GRK phosphorylation sites, is likely not being 
phosphorylated at a normal level in response to ligand. The resulting reduction in β-
arrestin recruitment and subsequent internalisation would therefore explain the 
observed increase in chemotactic efficacy. This would also suggest that CCR4-
mediated chemotaxis does not require β-arrestin signalling. 
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5.3.2 – Effect of site 2 mutation on antagonist activity 
Following characterisation of their phenotype, the site 2 point mutants and 
truncations were then tested against the site 2 antagonists in chemotaxis assays 
(figure 5-9, tables 5-10 and 5-12). The Δ45 and Δ50 truncations were not examined 
since they did not show a functional response. K310N transfectant responses to 
CCL17 could not be antagonised for the same reason. F305A, L307V, and L318A 
transfectants were also tested against antagonist 7, which was hypothesised to target 
site 1. This was performed as a control to determine that these mutations did not 
affect the hypothesised first site. The logIC50 values for antagonist 7 did not differ 
between WT and mutant transfectants, indicating that the activity of this antagonist 
was not affected by the site 2 mutations.  
Both F305 and L307 are hydrophobic amino acids, and modelling by 
GlaxoSmithKline suggested that they form part of a hydrophobic antagonist binding 
pocket. Since the site 2 antagonists and phenylalanine contain aromatic rings, π-
stacking interactions may occur. Studies of CXCR2 using the rhodopsin crystal 
structure have identified a hydrophobic antagonist binding pocket on the intracellular 
face of the receptor, consisting of residues from helices 2, 3, 6, 7 and 8 (Okada and 
Palczewski, 2001; Nicholls et al., 2008). 
 
The L318A transfectants did not show reduced potency to any of the three site 
2 antagonists in chemotaxis assays to both CCL17 and CCL22. K310N transfectants 
also did not show reduced potency to antagonists 2 and 5. The L307V transfectants 
however did show a reduced sensitivity to the antagonists; in CCL17 chemotaxis 
assays L307V transfectants were inhibited with reduced sensitivity to antagonist 2, 
and in CCL22 assays with reduced sensitivity to antagonist 5. 
Inhibition of binding of 
125
I-CCL22 to L307V by antagonist 2 resulted in a 
reduced potency of the antagonist compared to WT (figure 5-13). In chemotaxis 
assays however inhibition of L307V-induced migration by this antagonist did not 
differ to WT. Since binding assays showed a reduction in potency and the chemotaxis 
assays did not, it may indicate that the subtle effects on chemokine binding were 
being obscured by the amplification of signal that occurs after ligand binding to 
GPCRs. Ligand binding sets off a signalling cascade, in which G protein subunits 
trigger further activation of downstream signalling partners such as adenylyl cyclase, 
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phospholipase C, and kinases that in turn activate other proteins (see section 1.3.2.2). 
Due to the multiple and complex cellular events that arise from ligand binding and 
receptor signalling, relatively minor changes in chemokine binding may not translate 
through to observable differences in functional assays. This therefore may explain the 
observed discrepancy between antagonist potency in binding and chemotaxis assays. 
Another possible explanation is statistical rather than biological. The chemotaxis 
inhibition assays were variable in some cases, and further replicates may be needed to 
confirm whether certain mutations resulted in a reduction of antagonist sensitivity. 
Another interesting phenomenon is that the effect of F305A or L307V 
mutation on the inhibition of migration was chemokine-dependent. The decrease 
F305A transfectant sensitivity to antagonist 2 only occurred in response to CCL22 
migration, while the decrease in L307V transfectant sensitivity to antagonist 2 only 
occurred in response to CCL17. This suggests that the two chemokines utilise 
different sets of amino acids in order to transduce signal, and that the two chemokines 
may stabilise different receptor conformations. Since antagonist 2 is less effective at 
inhibiting CCL22-induced signalling through the L307V mutant, it implies that L307 
was required for full antagonist activity and therefore CCL22 signalling too required 
that amino acid. Antagonism of CCL17 was not affected, implying that L307 was 
dispensable for its signalling. This is reminiscent of the data described in chapter 3, 
regarding the stabilisation of distinct receptor conformations by the two chemokines. 
However in this case it is the unique responses of the antagonists that reveal the 
differences between the two ligands. 
The binding of 
125
I-CCL17 and 
125
I-CCL22 to K310N transfectants was also 
inhibited using antagonists 5 and 2, respectively (figure 5-13). It was previously 
described in this chapter and in chapter 3 that the K310N mutant, while being unable 
to induce chemotaxis to CCL17, still bound 
125
I-CCL17. It is interesting to note that 
antagonism of 
125
I-CCL17 binding was also unaffected by the mutant. This indicates 
that the K310N mutation affected receptor signalling while not affecting chemokine 
binding or antagonist activity. Inhibition of 
125
I-CCL22 binding was similarly 
unaffected. These data show that K310 is not required to maintain the site 2 
antagonist binding site. 
 
Since the Δ40 transfectants did not show any difference to WT transfectants 
with respect to inhibition of migration, it can be concluded that the last 40 amino 
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acids of the CCR4 C-terminus are dispensable for antagonism by both the site 1 and 
site 2 compounds. The binding site of the site 2 antagonists therefore likely lies in the 
region not truncated, namely helix VIII. 
The identification of intracellular CCR4 antagonists (Andrews et al., 2008) 
used C-terminal domain exchanges between CCR4 and CCR5; these receptors have a 
highly conserved group of amino acids around the NPXXY motif in transmembrane 
helix VII. It was here that the C-termini were exchanged. Antagonists active against 
CCR4 were also active against CCR5/4 (CCR5 with a CCR4 C-terminus). The 
antagonists could not inhibit CCR5 or CCR4/5 responses, indicating that they were 
specific for the C-terminal end of helix VII and the C-terminus of CCR4 (Andrews et 
al., 2008). The previously described F305A and L307V mutants are located within 
this exchanged region, supporting this finding. CCR5 also possesses a residue 
analogous to F305, and has the structurally related aliphatic valine instead of a 
leucine at position 307. In addition, data presented here on the CCR4 Δ40 truncation 
have narrowed down this binding site. Since the C-terminal swaps between CCR4 
and CCR5 were from histidine 296 in helix VII, and that data here show that the 
amino acids downstream of lysine 320 of CCR4 are not required for antagonist 
activity, the site 2 antagonist most likely bind to a region between these two points. 
 
C-terminal exchanges of the chemokine receptors CXCR1 and CXCR2 
revealed the presence of a similar intracellular allosteric site, and that K320 
(analogous to K310 of CCR4) of helix VIII of CXCR2 formed part of this binding 
pocket since mutation to asparagine reduced the level of antagonism of the receptor 
(Nicholls et al., 2008). 
Further mutational analyses of CXCR2 were performed to determine the 
specific interactions of the antagonists and intracellular binding sites. K320 of 
CXCR2 was mutated to alanine rather than asparagine, in order to disrupt ion pair 
interactions between the amino acid and the antagonist. Y314, part of the conserved 
NPXXY motif at the end of transmembrane helix VII, was also mutated to alanine to 
disrupt any π-stacking interactions of the binding pocket. D84 in the first intracellular 
loop was predicted to form an ion pair interaction with K320; this was also mutated to 
alanine to disrupt this interaction. All three mutations resulted in reduced antagonist 
affinity for the receptor, demonstrating that these residues were part of the 
intracellular antagonist binding pocket (Salchow et al., 2010). 
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The data presented here on CCR4 show that the site 2 antagonist binding site 
is not located in the last 40 amino acids of the receptor, and thus is likely made up of 
residues from the end of helix VII and in helix VIII. The F305A transfectants showed 
a small but significant increase in antagonist 2 potency while the L307V transfectants 
showed a decrease in potency, rather than a complete loss of sensitivity. The K310N 
and L318A mutants had no effect on antagonism. 
Based on previous studies on CXCR2, further mutation of K310 to alanine 
may be required to probe the importance of this amino acid in antagonist activity on 
the C-terminus of CCR4. The lysine to asparagine mutation performed in this project 
is fairly conservative, in that it changed the ionisation state of the residue with 
completely removing the bulk of the lysine side chain. Mutation to alanine, as was 
done for the majority of potential antagonist-binding amino acids in CCR4, may 
prove more effective in elucidating the role of K310. 
Since the Δ45 and Δ50 truncation mutants were non-functional and had 
severely reduced cell-surface expression levels, generation of additional helix VIII 
point mutants would allow further examination of their contribution to both receptor 
biology and antagonist activity. Mutation of hydrophobic residues such as F311, 
Y314, and F319 could be performed to determine the role of these residues in 
stabilisation of helical structure, and also their potential hydrophobic interactions in 
the intracellular antagonist binding pocket. Hydrophilic and charged residues within 
helix VIII such as K313 and K320 could be mutated to determine if they form 
interactions that are necessary for antagonist activity. Q317, a polar neighbour to 
K313, may form interactions with other residues in the receptor or with functional 
groups in the antagonists. 
In addition, while the current CCR4 homology model does not include this 
residue as part of the antagonist binding site, mutation of the conserved aspartic acid 
of the DRYLAIV motif may prove useful since CXCR2 it was shown to form part of 
the antagonist binding pocket as a partner for the analogous residues to K310, K320 
(Salchow et al., 2010). Despite its potential role in antagonism, mutation of this 
residue would allow investigation into a likely important domain required for CCR4 
function. 
 
  
208 
 
5.3.3 – Summary 
In conclusion, it has been shown in this chapter that the F305A and L307V 
mutants of CCR4 had reduced cell-surface expression relative to WT CCR4, with 
L307V transfectants migrating to CCL17 with a lower efficacy. Despite this, both 
mutants exhibited the typical chemotactic dose response, indicating that the mutated 
residues were not critical for receptor function. L307V transfectants showed reduced 
antagonist potencies in chemotaxis assays, and F305A transfectants showed a slight 
increase in potency. This highlights the role of these residues in antagonist binding, 
and suggests that the F305A mutation allowed the antagonist better access to the 
binding pocket. 
The L318A and K310N mutations had no effect on receptor antagonism; 
L318A also had no effect on receptor phenotype. K310N however was unresponsive 
to CCL17 in chemotaxis assays, meaning that its functional response could not be 
antagonised. This mutant did retain the ability to bind 
125
I-CCL17, which was easily 
antagonised by antagonist 5 with no differences to WT. Thus, while K310 was 
important for CCL17-induced function it was not shown to be required for antagonist 
activity. Based on previous studies in CXCR2, further study of this residue by 
mutation to other side chains may be required. 
The three successive C-terminal truncations of the CCR4 C-terminus highlight 
the importance of the putative helix VIII region, as the Δ45 and Δ50 truncations were 
non-functional. The Δ40 truncation showed increased chemotactic efficacy, possibly 
due to the removal of serine and threonine phosphorylation sites required for β-
arrestin recruitment. Antagonism of Δ40-induced chemotaxis did not show any 
differences to WT, showing that the last 40 amino acids of CCR4 are not part of the 
site 2 antagonist binding site. 
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6 – Probing antagonist binding sites within CCR4 
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6.1 – Introduction 
Molecular modelling performed by GlaxoSmithKline identified several amino 
acids within CCR4 that potentially were sites of antagonist contact. The CCR4 
antagonists were hypothesised to bind either a classical intrahelical site (site 1) or a 
novel intracellular site (site 2). In chapter 4, amino acids predicted to contact site 1 
antagonists were mutated; the resulting receptor point mutants were then transfected 
into L1.2 cells and assessed for cell-surface expression and chemotactic ability. 
Mutants that were both expressed and functional were then tested for their sensitivity 
to antagonism in chemotaxis assays. If a mutant was insensitive to an antagonist, it 
implied that the amino acid that had been mutated was required for antagonist 
activity. The ability of the antagonists to inhibit chemokine binding was also 
investigated. It was shown that the L118A, Y122F, and I125A mutants had reduced 
sensitivity to one of the site 1 antagonists in chemotaxis assays. L118A was also 
shown to have reduced sensitivity to inhibition of chemokine binding. 
The same process was repeated in chapter 5, for the site 2 compounds, which 
involved the mutation of residues in the C-terminus, including the highly conserved 
helix VIII region, in addition to truncations of the C-terminus of the receptor. The 
F305A and L307V mutants, located at the distal end of helix VII were shown to have 
reduced sensitivity to two of the site 2 compounds. 
The preceding chapters have thus used indirect methods to investigate the 
effects of point mutation on antagonist binding. In this chapter, the effects were 
directly measured using radiolabelled antagonists. GlaxoSmithKline provided 
3
H-
labelled versions of antagonist 3, which targets site 1, and antagonist 5, which targets 
site 2. 
Tritiated antagonists contain the radioactive isotope of hydrogen, 
3
H, in place 
of normal hydrogen atoms. The specific activities of the radioactively labelled 
compound 3 (
3
H-3) and compound 5 (
3
H-5) were 37 and 53 Ci/mmol, respectively. 
Since the maximum theoretical specific activity per tritium is 29 Ci/mmol, on average 
these antagonists contain more than one tritium atom. The structures of antagonist 3 
and 5 are shown in figure 6-1. Tritium decays into helium-3 by β-decay, resulting in 
the release of β particles, which are electrons. Since β particles emitted from 3H are 
relatively low energy compared to other forms of ionising radiation such as gamma 
rays (see chapters 4 and 5 for gamma-emitting 
125
I-chemokines), they cannot be 
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directly detected. Scintillants are therefore used to detect the radioactive emissions. 
Scintillants are compounds that emit light when excited by particles such as electrons. 
The light emission is then detected by a scintillation counter, which allows 
quantification of the amount of radiation released by the particle. This phenomenon 
was exploited in the antagonist binding assays used in this chapter. 
Saturation binding assays are commonly used assays that employ 
radiolabelled ligand. They involve incubating a cell or membrane expressing a 
receptor of interest with increasing and ultimately saturating concentrations of 
radiolabelled ligand. This allows the determination of the affinity of the ligand for the 
receptor, the Kd, and the number of binding sites for the ligand, the Bmax. 
Previous research involving point mutation of the chemokine receptor CXCR1 
and CXCR2 putatively identified an intracellular antagonist binding site (Nicholls et 
al., 2008), analogous to the intracellular CCR4 site hypothesised here. Subsequent 
research employed tritium-labelled antagonists to further investigate this site. A 
CXCR2 antagonist, SB265610, was labelled with tritium and used in membrane-
based assays. It was shown to be specific to CXCR2, since incubation with CXCR1-
expressing membranes did not result in the detection of light emitted from scintillant. 
This compound was also shown to have rapid dissociation kinetics; after 2.7 minutes 
the level of bound 
3
H-SB265610 was reduced by 50%. Saturation assays were used to 
determine its Kd and Bmax; these were 2.5 nM and 50 pmol/mg, respectively. 
Competition binding assays in which increasing concentrations of other CXCR2 
ligands were incubated with a fixed concentration of 
3
H-SB265610 showed that 
CXCL8 could not displace the antagonist. This demonstrated that the antagonist 
bound a site distinct to CXCL8. In addition, another CXCR2 antagonist could not 
displace the compound, indicating that 
3
H-SB265610 bound to a distinct site on 
CXCR2. This was believed to be the intracellular site previously described (de Kruijf 
et al., 2009). Further research used 
3
H-265610 and other radiolabelled CXCR2 
antagonists with a panel of point mutants to provide further information regarding the 
antagonist binding site. Several point mutants were made of amino acids believed to 
form the intracellular allosteric site. Mutants of K320 and Y314 in the C-terminus 
and D84 in the first intracellular loop showed reduced binding affinity for the 
antagonists, showing that these residues were required for antagonist contact 
(Salchow et al., 2010). These studies show that radiolabelled antagonists are an 
important and useful tool in probing antagonist binding to a receptor.  
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Figure 6-1 – Structures of antagonists 3 and 5 
Antagonist 3 and antagonist 5 were radioactively labelled with tritium. Tritium is an 
isotope of hydrogen that contains two neutrons, denoted as 
3
H. On average each 
antagonist molecule would contain 1-2 tritium atoms. 
3
H-3 
3
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6.2 – Binding of intrahelical allosteric CCR4 antagonists 
6.2.1 – Preparation of L1.2 cell membranes 
L1.2 cells were transiently transfected with the pcDNA3 plasmid containing 
the CCR4 insert, as previously described in section 3.2.1. Following confirmation of 
cell-surface expression of the receptor, the cells were homogenised and centrifuged, 
resulting in a stock of membranes expressing the receptor. The absorbance values of 
BSA standards in a BCA assay were analysed by linear regression, and the resulting 
equation used to determine the concentrations membrane stocks. Figure 6-2A shows 
the graph of the BSA standards; the linear regression equation generated from these 
data was: 
 
                   
 
Measurement of neat and serially diluted membrane concentration gave 
absorbance values, which were used to solve the equation by setting these values as y. 
The average of these concentration values was then used to determine the stock 
concentration. In this case, the WT CCR4-L1.2 membrane stock was at 2.05 mg/ml. 
This was aliquoted and stored at -80ºC until use in subsequent binding assays. 
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Dilution Neat 1:3 1:6 1:9 
Absorbance values 0.074 0.032 0.020 0.013 
Concentration (mg/ml) 1.48 0.65 0.40 0.26 
Concentration of stock (mg/ml) 1.48 1.94 2.42 2.35 
Mean stock concentration 
(mg/ml) 
2.05 
 
 
 
  
Figure 6-2 – Determination of membrane concentration with BCA assay 
BSA standards were incubated with the BCA assay reagents, and the results analysed by 
linear regression (A). The linear regression equation was used to calculate the 
concentrations of serial dilutions of WT CCR4-L1.2 membrane preps; these were used 
to generate an average stock concentrate to use in further assays (B). 
A 
B 
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6.2.2 – Comparison of SPA and filtration binding assays 
Two antagonist binding assays were available to use. The first was the 
scintillation proximity assay (SPA). In this assay, beads containing scintillant were 
coated with CCR4-expressing membranes. Wheat germ agglutinin (WGA) beads 
were used since this protein binds various carbohydrates commonly present on cell 
surfaces. The bead-membrane mixture was incubated with radiolabelled antagonist 
and either buffer or excess unlabelled antagonist. The emitted β-particles from tritium 
have a path length of 1.5 µm through water, meaning that scintillant is only excited if 
it is within this distance. The binding of the tritium-labelled antagonist to the receptor 
brought it in close enough proximity to the beads to allow excitation of the scintillant 
by the emitted β-particles. This emission was then detected using a MicroBeta 
scintillation counter. 
Figure 6-3A shows the results of SPA using control CCR4-CHO membranes 
and WT CCR4-L1.2 membranes. SPA gave a small window of 100 counts between 
total and non-specific binding for WT CCR4 L1.2 membranes. The binding window 
for the control CCR4-CHO membranes was also small, approximately 350 counts. 
These binding windows were too small to produce reliable results, meaning that 
another binding assay was tested. 
 
The second assay used involved filtration. Membranes were incubated with 
radiolabelled antagonist and then filtered using vacuum pressure through a glass fibre 
mat; the membranes were retained on the mat while free ligand was washed away. 
The mat was then cut into pieces, and each piece immersed in tubes containing liquid 
scintillant. The emission of light was then quantified using a Tri-Carb liquid 
scintillation counter. Total binding was measured by incubating the membranes and 
radiolabelled antagonist with buffer, while non-specific binding was measuring by 
incubating with 10 µM unlabelled antagonist. 
Figure 6-3B shows the results of filtration binding of control CCR4-CHO and 
WT CCR4-L1.2 membranes. This assay gave a large 7800 count window for the 
CHO membranes. WT CCR4 L1.2 membranes gave a window of 1600 counts. To 
confirm that this binding window was specific to the receptor, membranes from naive 
L1.2 cells were tested in the same assay. Figure 6-3C shows that there was no 
difference between total and non-specific binding, indicating that 
3
H-3 did not bind 
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non-specifically to the L1.2 membranes. Due to these results, filtration binding was 
used in subsequent antagonist binding assays. 
The data shown in figure 6-3 are those generated from the result of several 
rounds of optimisation, since initial tests showed high non-specific binding to L1.2 
membranes when compared to CCR4-CHO controls. The filtration assay was 
optimised in several ways; as described in section 2.2.4.4, the filter mat was soaked in 
0.3% PEI prior to filtration in order to neutralise its negative charge and thus reduce 
charge-dependent non-specific binding of the antagonist to the mat. Various assay 
membrane concentrations were also tested in order to give the optimal binding 
window and to ensure that ligand depletion did not occur. The optimised assay 
involved 20 μg of membrane per assay well and filtration through a mat pre-soaked 
for 3 hours in 0.3% PEI. 
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Figure 6-3 – SPA and filtration binding of CCR4-expressing and naive membranes  
CCR4-CHO and WT CCR4-L1.2 membranes were assayed for 
3
H-3 binding in SPA 
(A) and filtration binding (B). Membranes were incubated with 0.1 nM (A) or 1 nM (B 
and C) 
3
H-3 and either buffer (total binding; black bars) or 10 μM unlabelled antagonist 
3 (non-specific binding; grey bars). Data are shown as DPM, and are the mean ± SEM 
of one experiment. 
A 
B 
C 
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6.2.3 – Saturation of WT CCR4-L1.2 membranes 
Following optimisation of the filtration binding assay, saturation binding 
assays were performed on WT CCR4-L1.2 membranes. These assays involved the 
incubation of the membranes with increasing concentrations of radiolabelled 
antagonist, up to a level that saturated the antagonist binding sites. Membranes were 
also incubated with buffer or 10 µM unlabelled antagonist; thus for each 
concentration of 
3
H-3, total and non-specific binding values were generated. 
Saturation binding assays can be used to determine the affinity of the ligand for the 
receptor, the Kd, and the maximum number of ligand binding sites, the Bmax. 
Figure 6-4 shows the results of saturation binding on WT CCR4-L1.2 
membranes. Panel A shows both total and non-specific binding for a dose response of 
3
H-3. 0.03 nM 
3
H-3 showed a low level of binding; total binding for this 
concentration was 144 DPM, whereas non-specific binding was 127 DPM. As 
3
H-3 
concentration increased, so did the total radioactivity bound. Total binding for 6.15 
nM 
3
H-3 was 15733, while non-specific binding was 14254. 
Panel B shows specific binding plotted against 
3
H-3 concentration; this was 
calculated by subtracting the non-specific binding values from the total binding 
values from panel A. The specific binding data were analysed using non-linear 
regression, and the steepness of the curve quantified by the Hill slope. A Hill slope 
factor of 1 indicates that the slope is of standard steepness and that no cooperativity is 
occurring. A slope factor of greater than 1 indicates that multiple binding sites are 
present with positive cooperativity. The slope factor from this experiment was 1.34, 
shown in panel C. 
The Kd obtained from this fit was 0.85 nM, indicating that at a concentration 
of 0.85 nM 
3
H-3, half of the 
3
H-3 binding sites were occupied. The non-linear fit 
shows that the specific binding plateaued at higher 
3
H-3 concentrations, indicating 
that the antagonist binding sites were saturated. The Bmax obtained from the fit was 
1588 DPM. To convert this value into pmol/mg, the specific activity of 
3
H-3, 37 
Ci/mmol, was multiplied by 2.22 x 10
12
, since 1 Ci is equal to this value in DPM. 
These values were also divided by 10
9 
in order to derive DPM/mmol: 
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The Bmax was then divided by this number and the concentration of membrane in mg, 
to determine pmol/mg: 
 
    
           
      
 
Therefore, the Bmax of 
3
H-3 on WT CCR4-L1.2 membranes was 4.83 
pmol/mg. 
 
This assay was repeated several times; however these repeats provided very 
variable results. The non-specific binding of 
3
H-3 was often high enough to obscure 
the binding window shown in figure 6-4, such that saturation curves could not be 
plotted. The data shown in figure 6-4 are representative of two experiments that 
produced non-linear regression fits that gave Kd and Bmax values. In subsequent 
experiments, the non-specific binding of 
3
H-3 was too variable to produce consistent 
results. 
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Figure 6-4 – Saturation of WT CCR4-L1.2 membranes with 3H-3 
40 μg of WT CCR4-L1.2 membranes were incubated with increasing concentrations of 
3
H-3, and either buffer or excess antagonist 3 (A). Specific binding against 
3
H-3 
concentration, and analysed with non-linear regression and Hill slope (B); this was used 
to the generate Bmax and Kd values shown in panel C. The Hill slope factor is also shown 
in panel C. Data are representative of two independent experiments. 
A 
B 
C 
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6.2.4 – E290 mutant binding to antagonists 
Mutants of the conserved glutamine E290 (GluVII:06) in transmembrane 
helix VII of CCR4 have previously been shown to be unable to bind the chemokines 
CCL17 and CCL22 and thus render transfectants of these mutants unresponsive in 
chemotaxis assays (see sections 4.2.2 and 4.2.3). GluVII:06 is a highly conserved 
amino acid, and was predicted by scientists at GlaxoSmithKline using molecular 
modelling to be a major point of contact for the site 1 antagonists. The effect of the 
E290 mutations on antagonist binding was therefore directly probed using the 
radiolabelled antagonist 3, which was hypothesised to bind the intrahelical site 1. 
Figure 6-5 shows the results of saturation binding assays on WT (A), E290A 
(B), E290D (C) and E290Q (D) CCR4-L1.2 membranes. WT CCR4 gave a binding 
window at each 
3
H-3 concentration; for 0.08 nM 
3
H-3 total binding was 326 DPM 
and non-specific binding was 160 DPM, while at the highest concentration of 
3
H-3, 
12.64 nM, total binding and non-specific binding were 29466 DPM and 23216 DPM, 
respectively. The E290 mutants however showed a distinct lack of difference between 
total and non-specific binding at any 
3
H-3 concentration, indicating that they did not 
bind the radiolabelled antagonist. Panel E of figure 6-5 shows specific binding of the 
WT and E290 mutants plotted against 
3
H-3 concentration and analysed using non-
linear regression. As in figure 6-4, the WT saturation curves were variable; in this 
case the curve did not plateau, meaning that the Kd and Bmax could not be calculated. 
However from this graph and the bar charts it can still be seen that WT CCR4 bound 
antagonist 3, whereas the E290 mutants did not. 
 
As an alternative to saturation binding, homologous competition assays were 
performed on the E290 mutants in an attempt to provide as estimate of the Kd, since 
the saturation assays failed to provide repeatable results. Homologous competition 
assays were performed in a similar manner to saturation assays, except that the 
radiolabelled antagonist concentration remained fixed while the unlabelled 
concentration varied. In this case, the assay was performed with two fixed 
radiolabelled antagonist concentrations to provide a better estimate of the Kd. 
Figure 6-6A shows the results of a homologous competition assay performed 
on control CCR4-CHO membranes. Two curves are shown, one for 1.36 nM 
3
H-3 
and another for 5.22 nM 
3
H-3. Total binding in the absence of unlabelled antagonist 
222 
 
was 20777 DPM for 5.22 nM 
3
H-3 and 8901 DPM for 1.36 nM 
3
H-3, as was binding 
in the presence of 10 μM unlabelled antagonist; 7005 DPM for 5.22 nM 3H-3 and 
2315 DPM for 1.36 nM 
3
H-3. The graph shows that binding of both concentrations of 
3
H-3 was dose-dependently competed with by the increasing concentration of 
unlabelled antagonist 3. A shared non-linear regression analysis of the two curves 
gave a logKd of -8.72 (Kd = 1.9 nM). 
Since this assay proved successful in control CCR4-CHO membranes, it was 
performed on WT and E290 mutant L1.2 membranes. Figure 6-6, panels B-D show 
the results of these assays. In contrast to panel A, there was no sigmoidal curve 
generated from the competition data. The addition of unlabelled antagonist did not 
reduce 
3
H-3 binding to a low enough level to allow estimation of the Kd. Similar 
results were observed for two repeats of this experiment. 
Figures 6-5 and 6-6 therefore show that both saturation and homologous 
competition binding assays for 
3
H-3 are variable, likely due to the high non-specific 
binding of the compound. Despite this, it was determined that WT CCR4 was able to 
bind the radiolabelled antagonist, while mutation of E290 to alanine, aspartic acid and 
glutamic acid removed this binding site. 
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Figure 6-5 – E290 mutants do not bind 3H-3 in saturation assays 
40 μg of WT (A), E290A (B), E290D (C), and E290Q (D) CCR4-L1.2 membranes were 
incubated with increasing concentrations of 
3
H-3 and either buffer or excess antagonist 
3. The specific binding was then plotted against 
3
H-3 concentration and analysed using 
non-linear regression with a Hill slope (D). Data are representative of three independent 
experiments; due to the variability of this assay Kd and Bmax values could not be 
generated. 
A B 
C D 
E 
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Figure 6-6 – 3H-3 homologous competition assays of E290 mutants 
Homologous competition filtration assays were performed in which 5 μg CCR4-CHO 
membranes (A) and 40 μg WT (B), E290A (C), E290D (D), and E290Q (E) CCR4 L1.2 
membranes were incubated with fixed concentrations of 
3
H-3 and increasing 
concentrations of antagonist 3. Data were analysed using non-linear regression, and are 
representative of 3 independent experiments. 
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6.2.5 – Saturation binding of 3H-3 to L118A CCR4 
Saturation binding assays were also performed on the L118A mutant. This 
mutant has previously been shown to have reduced sensitivity to antagonist 7 in 
chemotaxis and chemokine binding assays. Antagonist 7 is a site 1 compound, and 
while it is not very structurally similar to antagonist 3, they both are hypothesised to 
bind to the same region of CCR4. Therefore, this mutant was investigated in 
3
H-3 
binding assays in order to determine whether this mutation had directly perturbed 
antagonist binding. 
Figure 6-7 shows the results of a saturation binding assay performed on WT 
and L118A CCR4-L1.2 membranes. As in figures 6-3 and 6-4, WT CCR4 bound 
3
H-
3, giving a window between total and non-specific binding, shown in panel A. L118A 
also gave a binding window, shown in panel B. Specific binding is shown in panel C, 
plotted against increasing 
3
H-3 concentration. Both curves plateaued, indicating that 
3
H-3 binding sites were saturated at the highest concentration. The L118A curve 
plateaued at a lower specific binding value that the WT curve; the maximum values 
were 1094 and 1693 DPM, respectively. 
The non-linear regression fit was used to calculate Kd and Bmax, shown in 
panel C. The Bmax of L118A CCR4 was lower than that of WT CCR4; 1120 DPM 
compared to 1904 DPM. These values were converted to 5.79 and 3.41 pmol/mg, 
respectively. They indicated that the L118A mutant had fewer 
3
H-3 binding sites. The 
Kd of L118A was also lower than the WT; 0.77 nM compared to 1.22 nM. This shows 
that the mutant receptor had a higher affinity for 
3
H-3 than the WT receptor. The Hill 
slope factors were 1.15 and 1.61, indicating positive cooperativity between multiple 
sites. However, these results could not be reliably reproduced. Due to the variability 
of the assay, other saturation curves resulted in ambiguous regression curve fits. 
Other assays showed binding windows for WT and L118A similar to those seen in 
panel A, but more complex analysis was hindered by the high non-specific binding of 
3
H-3. Therefore, making strong conclusions regarding the affinity and number of 
binding sites of 
3
H-3 may be premature. It can however be concluded that L118A was 
still able to bind 
3
H-3 due to the presence of a binding window. 
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Figure 6-7 – L118A mutation reduces total 3H-3 binding in saturation assays 
40 μg of WT (A) and L118A (B) CCR4-L1.2 membranes were incubated with 
increasing concentrations of 
3
H-3 and either buffer or excess antagonist 3. The specific 
binding was then plotted against 
3
H-3 concentration and analysed using non-linear 
regression with a Hill slope (C), which was used to determine Bmax and Kd values (D) 
Data are from one experiment. 
A B 
C 
D 
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6.2.6 – 3H-3 binding to the L92A and Y117A mutants 
The mutants L92A and Y117A were shown in section 4.2.2 to not induce 
migration of transfectants to either CCL17 or CCL22 in chemotaxis assays. 
Therefore, their sensitivity to antagonists in chemotaxis assays could not be 
investigated since this assay requires functional receptor to induce a chemotactic 
response. 
Previous data in this chapter have shown that saturation and competition 
assays using 
3
H-3 are variable due to high non-specific binding. Therefore, simple 
total/non-specific binding assays were performed in which WT, L92A and Y117A 
membranes were incubated with either 1.39 nM or 4.72 nM 
3
H-3 and either buffer or 
10 μM unlabelled antagonist 3. This was performed in order to test whether a binding 
window was observable at these concentrations of 
3
H-3. Since these 
3
H-3 
concentrations were lower than previously used in saturation assays, 20 μg rather than 
40 μg of membrane was used per well in order to reduce ligand depletion. 
Figure 6-8 shows the results of this assay, demonstrating that WT, L92A and 
Y117A bind 
3
H-3. Panel A shows binding of 1.39 nM 
3
H-3, while panel B shows 
binding of 4.72 nM 
3
H-3. Specific binding was calculated by subtracting non-specific 
binding from total binding, the results of which are shown in panel C. For both 
3
H-3 
concentrations, WT and L92A showed similar specific binding levels, while Y117A 
showed levels approximately 400-600 DPM higher. Figure 6-3C showed that naive 
L1.2 membranes did not bind 
3
H-3, demonstrating that results shown in figure 6-8 
were specific for the CCR4-expressing membranes. 
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Figure 6-8 – Y117A and L92A CCR4 mutants retain the ability to bind 3H-3 
20 μg of WT, L92A, and Y117A CCR4-L1.2 membranes were incubated with two 
concentrations of 
3
H-3; 1.39 nM (A) or 4.72 nM (B) bars, and either buffer (total 
binding; black bars) or 10 μM unlabelled antagonist 3 (non-specific binding; grey bars). 
Panel C shows the specific binding windows resulting from the subtraction of NSB 
from TB, in DPM. Data are representative of four independent experiments. 
A 
B 
C 
230 
 
6.3 – Binding of intracellular allosteric CCR4 antagonists 
6.3.1 – 3H-5 saturation assays 
Saturation binding assays were performed on CCR4-expressing membranes in 
a similar manner to those described previously; however in this case the radiolabelled 
site 2 antagonist, 
3
H-5, was used. Figure 6-9A shows a saturation assay using 
3
H-5 
performed on control CCR4-CHO membranes; as in previous figures, specific 
binding was calculated after subtraction of non-specific from total binding after 
incubation of membranes with increasing concentrations of the radiolabelled 
antagonist. The non-linear regression analysis gave a Kd of 1.29 nM, a Bmax of 41552 
DPM (472 pmol/mg), and a hill slope factor of 0.95. These results show that the 
antagonist bound to CCR4 with nanomolar affinity and without cooperativity, in 
agreement with previous observations by GlaxoSmithKline (personal 
communication). 
The same assay was performed for WT and mutant CCR4 membranes. L307V 
and K310N are mutants of C-terminal amino acids, predicted to be sites of 
intracellular antagonist contact. L307V CCR4 transfectants previously showed 
reduced sensitivity to antagonist 2 and 5 (see section 5.3.1) in chemotaxis assays; the 
direct effect of this mutation on antagonist binding was therefore investigated in this 
chapter using the radiolabelled antagonist 
3
H-5. K310 is located within the highly 
conserved helix VIII region, and has been shown to be important for receptor 
function. An analogous residue in CXCR2 has also been implicated in antagonist 
binding (Nicholls et al., 2008; Salchow et al., 2010); therefore the effect of this 
mutation on site 2 antagonist binding was also tested. 
Figure 6-9B shows the non-linear regression fit generated from a 
3
H-5 
saturation binding assay performed on WT, L307V and K310N CCR4-L1.2 
membranes. Unlike the CCR4-CHO control shown in panel A, the curves for the L1.2 
membranes did not plateau, and therefore Kd and Bmax values could not be generated. 
Figure 6-9C shows a similar assay performed on WT and E290 mutant CCR4-L1.2 
membranes, in which the same non-saturating results were observed. The 
concentrations of 
3
H-5 used for the saturation assay were five times higher than those 
in panel A, indicating that the concentration of radiolabelled antagonist was not an 
issue. 
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In addition, the specific activity of 
3
H-5 was 53 Ci/mmol compared to 37 
Ci/mmol for 
3
H-3. Since saturation had been observed for 
3
H-3 at 8 nM, using 
3
H-5 at 
comparable concentrations should have resulted in saturation since 
3
H-5 has a higher 
specific activity than 
3
H-3. 
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Figure 6-9 – CCR4-L1.2 membranes cannot be saturated with 3H-5 
Saturation assays were performed on 5 μg CCR4-CHO membranes, and specific 
binding plotted with a Hill slope; this generated a Kd of 1.29 nM and a Bmax of 41552 
DPM (472 pmol/mg). Saturation assays were also performed on 40μg L307V and 
K310N (B) and E290A, E290D, and E290Q (C) CCR4-L1.2 membranes along with WT 
CCR4-L1.2 membranes. These were not saturated, so Kd and Bmax values could not be 
generated. Data are representative of four independent experiments. 
A 
B 
C 
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6.3.2 – Identification of low affinity binding site on L1.2 membranes 
The results of section 6.3.1 showed that high concentrations of 
3
H-5 were not 
saturating the membranes, indicating a possible binding site on the L1.2 membranes 
for the antagonist. To investigate this, a saturation binding assay was performed on 
naive L1.2 membranes in the same manner as described previously. As can be seen 
from figure 6-10A, a binding window clearly exists on these naive membranes; at the 
highest concentration of 10.33 nM 
3
H-5, total binding was 90027 DPM while non-
specific binding was 62464 DPM. Figure 6-10B shows that this binding was not 
saturated even at this high concentration, in agreement with data shown in figure 6-9. 
These data indicated that a low-affinity site for 
3
H-5 was present on the naive 
L1.2 membranes. Since high concentrations of 
3
H-5 were used for the saturation 
assays shown in panels A and B, lower concentrations were thus used in an attempt to 
saturate the high-affinity site without hitting the low-affinity site. Panel C shows the 
results of this; even at low concentrations the binding did not saturate, indicating that 
the low affinity site was still being bound by 
3
H-5. 
 
In order to further probe this low affinity site, other site 2 compounds were 
used in place of unlabelled antagonist 5 to measure non-specific binding. Antagonist 
8, a compound structurally related to antagonist 5, was used in an effort to define 
non-specific binding in a 
3
H-5 saturation assay of naive L1.2 membranes. Figure 6-
11A shows that this compound gave similar results to figure 6-10. This shows that 
antagonist 8 acted in the same manner as antagonist 5, and did bind to the low-
affinity site on the naive L1.2 membranes. 
Antagonist 9 is another site 2 compound, structurally distinct from antagonist 
5. This was also used as a competing ligand in an effort to define the non-specific 
binding of antagonist 5. Figure 6-11B shows the results of a saturation assay on naive 
membranes; this compound removed the window observed for these membranes. 
However, when this antagonist was used to define NSB for a 
3
H-5 WT CCR4 
saturation assay, no binding window was observed. Figure 6-11C shows no difference 
between TB and NSB when antagonist 9 was used as NSB. This indicates that 
antagonist 9 failed to compete with the radiolabelled ligand for specific antagonist 
binding sites; this compound therefore cannot be used to investigate receptor binding. 
Ideally, it would have removed the binding window observed in the naive membranes 
234 
 
while preserving a window in CCR4 membranes. These data show that the low 
affinity site for 
3
H-5 cannot be blocked using alternative site 2 antagonists. Therefore, 
no further assays using 
3
H-5 were performed on L1.2 membranes. 
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Figure 6-10 – 3H-5 saturation assay reveals binding site on naive L1.2 membranes 
A 
3
H-5 saturation assay was performed on 20 μg naive L1.2 membranes; total and non-
specific binding (A) showed the presence of a binding window. Specific binding plotted 
with a Hill slope showed that this binding site could not be saturated even with high 
3
H-
5 concentrations (B). Lower concentrations of radiolabelled antagonist, on 5 μg of 
membranes (C), showed similar results. Data are representative of two independent 
experiments. 
A 
B 
C 
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Figure 6-11 – Alternative site 2 antagonists do not define non-specific binding site  
Saturation assays were performed on 5 μg naive L1.2 membranes using a different site 2 
compound to define non-specific binding (A), however a binding window was still 
observed. Another compound was used on naive membranes which removed the 
window (B). This compound also removed the binding window on 5 μg WT CCR4-
L1.2 membranes (C). Data are representative of two independent experiments. 
A 
B C 
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6.4 – Discussion 
6.4.1 – Direct binding of antagonists to CCR4 
In the preceding two chapters, the effects of CCR4 point mutation and 
truncation on receptor biology and antagonist potency were investigated. The 
antagonist assays used indirect methods to infer whether the mutation of a particular 
residue had disrupted an antagonist binding site. For example, chemotaxis assays 
were performed in which the migration of WT and mutant transfectants to chemokine 
was dose-dependently inhibited by an increasing concentration of antagonist. This 
was used to generate logIC50 values to determine potency. The logIC50 values for WT 
and the mutant were then compared, and if the mutant showed a reduction in 
antagonist potency then the site of mutation was concluded to be a site of antagonist 
contact. Similar assays were performed by inhibiting binding of radiolabelled 
chemokine to the transfectants. 
In this chapter, direct assays were performed on membranes expressing WT or 
mutant CCR4. These involved using radiolabelled antagonists to directly confirm 
whether a CCR4 mutation had disrupted antagonist binding. Two radiolabelled 
antagonists were provided by GlaxoSmithKline, which were tritiated versions of 
antagonists 3 and 5. 
3
H-3 was hypothesised to bind to the intrahelical site 1, and 
3
H-5 
was hypothesised to bind to the intracellular site 2. 
 
Initially, the scintillation proximity assay (SPA) and filtration binding assay 
were compared to determine which provided the largest window between total and 
non-specific binding. Both assays used membrane preparations of previously 
transfected L1.2 cells. The concentrations of the membrane preparations were 
measured using a BCA assay so that the assay concentration could be controlled 
(figure 6-2). This assay allowed reliable determination of the concentration of several 
L1.2 membrane preparations that were performed prior to binding assays. 
The comparison of SPA and filtration binding using 
3
H-3 (figure 6-3) showed 
that the latter gave the largest window between total and non-specific binding. For the 
control CHO cells, 0.1 nM 
3
H-3 gave a window of 350 counts in SPA whereas 1 nM 
3
H-3 gave a window of 7800 counts the filtration assay. The WT CCR4-expressing 
L1.2 membranes also gave a larger binding window in the filtration assay relative to 
the concentration of radiolabelled antagonist used. Filtration binding was therefore 
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used in subsequent binding assays. Naive L1.2 membranes were also shown to not 
bind 
3
H-3. 
Membrane preparations from Chinese hamster ovary (CHO) cells stably 
expressing CCR4 were used as a positive control in these assays. These had been 
optimised by GlaxoSmithKline to express high levels of the receptor in order to give 
a large binding window. In addition, since they were a non-leukocyte cell line the 
non-specific effects associated with using chemokines and chemokine receptor 
antagonists could be minimised. L1.2 membranes however were used to investigate 
the effect of point mutation of receptor antagonism. Due to time constraints, stably-
expressing mutant CCR4 in CHO cells would have been unfeasible, and would have 
meant switching cell lines when previous assays were carried out using the L1.2s. 
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6.4.2 – Binding of 3H-3 to site 1 CCR4 mutants 
The first radiolabelled antagonist to be investigated was 
3
H-3. Before it was 
tested against the CCR4 mutant membranes, it was used in saturation assays on WT 
CCR4 membranes. Figure 6-4 shows a saturation assay of WT CCR4-L1.2 
membranes; the plateau of the specific binding curve shows that the 
3
H-3 binding 
sites on the membranes were saturated at the highest antagonist concentration. This 
assay gave a Kd of 0.85 nM, which was similar to previous studies at GSK which had 
obtained a Kd of approximately 1 nM for this compound when using the control CHO 
membranes (personal communication). 
The non-specific binding of this compound when using the L1.2 membranes 
was higher than when compared to CHO membranes, which hindered the replication 
of the saturation assay shown in figure 6-4. The high non-specific binding often 
resulted in a loss of the binding window at several 
3
H-3 concentrations, which thus 
prevented the plotting of a saturation curve. The curve shown in figure 6-4 was thus 
representative of two experiments that provided curves with a reasonable Hill slope 
factor, which as described denotes the steepness of the curve. 
There are several possible reasons for the high non-specific binding observed 
here. 
3
H-3 has been shown to have a higher level of non-specific binding compared to 
3
H-5 in previous assays (personal communication). This is reflected in the use of 
different glass fibre mats in the filtration assays; thicker GF/B mats were used during 
the filtration step of 
3
H-5 assays, while thinner GF/C mats were used for 
3
H-3 assays 
(see section 2.2.4.4). The thinner mats were used in an effort to prevent excess 
3
H-3 
binding to the mats, which would have resulted in higher non-specific binding. In 
addition, GF/C mats were pre-soaked in a 0.3% solution of polyethyleneimine (PEI). 
PEI is a cationic polymer that is used to neutralise the negative charge of the glass 
fibre mat, preventing charge-dependent interactions of the compound with the filter 
mat. The filtration assay was also optimised in this project by soaking the mats in 
0.3% PEI for 3 hours rather than 10 seconds as the protocol initially described. 
Despite the high non-specific binding of 
3
H-3 and the variability of the 
saturation assays, it was clear that 
3
H-3 bound the WT CCR4 L1.2 membrane. The 
same assays were then repeated for mutant CCR4 membranes in order to determine 
the effect of the mutation on antagonist binding. 
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6.4.2.1 – Binding of 3H-3 to GluVII:06 mutants 
Saturation assays using 
3
H-3 were then performed on L1.2 membranes 
expressing WT CCR4 or those expressing one of the three GluVII:06 mutants, 
E290A, E290D and E290Q (figure 6-5). As with the WT assays described previously, 
the data were variable and often high non-specific binding of 
3
H-3 prevented the 
generation of a saturation curve, thus Kd and Bmax values could not be obtained. The 
bar charts however do show the presence of a binding window for the WT 
membranes. The E290A, E290D and E290Q mutants did not show a difference 
between total and non-specific binding. This indicates that all three E290 mutations 
prevented the site 1 antagonist from binding the receptor. 
Since the variability of the non-specific binding of 
3
H-3 prevented the 
determination of the Kd and Bmax of the antagonist in the saturation assays, 
homologous competition assays were performed as a way of estimating the Kd. These 
used a fixed 
3
H-3 concentration and an increasing concentration of unlabelled 
antagonist 3. To provide a better estimate of the Kd, two 
3
H-3 concentrations were 
used. As the variability of the saturation assays often occurred at higher 
concentrations, 
3
H-3 concentrations of lower than 6 nM were used since these often 
gave a binding window in the saturation assays. 
The use of CCR4-CHO membranes in homologous competition assays 
showed that increasing concentrations of unlabelled antagonist could compete with 
3
H-3, and provide an estimate of the Kd (figure 6-6). However when WT, E290A, 
E290D, and E290Q CCR4 L1.2 membranes were used, a sigmoidal inhibition curve 
could not be generated. If the E290 mutations disrupted the 
3
H-3 binding site, this 
would have been expected. However, the results of the competition assay using WT 
membranes also failed to produce a sigmoidal curve. The affinity of 
3
H-3 for WT 
membranes could thus not be estimated, meaning that a comparison to the E290 
mutants could not be performed. For the higher 
3
H-3 concentration, increasing 
unlabelled antagonist 3 did not reduce 
3
H-3 binding. For the lower concentration 
however, like the saturation assay bar charts of figure 6-5, a difference was observed 
between total binding in the absence of unlabelled ligand and non-specific binding in 
the presence of 10 μM unlabelled ligand. 
It can be concluded from the saturation and homologous competition assays 
that the data were too variable to reliably determine the Kd or Bmax of 
3
H-3. The data 
did however show that 
3
H-3 bound WT CCR4 L1.2 membranes, and that when tested 
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against the three E290 mutant membranes the binding window was lost. The three 
E290 mutations therefore removed the ability of the antagonist to bind CCR4. The 
three mutations were designed to investigate the respective roles of amino acid size 
and charge in antagonist binding; mutation to aspartic acid reduced the amino acid 
side group while retaining its negative charge, mutation to glutamine removed the 
negative charge while retaining side group size, while mutation to alanine removed 
both size and charge of the side group. Since each mutation resulted in the same loss 
of binding window, it indicates that both the size and charge of the glutamic acid side 
group were necessary for antagonist binding. 
These data are in agreement with previous studies that investigated the role of 
this conserved residue in antagonist binding. GluVII:06, as previously described is a 
highly conserved amino acid in the seventh transmembrane helix of chemokine 
receptors and has been shown in this project to be required for chemokine binding 
and thus receptor function (see chapter 3). Several studies have shown this amino 
acid is required for antagonist activity. For example, mutation of GluVII:06 in CCR5 
was used to determine that the antagonist TAK-779 bound a site within the 
transmembrane domains of the chemokine receptor (Dragic et al., 2000). Mutation of 
GluVII:06 of CCR1 to glutamine, removing the negative charge of glutamic acid, 
conferred resistance to the antagonist UCB35625, as migration of mutant 
transfectants was poorly inhibited by the antagonist. The basic quaternary nitrogen of 
the compound was modelled to form a salt bridge with the negatively charged 
GluVII:06, with the mutation disrupting this interaction (de Mendonça et al., 2005). 
The same compound was also used to investigate the role of GluVII:06 in CCR3 
antagonism; transfectants of CCR3 GluvII:06 mutants were similarly resistant to 
inhibition by UCB35625 (Wise et al., 2007). 
Another mutagenesis study identified GluVII:06 of CXCR4 as an important 
residue for the binding of the antagonist AMD3100 (Rosenkilde et al., 2004). This 
antagonist is atypical compared to other chemokine receptor antagonists, which often 
contain two or more aromatic and hydrophobic rings connected through bonds that 
constrain the conformation of the compound. AMD3100 however consists of two 
non-aromatic cyclam rings connected by a single aromatic phenyl group. Despite this, 
GluVII:06 of CXCR4 still was an important interaction point for the antagonist, 
indicating that basic groups within the compound were interacting with this 
negatively charged amino acid. It was hypothesised that a cyclam ring of this 
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compound was ‘sandwiched’ between GluVII:06 and an aspartic acid in 
transmembrane helix VI of CXCR4 (Rosenkilde et al., 2004). Interestingly, 
GluVII:06 of CCR1 and CCR8 was required for the activity of the small molecule 
agonist LMD-559, indicating that the intrahelical binding site for antagonists is also 
used by non-peptide agonists (Jensen et al., 2012). 
More recently, receptor modelling and alanine-scanning mutagenesis studies 
identified that a hydrogen atom bound to the quaternary nitrogen of DF2156A, a 
CXCR1/CXCR2 antagonist, formed hydrogen bonds with the negatively charged side 
group of GluVII:06 in both receptors. For CXCR2, another binding model was also 
proposed that instead involved an interaction of the compound with an aspartic acid 
residue in the seventh transmembrane helix (Bertini et al., 2012). In both cases, a 
negatively charged amino acid was interacting with a positively charged group on the 
compound, indicating the importance of these basic nitrogen atoms and the bonds 
they form with acidic amino acids in the receptor helices. 
The data presented in this chapter on CCR4 agree with the described studies. 
GluVII:06 of CCR4 (E290) likely forms a salt bridge with a positively charged side 
group of antagonist 3. Mutation of this residue to alanine, aspartic acid or glutamine 
disrupted this interaction and thus prevented binding of the compound to the receptor. 
 
6.4.2.2 – Binding of 3H-3 to L118A CCR4 
Saturation binding assays using 
3
H-3 were also performed on L118A CCR4-
expressing L1.2 membranes (figure 6-7). These were performed due to the fact that in 
section 4.3 L118A transfectants were less sensitive to inhibition of migration and 
chemokine binding by antagonist 7. Antagonist 7 was hypothesised to bind to the 
same intrahelical site as antagonist 3, and while antagonist 3 did not show a reduction 
in potency in these assays it was the only available tritiated site 1 antagonist and was 
therefore used to investigate the effect of mutations on site 1 antagonist binding. The 
β1- and β2-adrenergic receptors contain a valine residue in their antagonist binding 
pockets (Nygaard et al., 2009). Like valine, leucine is an aliphatic amino acid; L118 
in CCR4 may form hydrophobic interactions with the antagonists. 
Like the previous saturation experiments using WT and the GluVII:06 
mutants, the data were variable due to the high non-specific binding of 
3
H-3. For the 
saturation curve shown in figure 6-7, Bmax and Kd values were generated. These 
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suggest that the L118A mutation caused a reduction in the number of 
3
H-3 binding 
sites and a slight increase in affinity. It is important to note however that due to the 
variability of the assay it should not be concluded that the mutation had this effect on 
ligand binding. In addition, the flow cytometry data from chapter 4 showed an 
increase in L118A cell-surface expression compared to WT CCR4 (figure 4-4). It 
would be very surprising if a mutant caused a decrease in maximum binding but an 
increase in affinity, especially considering the observed increase in cell-surface 
expression of the mutant receptor; previous studies using mutagenesis to investigate 
antagonist binding show a reduction in Kd or a concomitant reduction in both Bmax 
and Kd. For example, mutation of C-terminal residues K320A and Y314A of CXCR2 
decreased both the maximum binding of the intracellular antagonist 
3
H-SB265610 as 
well as its affinity for the receptor (Salchow et al., 2010). 
The data presented here do however show that the L118A mutant retained the 
ability to bind 
3
H-3, since a window was observed between total and non-specific 
binding in the saturation bar charts. Since antagonist 3 did not show a reduction in the 
potency in chemotaxis and chemokine binding assays, the presence of a binding site 
in the tritiated antagonist assays may be due to the mutation not affecting the ability 
of this antagonist to interact with the receptor. Antagonist 7 only showed a reduction 
in potency in these assays and not a complete loss of activity, so it is may be possible 
that the L118A mutation perturbed 
3
H-3 to a small degree that is not apparent from 
the limited data presented here. 
 
6.4.2.3 – Binding of 3H-3 to Y117A and L92A 
The Y117A and L92A mutants were also investigated for their ability to bind 
3
H-3. Transfectants expressing both mutants were non-functional in chemotaxis 
assays and as such their migration could not be inhibited to determine if antagonist 
potency was affected. Due to the variability of the saturation binding assays, simple 
total and non-specific binding for these mutants was compared to WT CCR4 
membranes at two 
3
H-concentrations (figure 6-8). These data show that at these two 
3
H-3 concentrations, the mutants bound the radiolabelled antagonist. 
Mutation of Y113A in CCR1, analogous to the Y117A mutation here, 
conferred resistance to the antagonist UCB36525 in chemotaxis assays (de Mendonça 
et al., 2005), while the same mutation in CCR1 prevented the antagonist BX 741 from 
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inhibiting CCL3 binding to the receptor (Vaidehi et al., 2006). While these studies 
did not directly measure the effect of receptor mutation on antagonist binding, they 
showed that mutation of this conserved tyrosine inhibited antagonist activity. While it 
has been shown here in CCR4 that at two concentrations Y117A CCR4 membranes 
bound 
3
H-3, full saturation assays would be needed to determine the effect of the 
mutation on antagonist binding. Considering the fact that this tyrosine along with 
Y122 is highly conserved amongst chemokine receptors and plays a role in their 
antagonism, it is likely that Y117 plays a role in CCR4 antagonism. 
L92 is located within the TXP motif, a highly conserved motif located in the 
second transmembrane helix. While there are no previous studies indicating the 
importance of this amino acid in receptor antagonism, the TXP motif as a whole may 
play a role. This motif is important in receptor structure and thus chemokine binding, 
due to the kink the proline confers upon the helix of this region (Govaerts et al., 
2001). As we have seen with the GluVII:06 mutants, amino acids that have important 
roles in receptor function can also be involved in receptor antagonism. As with the 
Y117A mutant, saturation assays would be needed to determine whether this was the 
case for the L92A mutant. 
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6.4.3 – Binding of 3H-5 to site 2 mutants and identification of a low-affinity 
site 
To investigate the binding of site 2 antagonists to the site 2 CCR4 mutants, 
3
H-5 was used in saturation assays. The L307V and K310N CCR4 mutations were 
investigated in these assays since they were mutants of C-terminal regions. L307V 
transfectants were previously shown to have reduced potency to inhibition of 
chemotaxis to CCL17 and CCL22 by antagonist 2 and antagonist 5, respectively. The 
GluVII:06 mutants were also tested for their ability to bind 
3
H-5 to confirm that this 
mutation had not adversely affected receptor structure and disrupted the intrahelical 
antagonist binding pocket. As described in sections 5.4.2, L307 is located at the end 
of transmembrane helix VII and may form hydrophobic interactions with the site 2 
CCR4 antagonists. K320, an analogous residue to K310 in CXCR2, was involved in 
binding to intrahelical antagonists (Salchow et al., 2010). 
However after performing these saturation assays it became apparent that even 
at high 
3
H-5 concentrations the antagonist was not saturating its binding sites on the 
membranes, since specific binding did not plateau and instead increased with 
antagonist concentration (figure 6-9). To confirm that CCR4 could be saturated, 
3
H-5 
was used in saturation assays with CHO-CCR4 membranes, and in agreement with 
previous studies at GlaxoSmithKline a Kd of 1.29 nM was generated. The CCR4-L1.2 
membrane 
3
H-5 specific binding curves however did not produce a Kd value due to 
the inability of the compound to saturate the membranes. 
Due to this finding, it was speculated that a low-affinity binding site for 
3
H-5 
was present on the L1.2 membranes. This would explain the observation that high 
3
H-
5 concentrations were not saturating the binding sites for the ligand. While the CCR4 
expressed on the membranes may have been fully saturated, another low-affinity site 
would have continued to bind the antagonist even at high concentrations. To confirm 
the presence of another 
3
H-5 binding site, saturation assays were performed using 
naive L1.2 membranes, which had been prepared from untransfected cells that did not 
express CCR4 (figure 6-10). These naive membranes also showed a window between 
total and non-specific binding for 
3
H-5, indicating that a binding site was present. 
Like the previous saturation curves with WT, L307V, K310N, E290A, E290D, and 
E290Q membranes, the specific binding did not plateau and instead increased with 
3
H-5 concentration. 
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Since the inability to saturate the 
3
H-5 occurred up to high concentrations 
such as 10 nM, the concentrations used in the saturation assay were lowered to a 
maximum of 2 nM. This was done to determine whether the binding site on the naive 
membranes was of low enough affinity that it would not be detectable in assays of 
low concentration. If this was the case then saturation assays could be performed on 
CCR4 membranes using low concentrations, since at this range the low-affinity 
binding site would not be bound. However, when this lower concentration range was 
tested on naive L1.2 membranes, a 
3
H-5 binding site was still present. This indicated 
that the L1.2 
3
H-5 binding site was not of low enough affinity to be undetectable at 
low concentrations. 
 
Following on from the identification of the 
3
H-5 L1.2 binding site, different 
site 2 antagonists were used to define non-specific binding in an effort to remove the 
binding window present on the naive L1.2 membranes. If a compound was used that 
removed the binding window on naive L1.2 membranes while preserving a window 
on WT CCR4 L1.2 membranes, this could be used in subsequent saturation assays. 
Non-specific binding occurs when a ligand binds to sites not on the receptor 
of interest, such as to filter mats or the surface of the cell membranes. To measure 
non-specific binding (NSB), radiolabelled ligand and membranes expressing the 
receptor of interest are incubated with excess unlabelled antagonist. The unlabelled 
antagonist competes with the radiolabelled antagonist for binding to receptor, 
meaning that the radiolabelled antagonist can only bind to non-specific sites. Total 
binding (TB) is measured without unlabelled antagonist, meaning that radiolabelled 
antagonist binds to both specific and non-specific sites. The specific binding window 
is then calculated by subtracting non-specific values from total binding values. When 
there is only one specific site for the radiolabelled antagonist, the binding window is 
therefore specific to the receptor of interest. 
In the case of the saturation assays presented here, the low-affinity site for 
3
H-
5 acted as another specific site rather than as a non-specific site. This meant that in 
NSB wells, the excess unlabelled antagonist 5 competed with 
3
H-5 for the low-
affinity site, resulting in a binding window after subtraction of NSB from TB. This 
was likely the reason for the observed binding window in naive L1.2 membranes. A 
more suitable antagonist was therefore needed, one that did not compete with 
3
H-5 
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for the low-affinity site and thus allow 
3
H-5 to bind it as it would any other non-
specific site on the membrane. 
Antagonist 8, another site 2 CCR4 antagonist supplied by GlaxoSmithKline, 
was used to define non-specific binding in the 
3
H-5 saturation assays on naive L1.2 
membranes. This compound was structurally similar to antagonist 5. It was hoped 
that in NSB wells it would not compete with the low-affinity site, allowing 
3
H-5 to 
bind the low-affinity site in the same manner as non-specific sites. However, this did 
not prove to be the case since a binding window was still observed on the naive L1.2 
membranes (figure 6-11A). This shows that on naive L1.2 membranes, excess 
antagonist 8 in the NSB wells competed with 
3
H-5, such that the radiolabelled ligand 
only bound non-specific sites on the filter mats and membranes and not the low-
affinity site since these were filled by antagonist 8. Subtraction of non-specific 
binding from total binding thus gave a low-affinity site-specific window. 
Antagonist 9 was then used, which was another site 2 compound of a different 
structural class to antagonist 5. In the naive L1.2 membranes, no binding window was 
observed. This may have suggested that antagonist 9 did not outcompete 
3
H-5 for the 
low affinity site, allowing the radiolabelled ligand to bind it. To confirm this, 
antagonist 9 was used in a saturation assay of WT CCR4 L1.2 membranes. This assay 
also did not show a binding window. This result suggests that in addition to not 
competing with 
3
H-5 for the low-affinity site, antagonist 9 also did not compete with 
3
H-5 for binding to CCR4. 
In summary, the identification of a low-affinity binding site for 
3
H-5 on naive 
L1.2 membranes prevented the investigation of the effect of receptor mutation on the 
binding of the site 2 antagonist. Using different site 2 compounds as non-specific 
binding did not provide a solution to this, as antagonist 8 gave similar results to 
antagonist 5 while antagonist 9 was not of high enough affinity to compete at CCR4 
effectively. 
 
Following from these data, the next step was to determine what factor was 
binding 
3
H-5 at low-affinity. Previous studies at GlaxoSmithKline indicate that the 
site may be comprised of other chemokine receptors endogenously expressed on L1.2 
cells. Selectivity studies performed on antagonist 5 using [
35
S]GTPγS binding assays 
showed that the compound gave a logIC50 value of -8.2 (IC50 = 6.3 nM) for CCR4, 
indicating it was active against this receptor. 
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[
35
S]GTPγS binding assays measure GPCR activation using the non-
hydrolysable GTP analogue, [
35
S]GTPγS. As described in section 1.3, GPCR 
activation results in the displacement of GDP from the Gα subunit, allowing it to bind 
GTP. Gα-GTP then goes on to activate downstream signalling partners. This Gα-GTP 
dimer is then hydrolysed by GTPase activity of the Gα subunit, returning it to the 
inactive Gα-GDP form. The presence of [35S]GTPγS prevents hydrolysis to GDP, 
leading to accumulation of the [
35
S]GTPγS complex on the membrane. Due to its 
radioactivity, this accumulation can be measured (Harrison and Traynor, 2003). In the 
[
35
S]GTPγS binding assays, antagonist can be used to inhibit GPCR activation, and 
thus the potency of the antagonist quantified. 
These assays also showed activity against other chemokine receptors, shown 
in table 6-12. Antagonist 5 also showed activity against CCR5, with a logIC50 value 
of -7.5 (IC50 = 31.6 nM). CCR1 also showed sensitivity to the antagonist, with a 
logIC50 of -6.5 (IC50 = 316 nM). These data show that antagonist 5 is not specific for 
CCR4, and in fact antagonises other chemokine receptors. 
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Receptor CCR1 CCR2 CCR4 CCR5 CCR8 CCR10 CXCR1 CXCR3 CXCR4 
logIC50 -6.5 -5.8 -8.2 -7.5 -5.2 <5 <5 <5 <5 
 
 
 
  
Table 6-12 – Antagonist 5 selectivity data 
[
35
S]GTPγS accumulation was inhibited using antagonist 5. The table shows the logIC50 
values for each receptor. Data are from GlaxoSmithKline selectivity studies. 
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L1.2 cells are a pre-B cell lymphoma line, and therefore likely endogenously 
express chemokine receptors. No data were available on the specific chemokine 
receptor expression of these cells, however previous studies have shown that pre-B 
cells can express CCR5 (Honczarenko et al., 2002). It has been previously shown 
however that L1.2 cells respond to the CXCR4 ligand, CXCL12, and the CCR7 
ligands, CCL19 and CCL21, in chemotaxis assays (James Pease, personal 
communication). 
Figure 6-13 shows an alignment of the C-termini of the chemokine receptors. 
It shows the strong degree of conservation between these receptors in the putative 
helix VIII region. Since previous data shown in chapter 5 demonstrated that the last 
40 amino acids of CCR4 were not required by site 2 antagonists, they were concluded 
to therefore likely bind to helix VIII of the receptor. Considering the high homology 
of this region between receptors, the selectivity data showing antagonist 5 activity 
against CCR5 and CCR1 is perhaps unsurprising. 
These findings are in contrast to the previously published data on the 
identification of the intracellular allosteric site on CCR4. In this study, both WT 
CCR5 and a chimeric CCR4 construct with a CCR5 C-terminus showed a 50-fold 
reduction in antagonist potency compared to WT CCR4 and chimeric CCR5 construct 
with a CCR4 C-terminus (Andrews et al., 2008). It is important to note however that 
this study used compounds of a different structural class to antagonist 5; one 
compound in particular was antagonist 2 presented in chapter 5. Therefore the 
differences in CCR4/CCR5 selectivity between antagonist 5 shown here and 
antagonist 2 shown in the study may be due to structural differences of the 
compounds themselves. Saturation binding assays using radiolabelled antagonist 2 on 
naive L1.2 cells would determine whether the low-affinity site was specific to 
antagonist 5. 
  
251 
 
 
 
 
 
  
Figure 6-13 – Alignment of chemokine receptor C-termini 
Aligned sequences of 16 chemokine receptors show transmembrane helices VII and the 
C-terminus including helix VIII. Yellow highlights indicate amino acids conserved 
between all receptors, turquoise between the majority of the receptors. Green highlights 
indicate conservation of amino acid type, e.g. the polar serines and threonines. From 
James Pease (personal communication). 
252 
 
The identification of a low-affinity 
3
H-5 binding site on naive L1.2 
membranes prevented analysis of binding of the compound of site 2 mutants. It also 
highlights a potential problem in the future development of this antagonist for 
treatment of CCR4-driven pathologies since the antagonist is not specific for CCR4. 
However, antagonists that bind more than one chemokine receptor may have potential 
uses in therapy. 
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6.4.4 – Summary 
In summary, the use of the intrahelical antagonist 
3
H-3 to investigate site 1 
mutants revealed that the GluVII:06 mutants E290A, E290D, and E290Q did not bind 
the antagonist, indicating that this conserved residue was required for antagonist 
contact. The 
3
H-3 saturation assays were variable due to high non-specific binding of 
the antagonist, which prevented the generation of reproducible Kd and Bmax values for 
WT CCR4 in addition to the mutants L118A, Y117A and L92A. These mutants 
however were shown to contain a binding site for 
3
H-3. 
Saturation binding assays performed using the intracellular antagonist 
3
H-5 to 
investigate site 2 mutants were hindered due to the identification of a low-affinity site 
for this compound. Naive L1.2 membranes confirmed the presence of this site, and 
the use of other site 2 compounds as non-specific binding did not remedy the 
problem. Selectivity data for antagonist 5 from GlaxoSmithKline suggest this site 
may be comprised of other chemokine receptors. This compound therefore may have 
potential use as a promiscuous chemokine receptor antagonist. 
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7 – General discussion 
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7.1 – The biology of CCR4 
In this project, point mutants of CCR4 were made along with three receptor 
truncations. Chapter 3 investigated the impact of the mutations of GluVII:06 in 
transmembrane domain helix VII and K310 in the C-terminal helix VIII region. In 
chapters 4 and 5, point mutants of CCR4 were made to determine the role of the 
mutated regions in the activity of CCR4 antagonists. In doing so these mutants were 
also characterised in terms of their cell-surface expression, chemotactic and 
chemokine-binding ability. Thus in addition to the mutants of chapter 3, the mutants 
of chapters 4 and 5 revealed key determinants of CCR4 expression and function. 
 
The three GluVII:06 mutations, E290A, E290D, and E290Q were shown to 
remove the ability of the receptor to bind chemokine and thus induce chemotaxis of 
transfectants. This supported previous studies of this conserved residue in other 
chemokine receptors. Mutations of GluVII:06 in other chemokine receptors such as 
CCR1, CCR2, CCR3 and CCR5 showed that it was often required for chemotaxis and 
chemokine-binding. It is important to note however that in CCR1 and CCR5 
GluVII:06 mutants were still functional, in contrast to the CCR4 GluVII:06 mutants 
described here (Mirzadegan et al., 2000; de Mendonça et al., 2005; Wise et al., 2007; 
Hall et al., 2009). 
Figure 6-13 in chapter 6 shows an alignment of helices VII and the C-termini 
of 18 chemokine receptors, including CCR4. Of these 18, GluVII:06 is present in 14. 
It is only CCR7, CCR9, CXCR3 and CXCR7 that do not contain this residue. CCR9 
and CXCR7 contain a glutamine, which while polar is not charged at physiological 
pH. CCR7 has a bulky hydrophobic tyrosine while CXCR3 has a small polar serine. 
These may indicate potential π-stacking interactions and hydrogen bonds, 
respectively, as possible alternatives to salt bridges in this region. Due to its 
conservation with other receptors, and from the data presented here on CCR4, 
GluVII:06 has been shown to be a major determinant of CCR4 function. 
From the data presented in chapters 4 and 5, other CCR4 point mutants also 
revealed other amino acids required for receptor function. The most striking examples 
of CCR4 mutants that resulted in non-functional receptor were the Y117A, Y122A, 
and Y258A mutants. The Y117A mutation had no effect on CCR4 cell-surface 
expression, while the Y122A and Y258A mutations significantly reduced surface 
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levels of the receptor. All three mutants however had a significant effect on 
chemotaxis to CCL17 and CCL22; the mutants did not allow chemotaxis to either 
ligand at any concentration. The Y258A transfectants showed a slight increase in 
chemotactic index at high concentrations of CCL22, however this was not significant. 
As with GluVII:06, other chemokine receptors such as CCR3 and CCR5 possess 
conserved tyrosines in similar helical positions to the ones shown here for CCR4, 
although these residues were not critical for chemotaxis (de Mendonça et al., 2005; 
Wise et al., 2007). Another mutant that showed no chemotactic ability was L92A. 
This was a mutation of a residue within the TXP motif, which as described is a highly 
conserved structural determinant of receptor function (Govaerts et al., 2001, 2003; 
Blanpain et al., 2003). 
K310, located in the C-terminal helix VIII region of CCR4, was mutated to 
asparagine. This mutation was relatively conservative in that it changed the ionisation 
state of the amino acid at physiological pH but did not cause a large enough change to 
disrupt helical structure. Despite this, the K310N CCR4 mutant produced an 
interesting phenotype in that the receptor was able to bind both 
125
I-CCL17 and 
125
I-
CCL22 while only being able to mediate chemotaxis to CCL22. These data along 
with others presented in chapter 3 signified that CCL17 and CCL22 stabilise distinct 
conformations of CCR4, and that K310 is required for the functionality of one of the 
receptor states. As will be described in section 7.2.2, proteins such as FROUNT have 
been identified that bind to the C-termini of chemokine receptors. Since we 
hypothesise that K310 is required for the functionality of one CCR4 state, it may 
indicate that this amino acid requires an interaction with proteins that bind the CCR4 
C-terminus. 
Another mutant that exhibited differential effects upon chemokine binding 
and chemokine-induced migration was I286A CCR4, in which isoleucine 286 at the 
N-terminal face of transmembrane helix VII was mutated to alanine (see chapter 4). 
This mutant had normal cell-surface expression, but in chemotaxis assays the effects 
on CCL17 and CCL22 differed. CCL17-induced migration was significantly reduced 
in efficacy and potency, and only at 100 nM CCL17 was a low degree of migration 
observed. Chemotaxis to CCL22 was also reduced in potency, in that the response 
peaked at 10 nM rather than 1 nM (figure 4-5S). Interestingly, the efficacy of this 
response was significantly increased, as the chemotactic index for I286A transfectants 
at 10 nM was three-fold greater than the chemotactic index for WT transfectants at 1 
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nM (figure 4-5T). Assays investigating the ability of this mutant to bind chemokine 
however showed that the receptor did not bind either 0.1 nM 
125
I-CCL17 or 
125
I-
CCL22. Clearly, due to the observed chemotaxis of the mutant transfectant, I286A 
bound chemokine. Therefore, the affinity of the chemokines for the receptor has 
likely been reduced as a result of the mutation. 
As such, in contrast to the K310N mutant the apparent differential activity of 
the chemokines through the I286A mutant is likely due to an affinity change of the 
chemokines. I286 lies on the same side of transmembrane helix VII as the previously 
described GluVII:06 (E290), which was required for both receptor expression and 
chemokine binding. The I286 side chain may therefore be involved in similar 
interactions to GluVII:06 that are required for chemokine activity; the loss of the 
isoleucine in the I286A mutation may have disrupted interactions necessary for 
CCL17 binding. Alanine is a much less bulky residue than isoleucine, which may 
suggest that the I286A mutation has allowed a greater degree of helical movement to 
occur during CCL22-mediated activation of CCR4. As described in section 1.3.2.2, 
receptor activation according to the toggle switch model results in movement of the 
transmembrane helices, leading to an outward shift of the extracellular face of the 
receptor. This occurs along with intracellular portions of the receptor moving 
inwards, allowing the initiation of signalling. Since I286 is located at the top of 
transmembrane helix VII, it likely shifts during receptor activation. The mutation of 
this residue to alanine therefore may have facilitated this helical movement, resulting 
in the observed increase in CCL22 efficacy. 
To further investigate this, saturation assays would need to be performed with 
increasing 
125
I-chemokine concentrations in order to determine whether the I286A 
mutation caused a reduction in chemokine affinity. 
 
In addition to point mutation, CCR4 was also C-terminally truncated and the 
resulting mutants investigated for their cell-surface expression and ability to induce 
chemotaxis of transfectants. The Δ40 truncation cut downstream of the putative helix 
VIII region, and the resulting mutant had normal cell-surface expression but 
chemotactic responses that were significantly increased in efficacy. This was 
attributed to the removal of serine and threonines, which as described are 
phosphorylated by GRKs, leading to the recruitment of arrestins and subsequent 
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receptor desensitisation and internalisation (Oppermann et al., 1999; Borroni et al., 
2010; Vroon et al., 2006). 
The Δ45 and Δ50 C-terminal truncations were also made; these cut into the 
putative helix VIII region. These had reduced cell-surface expression, and in 
chemotaxis assays were non-functional, indicating the importance of this region in 
receptor function. Analogous truncations of the chemokine receptors CCR5, CCR3 
and CCR7 C-terminus have been shown to reduce receptor activation (Gosling et al., 
1997; Sabroe et al., 2005; Otero et al., 2008). As described in section 1.3.2.3, studies 
of other GPCRs such as BLT1 and PAR1 indicated that this region, which is highly 
conserved across GPCRs, is involved in G protein activation (Okuno et al., 2003, 
2005; Swift et al., 2006). In the crystal structure of squid rhodopsin, the detergent 
octyl glucoside bound to helix VIII and was believed to mimic Gαq (Murakami and 
Kouyama, 2008). The phenotypes of the Δ45 and Δ50 C-terminal truncations of 
CCR4 may therefore indicate a loss of G protein activation by the receptor. 
 
Many of the CCR4 point mutations from chapters 4 and 5 had little or no 
effect on cell-surface expression or chemotactic ability of the receptor. For example, 
mutation of isoleucine 113 in transmembrane helix 3 to alanine did not perturb 
expression or function of the receptor. Mutation of lysine 188 in the second 
extracellular loop to alanine similarly had no effect on receptor phenotype. Other 
mutations such as F121A resulted in normal cell-surface expression but a reduction in 
chemokine potency in chemotaxis assays. These results suggest that, as would be 
expected, some amino acids of CCR4 do not directly interact with chemokine or 
signalling partners. Others such as I113 likely do not provide critical structural 
stabilisation required for the shift in transmembrane helix conformation that occurs 
during receptor activation (see section 1.3.2.2). 
The data here presented have thus identified key regions of CCR4 that are 
required for its function. The residues that had the most drastic effect on CCR4 
phenotype are highlighted on a cartoon diagram of CCR4 shown in figure 7-1, along 
with the regions identified by the truncation mutants. 
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Figure 7-1 – Key regions of CCR4 
Cartoon of CCR4, showing the extracellular N-terminus and loops, the transmembrane 
helices, and the intracellular loops and C-terminus. Residues that were determined to be 
critical for chemokine binding and receptor function are highlighted in red. K310 and 
I286, which are required for CCL17-induced chemotaxis, are highlighted in blue. The 
green and purple brackets denote the roles of specific regions of the C-terminus. 
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7.1.1 – Further work on the biology of CCR4 
In section 1.3.2.2 the role of G proteins and β-arrestins in biased agonism was 
discussed; two ligands for the same receptor can induce differential effects on 
receptors signalling, such as the preferential recruitment of G proteins over β-
arrestins, or vice versa. The chemokine receptor CCR7 is phosphorylated on its C-
terminal serine and threonine residues by GRKs in response to CCL19 binding, but 
not in response to CCL21 binding. The receptor was thus internalised in response to 
one ligand and not the other (Bardi et al., 2001; Kohout et al., 2004). 
The data from the K310N mutant indicate that CCL17 and CCL22 may 
stabilise distinct conformations of CCR4, as described in section 3.3.3. The 
chemokines CCL17 and CCL22 also induce differential effects upon the receptor, 
such as the inability of CCL17 to fully desensitise CCR4 against CCL22 treatment or 
for it to completely displace CCL22 in homologous binding assays (chapter 3). 
We hypothesised that two populations of CCR4 exist; the first major 
population signals in response to CCL17 and CCL22 while the second minor 
population only signals in response to CCL22. We also hypothesised that K310 in the 
C-terminus played a role in the maintenance of the first population, as its mutation 
resulted in only CCL22-induced chemotaxis. To investigate these hypotheses, assays 
examining receptor activation and β-arrestin recruitment could be performed. 
One method of directly comparing the potential biased signalling outputs of 
CCR4 would be to perform fluorescence resonance energy transfer (FRET) assays. 
These assays can be used to investigate protein-protein interactions. The proteins of 
interests are labelled with fluorescent proteins such as cyan fluorescent protein (CFP) 
or yellow fluorescent protein (YFP). CFP, the donor fluorophore, is excited leading to 
the emission of cyan light (wavelength = 527 nM). If the two proteins of interest are 
in close proximity, excited CFP transfers energy to YFP, leading to the emission of 
yellow light. If the two proteins are not in proximity, only cyan light is emitted 
(wavelength = 477 nM). The interaction of two proteins can therefore be measured 
(Lohse et al., 2012). 
This assay has previously been used to examine interactions of G proteins and 
β-arrestins with the β2-adrenergic receptor (β2-AR). G protein activation was 
measured using FRET-based detection of cAMP, a secondary messenger produced as 
a result of GPCR activation. The formation of receptor/β-arrestin complexes were 
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also detected using FRET. The relative activation of these two signalling pathways 
were then compared for various ligands of β2-AR, and used to determine which 
generated biased outputs; for example the ligand CPB showed a relatively higher 
level of β-arrestin recruitment compared to cAMP production, while the ligand 
isoproterenol was unbiased in its signalling (Drake et al., 2008). This assay could be 
performed on CCR4, using both CCL17 and CCL22 to determine the potential bias of 
each ligand in terms of G protein activation or β-arrestin recruitment. To explore the 
role of K310 in the activity of the ligands, the K310N mutant could also be tested 
alongside the WT receptor. Since the K310N mutation rendered the receptor 
unresponsive to CCL17, it would not be expected to activate G proteins. However, 
CCL17 may still cause β-arrestin recruitment to the receptor. This FRET-based assay 
would allow direct investigation of the relative roles of both CCL17 and CCL22 and 
the signalling pathways they utilise. 
 
Murine embryonic fibroblast (MEF) β-arrestin knockouts have previously 
been used to investigate the role of β-arrestins in β2-adrenergic and angiotensin II 
type 1A receptor internalisation; it was found that the receptors internalised to a lower 
degree in the β-arrestin knockout cells when compared to WT cells (Kohout et al., 
2001). Since β-arrestins are involved in the desensitisation, endocytosis, and 
signalling of GPCRs including chemokine receptors (see section 1.3.2.2), their role in 
CCR4 could be determined through the use of β-arrestin knockout cells. The Δ40 
CCR4 truncation in particular would be an interesting target for this assay, as it was 
hypothesised that the truncation removed serine and threonine sites required for GRK 
phosphorylation and thus β-arrestin recruitment (chapter 5). 
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7.2 – Allosteric antagonism of CCR4 
The second portion of this project, encompassing chapters 4 – 6, addressed the 
action of allosteric antagonists of CCR4 and how they interacted with the receptor. 
Two classes of allosteric CCR4 antagonists were supplied by GlaxoSmithKline; the 
first class was hypothesised to bind to the intrahelical site 1 while the second class 
was hypothesised to bind to the intracellular site 2. 
Chapters 4 and 5 probed the effect of CCR4 mutation on the ability of 
antagonists to inhibit chemotaxis or chemokine binding. These assays were indirect in 
that they inferred a loss of binding site if a mutant was less sensitive to inhibition. 
Chapter 6 however used direct assays to measure the effects of CCR4 mutation, by 
investigating the binding of radiolabelled antagonists to the mutant receptors. 
 
7.2.1 – Site 1 antagonists 
It was hypothesised that the first class of CCR4 antagonists bound to site 1, 
within the transmembrane helices of the receptor. Chemotaxis and chemokine-
binding assays were performed in chapter 4 on site 1 mutants, and assays using 
3
H-3 
were performed in chapter 6. The hypothesis was confirmed, due to the fact that 
several site 1 mutants showed reduced sensitivity to the site 1 antagonists. 
In chapter 4 it was shown that L118A transfectants had significantly reduced 
potency in chemotaxis assays to 1 nM CCL17 and CCL22 when inhibited by 
antagonist 7. This result was supported by binding assays, in which the same 
transfectants showed reduced sensitivity to inhibition of 
125
I-CCL17 and 
125
I-CCL22 
by antagonist 7. The L118A mutation was of a residue in the third transmembrane 
domain, in a cluster of amino acids that were predicted to form part of the intrahelical 
antagonist binding site. Two other mutants, Y122F and I125A, also showed 
reductions in antagonist potency in chemotaxis assays. 
Assays in chapter 6 revealed that mutants of the highly conserved amino acid 
GluVII:06 in the seventh transmembrane helix did not bind the tritium-labelled 
antagonist 3 (
3
H-3). However, due to issues regarding the non-specific binding of this 
compound to L1.2 membranes, the variability of the 
3
H-3 assays was high and as 
such saturation assays to determine ligand affinity for the mutant receptors could not 
be performed. This assay also prevented detailed investigation of other site 1 mutants 
such as L118A, Y117A, and L92A. These mutants were assayed with limited 
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concentration ranges of 
3
H-3, at which they showed the ability to bind the antagonist. 
However, due to the variability of the assay any change in affinity resulting from the 
receptor mutation could not be investigated. 
This loss of the 
3
H-3 binding site in the GluVII:06 mutants supports previous 
studies into the role of this amino acid in receptor antagonism. As has been described 
in chapter 6, this conserved amino acid was involved in the binding of antagonists 
such as TAK-779, UCB3625 and AMD3100 to the receptors CCR5, CCR1 & CCR3, 
and CXCR4 (Dragic et al., 2000; de Mendonça et al., 2005; Wise et al., 2007; 
Rosenkilde et al., 2004). 
From the eighteen residues predicted to form the site 1 antagonist binding site, 
the results from these assays have shown that three from the third transmembrane 
helix and one from the seventh helix are involved in antagonist binding to CCR4. 
Figure 7-2 shows the location of the residues identified to be contact points for 
antagonist. 
  
265 
 
 
 
 
  
K
COOH
NH2
MNPTTTS DE LIYSNYYLY
S
I
P
K
E
P
C
T
K
E
G
I
K
A
A
D
Q
W
V
L
GF
G
L
C
K
E
K
F
R
K
Y
I
L
Q
F
L
C T KG RLFVLCQYCGLLQIYS
A
D
T P S S S Y T Q S T M D H D I V FL H D
DIAD
A
F
G
E
F
L
L
PP L
YS
L
V
FV
F
GL
L
G
NS V
VV
L
V
LF K
Y
L
L
N
AL
I
S D
L
L
F V
F
S L
P
F
W G
Y
Y
M
I
S
WM Y
V
G
FS
G
F
F
V
M
M
L
S
L
T
Y
G V
I
T S
L
A
T W
S
V A
V
F
A S
L
P G
F
L
F N
I
L
GL V
IP
L
G
IM
L
FC
Y
S
MI
I
M
I
F A
V
V V
L
F
L G
F
W T
P
Y
N I
V
L F
L
E
T
L A I
Q
AT
TL
A
F
VH C
CL
N
P
II Y
FF
L
G
A L
E
L
E
V
L
Q
D C T F
E
R
Y
L
D
YV
H
L
Q
C
K
N
K
N
KE
K
A
V
R
T
K
T
H
Y
N
Y
RT
E
C
T
K Y
S L
N
TS
K
S
T
C
K
T
W
V
L
S
S
L
E
I
S
S
I
D
R
Y
L
H
S
L
R
A
A
I
V
A V F
R
T
R
L
R S M
T
D
V
Y
L
Y
I
E
308
320
340
266
98 112
285
Figure 7-2 – CCR4 residues involved in site 1 antagonist activity 
Chapters 4 and 6 used indirect and direct antagonist-based assays to investigate the role 
of several helical and extracellular loop mutants in site 1 antagonist activity. The 
residues that when mutated showed reduced ability to antagonise or bind the receptor 
are highlighted in red. L118, Y122, and I125 in transmembrane helix III were identified 
using chemotaxis assays. E290/GluVII:06 in transmembrane helix VII was identified 
using 
3
H-3 binding assays. 
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These results of the site 1 study can be used to suggest putative interactions 
for these residues with elements of the antagonist structures. In WT CCR4, GluVII:06 
likely forms ionic interactions with positively charged groups in the site 1 
antagonists. This interaction requires both the acidic nature of glutamic acid in 
addition to its size, since mutation to both aspartic acid and alanine rendered it unable 
to bind 
3
H-3. 
The transmembrane domain mutants, L118A, Y122F, and I125A, suggest that 
this region in WT CCR4 forms hydrophobic interactions with the antagonists. 
Tyrosine contains an aromatic group, which as described can form π-stacking 
interactions with other aromatic groups. These groups are present in the antagonists. 
In addition, the hydroxyl group of tyrosine can also form hydrogen bonds; mutation 
of a conserved tyrosine of CCR5 to phenylalanine reduced antagonist binding, 
indicating that the hydrogen bonding capacity of tyrosine is also required for 
receptor-antagonist interactions (James Pease, personal communication). Branched 
chain hydrophobic amino acids such as leucine and isoleucine may supply 
hydrophobic interactions in the antagonist binding pocket, as has been suggested for 
the antagonists aplaviroc, UCB36525, and reparixin that bind the receptors CCR5, 
CCR1, and CXCR4, respectively (Allegretti et al., 2008). 
 
The site 1 antagonists have been shown to inhibit CCR4-induced migration, 
and also to bind to an intracellular pocket in a similar manner to previously described 
chemokine receptor antagonists, in that they bind GluVII:06 in transmembrane helix 
VII and several residues in helix III (see section 6.4.2.1). These CCR4 antagonists 
may therefore be useful as therapeutic agents in the treatment of CCR4-driven 
diseases. Such diseases include asthma, atopic dermatitis, and various cancers such as 
non-Hodgkin lymphoma and adult T-cell leukaemia (see section 1.4.2). 
Allosteric antagonists of other chemokine receptors have had mixed success 
in clinical trials, as described in section 1.4.4. For example, the CCR5 antagonist 
Maraviroc binds in an allosteric manner to a similar helical pocket to the one 
described here for CCR4, as does the CCR1 antagonist BX 741. However, while 
Maraviroc is currently approved for HIV therapy, the development of BX 741 for the 
treatment of multiple sclerosis was halted due to a lack of efficacy. This may be 
explained by the fact that inflammatory disease involve multiple chemokines and 
chemokine receptors, while HIV can only enter macrophages through CCR5, 
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meaning that a chemokine receptor-specific drug would be more effective in this case 
(Dorr et al., 2005; Watson et al., 2005; Garcia-Perez et al., 2011; Pease and Horuk, 
2009; Allegretti et al., 2012). 
It has been suggested that the clinical failure of some chemokine receptor 
antagonists may be in part due to the effective dose of the antagonist used in the 
trials. As described in section 1.4.4, over 90% of receptors need to be occupied by the 
antagonist in order to give an efficacious response, since a small number of 
unoccupied receptors can drive inflammation through positive feedback. An effective 
antagonist would also need to be potent, in order to reduce the concentration of 
compound required to inhibit a response. In the in vitro chemotaxis assays shown in 
figure 4-7, antagonist 7 proved to be the most potent at inhibiting both CCL17 and 
CCL22-induced migration of transfected cells. While further assays would be needed 
to determine if this translated to an in vivo setting, antagonist 7 would likely be the 
most attractive target for therapy in this regard. This antagonist could be further 
developed by examining the structure-activity relationship (SAR) of the compound 
and modifying it to improve its potency or specificity for the receptor. 
CCR4 antagonists have been previously optimised for potency by exploring 
the SAR of three functional groups. An initial screen of an antagonist library resulted 
in the identification of several thiazolidinone-based compounds. These contained an 
amide linker, a central aromatic ring, and an amide group. The modification of these 
three groups by introduction of halogens, sulphonamides and phenyl rings in various 
combinations resulted in compounds that could inhibit CCL22 binding to CCR4 with 
IC50 values of between 100 and 200 nM, compared to the initial compound which had 
an IC50 of 2.4 µM (Allen et al., 2004). The antagonists presented in this project, 
particularly antagonist 7, could therefore be further developed in order to improve 
their activity against CCR4. 
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7.2.2 – Site 2 antagonists  
It was hypothesised that the site 2 antagonists bound to an intracellular site on 
the C-terminus of CCR4. In chapter 4, the F305A and L307V mutants showed 
reduced sensitivity to two of the site 2 antagonists, confirming this hypothesis. These 
mutants however did not show a complete lack of sensitivity to the antagonists, 
indicating that other regions of the C-terminus were involved in antagonist binding. 
Three truncation mutants were created in order to determine the role of 
successive portions of the CCR4 C-terminus in antagonist binding to this site. The 
Δ45 and Δ50 truncation mutants, which cut into the highly conserved helix VIII 
region, were non-functional. Transfectants of these mutants could therefore not be 
investigated for their ability to be inhibited by the site 2 antagonists in chemotaxis 
assays. The Δ40 construct however did prove to be functional, and in chemotaxis 
assays it was determined that it did not differ to WT with respect to inhibition of 
migration. The last 40 amino acids of CCR4 were thus shown to be dispensable for 
the action of the site 2 antagonists, meaning that they must bind to a site upstream of 
the truncation point. This site likely lies within the conserved helix VIII region, since 
other studies of chemokine receptors have identified an intracellular antagonist site 
involving the helix VIII region (Nicholls et al., 2008; Salchow et al., 2010). 
K310N transfectants, which did not migrate to CCL17, were assayed in 
CCL22 chemotaxis antagonism assays and showed no difference to WT transfectants. 
L318A transfectants also showed no difference to WT transfectants in chemotaxis 
antagonism assays. 
These data therefore showed that F305 and L307 at the end of transmembrane 
helix VII are involved in site 2 antagonist activity, while the last 40 amino acids of 
CCR4 are not required for antagonist activity. A summary of this is shown in figure 
7-3. 
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Figure 7-3 – CCR4 residues involved in site 2 antagonist activity 
Chapter 5 used indirect antagonist-based assays to investigate the role of several helical 
and extracellular loop mutants in site 1 antagonist activity. F305 and L307 were 
identified in chemotaxis assays as having a role in antagonist activity. Truncation 
mutants demonstrated that the distal 40 amino acids of the C-terminus of CCR4 were 
not required for antagonism. 
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Chapter 6 involved the use of 
3
H-5, a tritiated site 2 antagonist, to investigate 
binding of antagonist to L1.2 membranes expressing the site 2 mutants. This analysis 
however was hindered by the identification of a low-affinity binding site for 
3
H-5 on 
the L1.2 membranes. Even at high 
3
H-5 concentrations, the CCR4-expressing 
membranes were not saturated, indicating the presence of another site for the 
compound. This site was confirmed using naïve L1.2 membranes, and the use of 
different site 2 compounds to define non-specific binding did not remedy the 
problem. 
Selectivity data provided by GlaxoSmithKline showed that antagonist 5 had 
some activity against other chemokine receptors, particularly CCR1 and CCR5. Since 
the C-termini of chemokine receptors are highly conserved, it is perhaps unsurprising 
that antagonist 5 showed activity against other receptors. L1.2 cells are a leukocyte 
line and therefore likely endogenously express chemokine receptors, which may 
explain the presence of a 
3
H-5 binding site on the L1.2 membranes. 
While this finding prevented analysis of the direct binding of 
3
H-5 to the site 2 
mutants, it does suggest that antagonist 5 may have potential as a promiscuous 
antagonist of chemokine receptors. As described in section 6.4.3, several 
promiscuous receptor antagonists have been discovered. If antagonist 5 showed 
activity against multiple chemokine receptors in further studies, it may have the 
potential to be developed for therapy for disease involving multiple chemokine 
receptors. 
Asthma for example involves CCR7-expressing dendritic cells presenting 
antigen to CCR7-expressing naïve T cells, which differentiate into CCR4- and CCR8-
expressing TH2 cells. These TH2 cells produce IL-5, which drives the production and 
survival of CCR3-expressing eosinophils. TH2 cells also produce IL-13, which 
stimulates CXCR5-expressing B cells to produce IgE which activates CCR2-
expressing mast cells (see section 1.1). A CCR4-specific antagonist would only target 
TH2 cells in this disease, while a more promiscuous antagonist could potentially 
target multiple cell types. Antagonist 5 for example could be used to inhibit both TH2 
and mast cell migration, since it was shown that it had activity against CCR2. CCR2 
is expressed on mast cells, which as described in section 1.1 release the inflammatory 
mediator histamine in response to binding of IgE cross-linked by antigen. By 
blocking CCR2-mediated migration of mast cells the histamine response could be 
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prevented from occurring in tissues, along with the inflammation caused by CCR4-
expressing TH2 cells. 
 
Research into interaction partners of chemokine receptors may shed light on 
the action of intracellular allosteric antagonists. The protein FROUNT was identified 
to bind the CCR2 C-terminus, and was shown to play an important role in the 
function of this receptor. Upon stimulation by the CCR2 ligand CCL2, FROUNT 
trafficks to the cell membrane and interacts with CCR2 at the leading edge of the 
migrating cell. FROUNT was also shown to mediate the formation of CCR2 clusters 
at this leading edge, which led to the formation of pseudopodia and ultimately cell 
migration (Terashima et al., 2005). It was later shown that CCR5 also bound 
FROUNT. A dominant-negative version of FROUNT inhibited CCR5-mediated 
chemotaxis of cells, and as with CCR2, FROUNT was shown to co-localise with the 
receptor at the leading edge of the cell upon chemokine stimulation (Toda et al., 
2009). 
Truncations of CCR2 and CCR5 had previously been shown to result in 
impaired chemotaxis of cells expressing these receptor mutants (Arai et al., 1997; Le 
Gouill et al., 1999; Kraft et al., 2001). It was hypothesised that these truncations 
prevented the binding of FROUNT, and due to the role this protein played in 
receptor-mediated chemotaxis, perturbed the ability of the truncated receptors to 
induce cell migration (Toda et al., 2009). 
The region truncated in CCR2 and CCR5 corresponds to the helix VIII region 
previously described (see section 1.3.2.3). The Δ45 and Δ50 truncations shown in 
chapter 5 are also truncations of this region. It was speculated that due to the 
conservation of this C-terminal region, there may be other FROUNT-like proteins 
that mediate chemotaxis of other chemokine receptors. Helix VIII is believed to 
interact with G proteins and play a role in receptor activation. The Δ45 and Δ50 
CCR4 truncations were therefore hypothesised to have removed the ability of CCR4 
to couple to G proteins and initiate signalling (see section 5.4.1.2). It may also be the 
case that helix VIII of CCR4 is necessary for the recruitment of FROUNT-like 
proteins to facilitate cell migration. 
 
The identification of FROUNT and the possibility of FROUNT-like proteins 
mediating CCR4 chemotaxis also has implications for the mechanism of the site 2 
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allosteric CCR4 antagonists. As described above, helix VIII was hypothesised to 
couple to G proteins. This may suggest that this class of antagonists inhibit receptor 
signalling by preventing their coupling to G proteins. 
Considering the high degree of conservation of the C-terminal helix VIII 
region between chemokine receptors, it would not be surprising if a FROUNT-like 
protein was discovered that mediated cell migration in a similar manner to that 
described for CCR2 and CCR5. The cytoplasmic end of transmembrane helix VII and 
the beginning of helix VIII in particular are almost identical across all chemokine 
receptors, and compared to CCR2 and CCR5, CCR4 only differs in this region in one 
amino acid; it contains a phenylalanine directly after the NPXXY motif (F305) rather 
than an alanine in CCR2 and CCR5. FROUNT-like proteins may bind to this region 
as it possesses the same amino acids that would facilitate these interactions. 
Therefore, a possible alternative mechanism for site 2 antagonist inhibition of CCR4 
may be the blocking of an interaction between a FROUNT-like protein and the CCR4 
helix VIII region. 
One way to examine the potential interactions that helix VIII has with other 
proteins would be to perform yeast two-hybrid screening. This technique is used to 
discover protein-protein interactions. The ‘bait’ protein, in this case CCR4, is cloned 
into a plasmid containing the sequence for the DNA binding domain (BD) of the 
Gal4 transcription factor. Fragments of genomic DNA are cloned into plasmid 
vectors containing the sequence for the Gal4 activation domain (AD). When these 
two plasmids are transformed into yeast cells, bait-BD and prey-AD are expressed. If 
the prey protein is a binding partner for the bait protein, the two domains of the Gal4 
transcription factor are able to activate transcription of a reporter gene (Brückner et 
al., 2009). This assay could therefore be used to identify possible FROUNT-like 
proteins that bind the CCR4 C-terminus. 
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7.2.3 – Further work on the CCR4 allosteric antagonists 
There are many potential avenues for further work on the CCR4 antagonists. 
Some of the site 1 mutants were not tested against all the site 1 antagonists in 
chemotaxis assays; these assays would need to be performed in order to provide a 
complete picture of the effect of receptor mutation on the activity of the antagonists. 
Additional CCR4 point mutants could also be made to further investigate the 
role of various residues in antagonist activity. For example, K310 could be mutated to 
alanine (K310A) instead of asparagine (K310N) to determine whether this more 
extreme mutation had any effect on antagonist activity. In CXCR2, K320 was 
mutated to alanine in order to disrupt an ion-pair interaction between the receptor and 
an intracellular antagonist (Salchow et al., 2010). Since the CCR4 Δ45 and Δ50 
truncation mutants were non-functional, additional point mutation of specific helix 
VIII residues would allow the contribution of this region to antagonist activity to be 
determined. 
 
Another major avenue for investigation would be optimising the use of the 
tritiated antagonists in the filtration binding assays. Ideally the CCR4 point mutants 
would be stably-transfected into CHO cells; these are a non-leukocyte line and have a 
low degree of non-specific binding for the radioactively labelled antagonists. The 
high variability of 
3
H-3 in the investigation of the GluVII:06 and other site 1 mutants 
prevented detailed analysis of the effect of the mutation on antagonist affinity and 
binding sites. CHO-transfectants may provide a way to determine potential reductions 
in antagonist affinity as a result of CCR4 mutation. 
The use of CHO membranes would also allow investigation of the site 2 
mutants, since L1.2 membranes possessed a low-affinity binding site for 
3
H-5. It has 
been established that this site is not present on CHO membranes, meaning that CHO-
transfectants would provide a way to determine if site 2 point mutation or truncation 
resulted in reduced 
3
H-5 affinity. 
The non-functional CCR4 mutants such as the Δ45 and Δ50 truncations would 
be of particular interest for 
3
H-5 saturation assays, since there was no data regarding 
the effect of these truncations on the activity of the site 2 antagonists. Since it was 
determined that the antagonists did not require the amino acids downstream of helix 
VIII for activity, it was hypothesised that these intracellular antagonists bound to a 
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site within helix VIII. Performing saturation assays on membranes expressing these 
truncations would determine the contribution of this region to antagonist binding and 
conclusively determine the role of helix VIII in CCR4 antagonism. 
While only two tritiated antagonists were available, 
3
H-3 and 
3
H-5, the effect 
of receptor mutation on the binding of the remaining five antagonists could also be 
determined using competition assays in which membranes expressing CCR4 are 
incubated with a fixed concentration of a tritiated antagonist and an increasing 
concentration of unlabelled antagonist. This heterologous competition assay could be 
used to determine the IC50 of the unlabelled antagonist for WT and mutant CCR4; if a 
receptor mutation disrupted antagonist binding we would expect to see a less potent 
competition of the radiolabelled antagonist by the unlabelled antagonist. 
Assays to investigate the kinetics of the radiolabelled ligands could also be 
performed, which would involve measuring specific binding at various intervals. 
Binding of the ligand to receptor can take time to equilibrate, which would require 
association assays to be performed to determine at what time equilibrium occurs. The 
assays performed in chapter 6 were incubated for 3 hours, which was after the 
equilibrium point. An association assay using intervals from 0 hours up to 3 hours 
could be performed. In addition, measuring specific binding at time points after 3 
hours could also be performed in order to investigate the dissociation rate of the 
ligand. By performing these assays on both WT CCR4- and mutant CCR4-CHO 
membranes the potential effects of ligand kinetics resulting from the mutations could 
be determined. 
 
Another potential avenue for investigation would be to determine which 
chemokine receptors L1.2 cells endogenously express. Flow cytometry using a panel 
of chemokine receptor antibodies could be performed on naïve L1.2 cells to 
determine cell-surface expression of the receptors. Following identification of these 
receptors, plasmids containing receptor cDNA could be transfected into CHO cells, 
and the resulting membranes used in 
3
H-5 saturation assays and compared to CCR4-
expressing membranes. This would allow the relative affinity of the ligand for the 
different receptors to be determined. 
 
As described in section 7.2.2, broad-spectrum chemokine receptor antagonists 
could have therapeutic potential. Several such antagonists have previously been 
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identified. An example of such an antagonist is TAK-779, an allosteric antagonist that 
binds an intrahelical pocket of the chemokine receptors CCR2 and CCR5 (Baba et al., 
1999; Shiraishi et al., 2000). TAK-779 was later shown to target the chemokine 
receptor CXCR3 (Gao et al., 2003). TAK-779 and its derivative TAK-652 were 
investigated for their ability to inhibit HIV-1 replication, since the virus uses CCR5 to 
enter macrophages (Moore et al., 1997). The agonist UCB35625 inhibits activity of 
the related receptors CCR1 and CCR3 (Sabroe et al., 2000), and was shown to bind 
similar intrahelical residues including GluVII:06 of both receptors (de Mendonça et 
al., 2005; Wise et al., 2007). 
Therapies targeting multiple receptors have had some success. Zyprexa is a 
benzodiazepine used to treat schizophrenia, which binds to multiple GPCRs including 
those from the dopamine, histamine, and serotonin families (Pease and Horuk, 2009). 
Broad-spectrum antagonists may provide potential for chemokine receptor-driven 
diseases, since these pathologies involve multiple immune cells each of which 
express many different receptors. For example, asthma involves migration to the lung 
of TH2 cells expressing both CCR4 and CCR8; these then release cytokines such as 
IL-5 which causes the development and recruitment of eosinophils expressing CCR3. 
CCR2-expressing mast cells are also involved in the pathogenesis of the disease (see 
section 1.4.1). Therefore, an antagonist targeting multiple receptors could provide a 
way to target the multi-faceted aspects of an inflammatory condition such as asthma. 
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7.3 – Summary 
This project investigated both the biology of the human chemokine receptor 
CCR4 and the action of seven allosteric antagonists. 
The highly conserved GluVII:06 of transmembrane helix VII was determined 
to be critical for chemokine binding and thus receptor function. Mutation of K310, an 
amino acid located within the highly conserved helix VIII region, rendered the 
receptor unable to induce migration to CCL17; however the mutant receptor was still 
able to induce migration to CCL22. Both chemokines bound the receptor in the same 
manner as WT CCR4, indicating that the mutation affected activation of the receptor 
in response to CCL17. This finding was novel in that it was the first identified case of 
an amino acid change causing differential effects on ligand-induced responses. 
Previous studies highlighted the dominance of CCL22 over CCL17 in CCR4-
desensitisation, internalisation, and chemokine binding assays. In conjunction with 
the data presented in this project it was concluded that CCL17 and CCL22 stabilise 
distinct conformations of CCR4. 
Mutations of other regions within CCR4, such as conserved tyrosines in 
transmembrane helix III and L92 of the TXP motif demonstrated that these amino 
acids were required for receptor function. 
 
Two classes of allosteric CCR4 antagonists were supplied by 
GlaxoSmithKline. The first class was hypothesised to bind to a classical intrahelical 
site, while the second hypothesised to bind to a novel intracellular site. Residues of 
CCR4 were mutated to confirm these hypotheses. 
The investigation of the site 1 antagonists showed that L118, Y122, and I125 
of transmembrane helix III and E290 (GluVII:06) of transmembrane helix VII were 
involved in the activity of these antagonist, through the use of both indirect and direct 
antagonist-based assays. The indirect antagonists assays were also used to determine 
that F305 and L307 at the extracellular face of transmembrane helix VII were 
involved in site 2 antagonist activity. 
Direct assays using a radiolabelled site 2 antagonist were hindered by the 
identification of a low-affinity binding site for the antagonist on the L1.2 membranes 
used in the binding assays. This site was hypothesised to be comprised of other 
chemokine receptors endogenously expressed on the cells, possibly CCR2 and CCR5, 
277 
 
based on antagonist selectivity data provided by GlaxoSmithKline. Despite this, the 
site 2 antagonist may have potential as a promiscuous chemokine receptor antagonist. 
Since many inflammatory conditions involve multiple cell types expressing a range of 
chemokine receptors, an antagonist that targets a variety of receptors may prove to be 
an effective therapeutic agent. 
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9.1 – Sequences 
9.1.1 – Sequence of CCR4 
 
ATGAACCCCACGGATATAGCAGACACCACCCTCGATGAAAGCATATACAGCAATTACTAT 
 M  N  P  T  D  I  A  D  T  T  L  D  E  S  I  Y  S  N  Y  Y  
CTGTATGAAAGTATCCCCAAGCCTTGCACCAAAGAAGGCATCAAGGCATTTGGGGAGCTC 
 L  Y  E  S  I  P  K  P  C  T  K  E  G  I  K  A  F  G  E  L  
TTCCTGCCCCCACTGTATTCCTTGGTTTTTGTATTTGGTCTGCTTGGAAATTCTGTGGTG 
 F  L  P  P  L  Y  S  L  V  F  V  F  G  L  L  G  N  S  V  V  
GTTCTGGTCCTGTTCAAATACAAGCGGCTCAGGTCCATGACTGATGTGTACCTGCTCAAC 
 V  L  V  L  F  K  Y  K  R  L  R  S  M  T  D  V  Y  L  L  N  
CTTGCCATCTCGGATCTGCTCTTCGTGTTTTCCCTCCCTTTTTGGGGCTACTATGCAGCA 
 L  A  I  S  D  L  L  F  V  F  S  L  P  F  W  G  Y  Y  A  A  
GACCAGTGGGTTTTTGGGCTAGGTCTGTGCAAGATGATTTCCTGGATGTACTTGGTGGGC 
 D  Q  W  V  F  G  L  G  L  C  K  M  I  S  W  M  Y  L  V  G  
TTTTACAGTGGCATATTCTTTGTCATGCTCATGAGCATTGATAGATACCTGGCAATTGTG 
 F  Y  S  G  I  F  F  V  M  L  M  S  I  D  R  Y  L  A  I  V  
CACGCGGTGTTTTCCTTGAGGGCAAGGACCTTGACTTATGGGGTCATCACCAGTTTGGCT 
 H  A  V  F  S  L  R  A  R  T  L  T  Y  G  V  I  T  S  L  A  
ACATGGTCAGTGGCTGTGTTCGCCTCCCTTCCTGGCTTTCTGTTCAGCACTTGTTATACT 
 T  W  S  V  A  V  F  A  S  L  P  G  F  L  F  S  T  C  Y  T  
GAGCGCAACCATACCTACTGCAAAACCAAGTACTCTCTCAACTCCACGACGTGGAAGGTT 
 E  R  N  H  T  Y  C  K  T  K  Y  S  L  N  S  T  T  W  K  V  
CTCAGCTCCCTGGAAATCAACATTCTCGGATTGGTGATCCCCTTAGGGATCATGCTGTTT 
 L  S  S  L  E  I  N  I  L  G  L  V  I  P  L  G  I  M  L  F  
TGCTACTCCATGATCATCAGGACCTTGCAGCATTGTAAAAATGAGAAGAAGAACAAGGCG 
 C  Y  S  M  I  I  R  T  L  Q  H  C  K  N  E  K  K  N  K  A  
GTGAAGATGATCTTTGCCGTGGTGGTCCTCTTCCTTGGGTTCTGGACACCTTACAACATA 
 V  K  M  I  F  A  V  V  V  L  F  L  G  F  W  T  P  Y  N  I  
GTGCTCTTCCTAGAGACCCTGGTGGAGCTAGAAGTCCTTCAGGACTGCACCTTTGAAAGA 
 V  L  F  L  E  T  L  V  E  L  E  V  L  Q  D  C  T  F  E  R  
TACTTGGACTATGCCATCCAGGCCACAGAAACTCTGGCTTTTGTTCACTGCTGCCTTAAT 
 Y  L  D  Y  A  I  Q  A  T  E  T  L  A  F  V  H  C  C  L  N  
CCCATCATCTACTTTTTTCTGGGGGAGAAATTTCGCAAGTACATCCTACAGCTCTTCAAA 
 P  I  I  Y  F  F  L  G  E  K  F  R  K  Y  I  L  Q  L  F  K  
ACCTGCAGGGGCCTTTTTGTGCTCTGCCAATACTGTGGGCTCCTCCAAATTTACTCTGCT 
 T  C  R  G  L  F  V  L  C  Q  Y  C  G  L  L  Q  I  Y  S  A  
GACACCCCCAGCTCATCTTACACGCAGTCCACCATGGATCATGATCTCCATGATGCTCTG 
 D  T  P  S  S  S  Y  T  Q  S  T  M  D  H  D  L  H  D  A  L  
 
 
  
Figure 9-1 – Sequence of CCR4 
DNA and protein sequence of CCR4. Red text denotes extracellular portions of 
the receptor. Black text denotes transmembrane helices. Green text denotes 
intracellular portions of the receptor. Purple text corresponds to the C-terminal 
helix VIII region. 
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9.1.1 – Primer sequences 
9.1.1.1 – Primers for site 1 CCR4 point mutants 
L92A forward (F; top) and reverse (R; bottom): 
5’ GCTCTTCGTGTTTTCCGCCCCTTTTTGGGGCTACTATGC 3’ 
5’ GCATAGTAGCCCCAAAAAGGGGCGGAAAACACGAAGAGC 3’ 
 
I113A: 
5’ GCTAGGTCTGTGCAAGATGGCTTCCTGGATGTACTTGGTGGG 3’ 
5’ CCCACCAAGTACATCCAGGAAGCCATCTTGCACAGACCTAGC 3’ 
 
S114A: 
5’ GGTCTGTGCAAGATGATTGCCTGGATGTACTTGGTGGGC 3’ 
5’ GCCCACCAAGTACATCCAGGCAATCATCTTGCACAGACC 3’ 
 
Y117A: 
5’ GCAAGATGATTTCCTGGATGGCCTTGGTGGGCTTTTACAGTGG 3’ 
5’ CCACTGTAAAAGCCCACCAAGGCCATCCAGGAAATCATCTTGC 3’ 
 
Y117F: 
5’ GCAAGATGATTTCCTGGATGTTCTTGGTGGGCTTTTACAGTGG 3’ 
5’ CCACTGTAAAAGCCCACCAAGAACATCCAGGAAATCATCTTGC 3’ 
 
L118A: 
5’ GATGATTTCCTGGATGTACGCGGTGGGCTTTTACAGTGGC 3’ 
5’ GCCACTGTAAAAGCCCACCGCGTACATCCAGGAAATCATC 3’ 
 
F121A: 
5’ CCTGGATGTACTTGGTGGGCGCTTACAGTGGCATATTCTTTG 3’ 
5’ CAAAGAATATGCCACTGTAAGCGCCCACCAAGTACATCC 3’ 
 
Y122A: 
5’ GGATGTACTTGGTGGGCTTTGCCAGTGGCATATTCTTTGTC 3’ 
5’ GACAAAGAATATGCCACTGGCAAAGCCCACCAAGTACATCC 3’ 
 
Y122F: 
5’ GGATGTACTTGGTGGGCTTTTTCAGTGGCATATTCTTTGTC 3’ 
5’ GACAAAGAATATGCCACTGAAAAAGCCCACCAAGTACATCC 3’ 
 
312 
 
I125A: 
5’ GGTGGGCTTTTACAGTGGCGCATTCTTTGTCATGCTCATG 3’ 
5’ CATGAGCATGACAAAGAATGCGCCACTGTAAAAGCCCACC 3’ 
 
F126A: 
5’ GGTGGCTTTTACAGTGGCATAGCCTTTGTCATGCTCATGAGCATTG 3’  
5’ CAATGCTCATGAGCATGACAAAGGCTATGCCACTGTAAAAGCCACC 3’ 
 
F173A: 
5’ GTTCGCCTCCCTTCCTGGCGCTCTGTTCAGCACTTGTTATAC 3’ 
5’ GTATAACAAGTGCTGAACAGAGCGCCAGGAAGGGAGGCGAAC 3’ 
 
K188A: 
5’ CGCAACCATACCTACTGCGCAACCAAGTACTCTCTCAAC 3’ 
5’ GTTGAGAGAGTACTTGGTTGCGCAGTAGGTATGGTTGCG 3’ 
 
S202A: 
5’ CACGACGTGGAAGGTTCTCGCCTCCCTGGAAATCAACATTC 3’ 
5’ GAATGTTGATTTCCAGGGAGGCGAGAACCTTCCACGTCGTG 3’ 
 
E205A: 
5’ GAGGGTTCTCAGCTCCCTGGCAATCAACATTCTCGGATTG 3’ 
5’ CAATCCGAGAATGTTGATTGCCAGGGAGCTGAGAACCCTC 3’ 
 
E205D: 
5’ GAGGGTTCTCAGCTCCCTGGACATCAACATTCTCGGATTG 3’ 
5’ CAATCCGAGAATGTTGATGTCCAGGGAGCTGAGAACCCTC 3’ 
 
E205Q: 
5’ GAGGGTTCTCAGCTCCCTGCAAATCAACATTCTCGGATTG 3’ 
5’ CAATCCGAGAATGTTGATTTGCAGGGAGCTGAGAACCCTC 3’ 
 
I206A: 
5’ GTTCTCAGCTCCCTGGAAGCCAACATTCTCGGATTGGTG 3’ 
5’ CACCAATCCGAGAATGTTGGCTTCCAGGGAGCTGAGAAC 3’ 
 
L209A: 
5’ CTCCCTGGAAATCAACATTGCCGGATTGGTGATCCCCTTAG 3’ 
5’ CTAAGGGGATCACCAATCCGGCAATGTTGATTTCCAGGGAG 3’ 
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Y258A: 
5’ CTTGGGTTCTGGACACCTGCCAACATAGTGCTCTTCCTAG 3’ 
5’ CTAGGAAGAGCACTATGTTGGCAGGTGTCCAGAACCCAAG 3’ 
 
Y258F: 
5’ CTTGGGTTCTGGACACCTTTCAACATAGTGCTCTTCCTAG 3’ 
5’ CTAGGAAGAGCACTATGTTGAAAGGTGTCCAGAACCCAAG 3’ 
 
I286A: 
5’ GATACTTGGACTATGCCGCCCAGGCCACAGAAACTCTG 3’ 
5’ CAGAGTTTCTGTGGCCTGGGCGGCATAGTCCAAGTATC 3’ 
 
E290A: 
5’ GCCATCCAGGCCACAGCAACTCTGGCTTTTGTTC 3’ 
5’ GAACAAAAGCCAGAGTTGCTGTGGCCTGGATGGC 3’ 
 
E290D: 
5’ GCCATCCAGGCCACAGATACTCTGGCTTTTGTTC 3’ 
5’ GAACAAAAGCCAGAGTATCTGTGGCCTGGATGGC 3’ 
 
E290Q: 
5’ GCCATCCAGGCCACACAAACTCTGGCTTTTGTTC 3’ 
5’ GAACAAAAGCCAGAGTTTGTGTGGCCTGGATGGC 3’ 
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9.1.1.2 – Primers for site 2 CCR4 point mutants and truncations 
F305A: 
5’ CCTTAATCCCATCATCTACGCTTTTCTGGGGGAGAAATTTCG 3’ 
5’ CGAAATTTCTCCCCCAGAAAAGCGTAGATGATGGGATTAAGG 3’ 
 
L307V: 
5’ CCCATCATCTACTTTTTTGTGGGGGAGAAATTTCGCAAG 3’ 
5’ CTTGCGAAATTTCTCCCCCACAAAAAAGTAGATGATGGG 3’ 
 
K310N: 
5’ CTACTTTTTTCTGGGGGAGAACTTTCGCAAGTACATCCTAC 3’ 
5’ GTAGGATGTACTTGCGAAAGTTCTCCCCCAGAAAAAAGTAG 3’ 
 
L318A: 
5’ CGCAAGTACATCCTACAGGCCTTCAAAACCTGCAGGGGC 3’ 
5’ GCCCCTGCAGGTTTTGAAGGCCTGTAGGATGTACTTGCG 3’ 
 
Δ40 truncation: 
5’ ATCCTACAGCTCTTCAAATGATGCAGGGGCCTTTTTGTG 3’ 
5’ CACAAAAAGGCCCCTGCATCATTTGAAGAGCTGTAGGAT 3’ 
 
Δ45 truncation: 
5’ GAGAAATTTCGCAAGTACATCTGACAGCTCTTCAAAACCTGCAGG 3’ 
5’ CCTGCAGGTTTTGAAGAGCTGTCAGATGTACTTGCGAAATTTCTC 3’ 
 
Δ50 truncation: 
5’ CTTTTTTCTGGGGGAGAAATGACGCAAGTACATCCTACAGC 3’ 
5’ GCTGTAGGATGTACTTGCGTCATTTCTCCCCCAGAAAAAAG 3’ 
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9.2 – Plasmid 
 
 
 
 
 
Figure 9-2 – Plasmid map of pcDNA3 
Plasmid map of pcDNA3, showing the sites of various promoters, antibiotic 
resistance genes, origins of replication and the multiple cloning site. * - there is 
another ATG upstream of the Xba I site.  
